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Abstract 
The gene therapy field is devoted to treating disease by adding, altering, or 
inhibiting gene expression. This type of therapy holds great promise for the 
treatment and even cure of monogenic diseases such as cystic fibrosis, 
Duchenne muscular dystrophy, hemophilia A and B, and epidermolysis bullosa. 
To produce therapeutic effect, nucleic acids must be delivered and expressed in 
cells of interest. Deoxyribonucleic acids (DNA) and ribonucleic acids (RNA) in 
many forms can be delivered using viral or non-viral vehicles. Viral vectors 
provide efficient DNA delivery; however, packaging limitations and occasional 
safety issues such as immune responses are major issues. In contrast, non-viral 
vectors are cheaper and easier to mass produce and can package any length of 
nucleic acid; however, non-viral vectors struggle to deliver genetic cargo at 
therapeutically beneficial levels.  
Polymers with the ability to condense and protect genetic material make 
promising non-viral vectors. They are relatively easy to produce compared to 
viral vehicles, can safely package various plasmid sizes, and have shown 
significant uptake in a wide variety of human cell lines. Cationic polymers 
complex with the negatively charged phosphodiester backbone of DNA or RNA, 
forming inter-polyelectrolyte complexes termed polyplexes. Herein, we explore 
using experiments in vitro, ex vivo, and in vivo to probe the structure-function 
relationships dictating polyplex gene delivery and other glycomaterial 
applications. 
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CHAPTER 1: ELUCIDATING GLYCOPOLYCATION 
STRUCTURE-FUNCTION RELATIONSHIPS FOR IMPROVED 
GENE THERAPY 
Synopsis 
Gene therapy is a field devoted to the treatment of disease by adding, 
altering, or inhibiting gene expression. In contrast, non-viral polymeric gene 
delivery vehicles can package any length of nucleic acid; however, delivery of 
non-viral vectors into cells is generally very difficult to achieve at levels that have 
therapeutic efficacy. This chapter discusses gene delivery hurdles and how 
strategic polymer design builds vehicle functionality to overcome those hurdles. 
Additionally, it makes and argument for the benefits of using a combination of in 
vitro, ex vivo, and in vivo studies to probe the structure-function relationships 
dictating polyplex gene delivery and other glycomaterial applications. 
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1.1 BACKGROUND 
1.1.1 Polymer Nucleic Acid Delivery Vehicles 
Gene therapy is a field devoted to the treatment of disease by adding, 
altering, or inhibiting gene expression.1 This type of therapy holds great promise 
for the treatment and even cure of monogenic diseases such as cystic fibrosis, 
Duchenne muscular dystrophy, hemophilia A and B, and epidermolysis bullosa.2-
13 To produce the therapeutic effect, nucleic acids must be delivered and 
expressed in cells of interest. Deoxyribonucleic acids (DNA) or ribonucleic acids 
(RNA) in many forms can be delivered using viral or non-viral vehicles. Viral 
vectors provide efficient DNA delivery;14-16 however, packaging limitations, 
occasional safety issues such as immune responses, and the high costs 
associated with mass production of clinical-grade viruses for treating large 
patient populations are major issues.17, 18 In contrast, non-viral vectors can 
package any length of nucleic acid; however, delivery of non-viral vectors into 
cells is generally very difficult to achieve at levels that have therapeutic efficacy.19  
Polymers with the ability to condense and protect genetic material offer a 
promising delivery alternative to viral vectors. They are relatively easy to produce 
compared to viral vehicles, can safely package various plasmid sizes, and have 
shown significant uptake in a wide variety of human cell lines.4, 17, 18, 20-22 Cationic 
polymers complex with the negatively charged phosphodiester backbone of DNA 
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or RNA, forming inter-polyelectrolyte complexes termed polyplexes. Typically, 
polyplexes contain an excess of polymer, which yields a complex that has a net 
positive charge. A net positive charge has been shown to aid cellular uptake in 
cell culture,23 which makes cationic polyplexes promising vehicles for cell-based 
gene therapy. However, cationic surface charge can also cause toxicity.24, 25 Not 
all diseases can be treated with cell therapy (which is directly editing cells in 
culture, then transplanting them back into the body), so another desirable 
delivery method is to inject vehicles into the bloodstreams for systemic nucleic 
acid delivery. However, when previous studies introduced positively charged 
polyplexes into the blood stream, they aggregated with various negatively 
charged blood serum proteins in a process called opsonization.26 Opsonization 
prevents gene delivery by not only hindering polyplex cellular uptake,27 but also 
by making polyplexes targets for active removal by the body’s mononuclear 
phagocyte system (also called the reticuloendothelial system).4, 26, 28 Aggregated 
polyplexes even proved toxic to the in vivo hosts by becoming entrapped in lung 
capillary beds4, 27, 29, 30 To combat cytotoxicity and aggregation, non-charged 
“stealth” polyplex coatings were developed by adding an uncharged hydrophilic 
block to the cationic polymer. During polyplex formation, it is hypothesized that 
the hydrophilic block arranges itself around the outside of the polyplex, forming a 
neutral and steric shell-like barrier around the cationic polyplex core to further 
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protect the genetic material from degradation by nucleases, decrease cell 
exposure to positive charge and nonspecific uptake, and prevent polyplex 
aggregation and premature blood clearance20, 31 Protein aggregation is not the 
only issue hindering polyplex gene delivery. There are many intracellular and 
extracellular hurdles polyplexes must overcome to prove effective gene delivery 
vehicles. 
1.1.2 Gene Delivery Hurdles 
The hurdles polymeric gene delivery vehicles encounter depend on the 
types of nucleic acid being delivered, the end point for delivery, and the 
administration route.20 Gene delivery hurdles can be generally divided into two 
categories: intracellular and extracellular. Intracellular hurdles include obstacles 
from cellular uptake all the way through the cell to nucleic acid expression. 
Extracellular hurdles include all barriers between polyplex formulation and 
cellular uptake.20 Some extracellular barriers, such as nucleic acid packaging, will 
apply whether the vehicles are being administered to cells in culture or to whole 
living organisms. Other hurdles such as the innate immune response and 
nonspecific tissue capture will vary by administration route and tissue target.  
The structure-function relationships that determine the delivery efficiency of 
polymer vehicles also vary depending on the polymer type. First the intracellular 
and extracellular delivery hurdles will be described to illustrate the obstacles 
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polymer gene delivery vehicles face. Then, to limit the scope of this discussion, 
this section will include a comprehensive description of the structure-function 
relationships that glycopolymers and their closely related controls, PEG and PEI, 
have demonstrated in the field thus far. 
1.1.2.1 Intracellular Hurdles 
Intracellular hurdles include obstacles from cellular uptake all the way 
through the cell to nucleic acid expression (Figure 1.1). The figure depicts 
hurdles that a successful nonviral vehicle should overcome. Vehicles should: a) 
package therapeutic genes, b) protect genetic material in culture media, c) cell 
uptake (by endocytosis/other), d) escape from endo- or lysosomal degradation, 
e) traffic to nucleus, f) release DNA, g) permit gene expression, h) degrade. Most 
polyplexes are actively taken up by cells through endocytosis.4, 20 The first 
intracellular hurdle gene delivery vehicles encounter is cellular uptake. 
Endocytosis is an energy dependent process where the cell membrane 
invaginates to take up extracellular material into vesicles of about 0.05 to 0.1 µm 
in diameter.4, 32 There are three types of endocytosis: micropinocytosis, 
phagocytosis, and receptor-mediated endocytosis.4 Receptor-mediated uptake 
(also known as clathrin-mediated endocytosis, which the most common protein 
found coating receptor-mediated uptake vesicles)32 can be triggered by including 
one of a variety of ligands on the vehicle. Common ligands for eukaryotic cells 
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are cholesterol, transferrin, insulin and other protein hormones, and glycoproteins 
with terminal glucose, galactose, and mannose.32 Phagocytosis is used by 
specialized cells such as monocytes, macrophages, and neutrophils to take up 
foreign particles for digestion and elimination.33 Therefore, phagocytosis is 
generally not a preferred route of polyplex uptake. Micropinocytosis is similar to 
phagocytosis in that it is a non-receptor-mediated route for taking up material to 
be digested, but it takes up larger particles in 0.02 to 5 µm diameter vesicles.4, 34 
Most polyplexes are taken up via a receptor-dependent route.4, 35 
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Once polyplexes are endocytosed into the cell, they are destined for 
digestion by the lysosome unless they can escape the endosome in time. There 
are several proposed endosomal escape theories. The most popular theory is the 
pH-buffering effect (also known as the proton sponge effect) in which agents with 
a high buffering capacity and the ability to swell upon protonation rupture the 
endosome. A second proposed mechanism is to form endosomal membrane 
pores using cationic amphiphilic peptides to stress the lipid bilayer.36 Another 
 
Figure 1.1. Scheme of possible cellular transfection route. Anionic DNA 
plasmids are red. Cationic polymers block copolymers are green and purple. 
Purple cationic spheres represent complexed plasmids and polymers. See text 
for descriptions of parts (a)-(h). 
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escape option is destabilize the membrane not by pore formation but by fusion to 
the cellular membrane. This fusion is driven by fusogenic peptides, such as 
haemagglutinin from the influenza viral coat, that undergo conformational 
changes when triggered by an environmental change such as a drop in pH.36 
Finally, a fourth possible mechanism is membrane disruption by a multitude of 
protein, peptide, or chemical endosomal membrane disruption agents.36 The 
difficulty in adapting one of the last three methods to aid polyplex uptake is that 
the process of disrupting the endosome can be toxic to the cell or patient.36-38 
Therefore, it would be ideal to use polymer delivery vehicles that can buffer the 
endosome without adding a potentially toxic escape agent. Polyethyleneimine 
(PEI) is one such polymer that has demonstrated a strong ability to buffer and 
escape endosomes, however, it is also widely known that PEI can be toxic.38 
This toxicity limits its application in vivo, but its effectiveness and commercial 
availability make it a high standard by which to compare novel polymer vehicle 
structures. 
The remaining intracellular hurdles are less well studied than endosomal 
escape, but no less crucial to gene delivery success. At some point, the nucleic 
acid cargo must be released from the vehicle in order for it to be expressed.20, 39 
Additionally, DNA must be trafficked to the nucleus and most RNA (such as short 
interfering or messenger RNA) must end up in the cytosol.20, 40, 41 Finally, if 
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genome engineering is desired, the nucleic material can be inserted into the cell 
genome to be constitutively expressed over time, even in daughter cells.42, 43 
Genome engineering is not always necessary for a therapeutic treatment, but it is 
often the only permanent cure for many genetic diseases.19, 42 
Many in-depth studies have been conducted to tease out what structure-
function relationships will lead to better endosomal escape, cargo release, and 
nuclear localization.20, 24, 40, 44 Genome engineers specialize in developing new 
genome engineering systems and understanding exactly how they work once 
they get inside the nucleus.42, 45-47 What remained less clear at the initiation of 
the studies documented herein was what polymer structure-function relationships 
existed for clearing extracellular hurdles, particularly for systemic delivery by 
cationic glycopolyplexes via the bloodstream.48 
1.1.2.2 Extracellular Hurdles 
Extracellular hurdles occur from the time of polyplex formation until cell 
uptake begins (Figure 1.2). The foremost purpose of any gene delivery vehicle is 
to package and protect nucleic acid cargo from degradation by nucleases. It must 
compact the material, especially large DNA plasmids, down to a size where 
endocytosis can occur, generally from 25 to 500 nm in diameter (with 25-50 nm 
seen as the ideal endocytosis size).49, 50 Most cationic delivery vehicles can 
accomplish the task, but it can be difficult to maintain a small diameter in the salt 
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and serum solutions typically used for cell culture.31 This stability becomes 
increasingly important in more complex environments such as the blood stream, 
lymphatic ducts, gastrointestinal tract, or lung fluid.51 From here on, the 
extracellular obstacles vary widely based on administration route and tissue 
target. For our purposes, we will limit the discussion to systemic delivery hurdles 
for vehicles administered intravenously. 
 
Intravenous injection is a simple method for obtaining systemic exposure of 
a therapeutic drug or material. In humans, it takes only from 10-25 s for 
computerized tomography (CT) contrast medium to complete one full circulation 
cycle back to its injection site.52 In mice, this circulation time drops to only 15 
sec.53 As long as the delivery vehicle remains intact through the needle shear 
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Figure 1.2. Scheme of extracellular hurdles for systemic delivery. Several key 
interactions and filtration organs are labeled. 
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and remains colloidally stable during circulation, it stands a good chance of 
reaching even the smallest capillary beds within minutes. For example water 
soluble single-walled nanotubes from 200-500 nm in length successfully 
distribute to the liver, lungs, muscle, and kidneys of mice in about 15 seconds.54 
Once in the bloodstream, polyplexes must remain colloidally stable to remain in 
circulation long enough to passively reach the intended tissue. This colloidal 
function is determined by the chain length of the hydrophilic polymer block, 
cationic block charge density, and the hydrophilic:polycation ratio use in the 
polyplex formulation.4, 30 Additionally, it is almost always desired to reach a 
specific tissue of interest. Widespread unspecific delivery means less nucleic 
acid cargo is available to the tissues and cells that need to express the DNA or 
RNA, and could even lead to negative off target effects such as an immune 
response.55 To avoid the off target issues associated with systemic delivery, an 
injection method was developed to direct materials to the liver and improve 
hepatocyte (liver cell) uptake. This method, first referred to as hydrodynamic 
injection by Budker et al.,56 rapidly injects high volume solutions, thereby creating 
high pressure in the liver tissue that permeabilizes cell membranes. The method 
results in high transfection efficiency and gene expression, but cannot be used 
on mammals outside the rodent family due to high toxicity, so is typically used to 
generate disease or genome editing models.57  In fact, hydrodynamic injection 
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was used in one of the following studies to verify that polyplexes could 
successfully deliver plasmid DNA (pDNA) for in vivo liver expression.58 When 
complexed with a cationic trehalose polymer prior to injection, the pDNA was still 
expressed, and both the pDNA and the polymer vehicle were taken up by 
hepatocytes.58 This initial in vivo study set the precedent for possible in vivo 
systemic delivery of pDNA to the liver using cationic glycopolyplexes.  
Another hurdle polyplexes encountered while still in the blood stream is the 
immune response. The immune system can be generally divided into adaptive 
and innate immunity as well as cell- or humorally-mediated immunity.59 Adaptive 
immunity is the part of the immune system that ‘learns,’ or adapts, from exposure 
and infection. The adaptive branch requires previous exposure to be activated, 
but the innate system can be activated by some antigens without any prior 
contact. Previous clinical tragedies have shown how vital it is to thoroughly test 
both viral and non-viral materials for immune response prior to clinical use.18, 60 
Due to the complexity and flexibility of the immune system, this in-depth 
preclinical testing should be directed by a specialist, but some simple immune 
response screens can (and arguably should) be conducted at the early stages of 
vehicle development.61 It has been shown that even widely used biocompatible 
polymers such a polyethylene glycol (PEG) can induce humoral immune 
reactions during the first injection, which creates antibodies against the polyplex 
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vehicles.62 These antibodies rapidly clear any future injections, rendering the 
treatment useless.1, 63 In other cases, nonviral nanocapsule vehicles coated in 
PEG activated complement protein in vitro,64 which could lead to complement 
activation-related pseudoallergy (CARPA).65 CARPA is a potentially lethal 
immune response where symptoms such as skin rash, rise in pulmonary arterial 
pressure, and other hematological changes resemble those cause by an allergic 
reaction, but the exact mechanism underlying the symptoms differs from a true 
allergic reaction.65 Not only can the delivery vehicle trigger an immune response, 
but so can the genetic cargo it carries.66, 67 
As mentioned previously, nonspecific tissue capture is another obstacle 
which gene delivery vehicles must avoid to preserve bioavailability for the tissues 
and cells of therapeutic intent. Aside from hydrodynamic injection, there are 
several other methods for targeting specific tissues. Targeting has previously 
been achieved by carefully controlling vehicle diameter,68 coupling vehicles with 
ligands specific for a cell type such as vitamin A or N-acetyl galactose (GalNAc) 
for hepatocytes,69, 70 or with antibodies for specific cells.71 Recently, stimuli-
sensitive systems have been developed that respond to pH,72 temperature,73 
redox environment,74, 75 and enzyme activity.76 Targeting is a crucial function to 
achieve gene delivery at clinically relevant levels, and will be an important 
function for future glycoplexes to incorporate.4, 20 
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1.1.3 Understanding Polymer Structure-Function Relationships 
Strategic polymer design can create delivery vehicles that successfully 
overcome multiple intracellular and extracellular hurdles such as promoting 
endocytosis and endosomal escape, trafficking to the nucleus, and gene 
expression as well as avoiding aggregation, off-target circulation clearance, and 
immune responses.20, 49 There is a large body of existing research probing the 
structure-function of different polymeric delivery systems. The diversity of 
polymeric systems makes some direct comparisons difficult, but previous work 
within the class of glycopolymer vehicles offers a wealth of structure-function 
data to help design polymers to overcome extracellular hurdles for systemic 
delivery. 
1.1.3.1 Polymer Design to Overcome Extracellular Hurdles 
The extracellular hurdles discussed above can be generally divided into 
three categories: aggregation, off-target clearance, and immune response. 
Polymer vehicles that overcome those hurdles will possess colloidal stability, 
bioavailability, and nonantigenic functionalities. Each functionality can be 
achieved in multiple different ways. This section explores how other 
glycopolymers (and some closely related non-glycopolymers) have achieved 
these functionalities. 
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Colloids are noncrystalline large molecules or sub-microscopic materials 
that homogenously dispersed in a substance from which they cannot settle or be 
centrifuged out. Cationic polyplexes are colloidal in water, but can aggregate or 
settle out of solutions with high ionic strength or negatively charged proteins.77-79 
Once common way to promote colloidal stability in salt and serum solutions is to 
add a hydrophilic, neutral polymer block to the cation polymer.31, 80, 81 This neutral 
block can reduce toxicity, immunogenicity, and nonspecific protein absorption by 
sterically hindering direct cationic exposure to cell membranes and proteins.82 
One vast improvement to the design of these neutral hydrophilic polymer blocks 
was to add bulk by incorporating biocompatible carbohydrate moieties. This 
added bulk increased polyplex colloidal stability compared to the more linear 
P(EG) blocks.31, 80, 83 It is hypothesized that the bulkier hydrophilic blocks are 
sterically pushed towards the outside of the polyplexes forming a micelle-like 
corona that better shields polyplexes and their cargo from protein aggregation 
and nuclease enzymes that would degrade the pDNA cargo if it were exposed.31 
Colloidal stability is a critical functionality as vehicles that lack this stability have 
lower bioavailability and can trigger an immune response through polyplex 
destabilization and protein opsonization (protein aggregation that targets 
materials for phagocytic clearance).81, 82 
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Polymer vehicles that demonstrate colloidal stability usually have promising 
bioavailability and nonantigenic properties as well. One generally accepted 
method for improving bioavailability focuses on improving vehicle circulation time 
and penetration. For example, PEGylating poly(ethylene imine) (PEI) improved 
polyplex stability and circulation time in vivo, which allowed the polyplexes to 
avoid lung accumulation and further circulate to other organs, and also lowered 
the acute toxicity as compared to non-PEGylated PEI polyplexes.84 However, 
colloidal stability doesn’t always correlate with increased gene expression, and 
the PEGylated PEI polyplexes showed decreased levels of gene expression 
compared to non-PEGylated PEI polyplexes despite significantly accumulation in 
the liver, lungs and spleen.84 In this case, an increased circulation time correlated 
with decreased non-specific lung capture and decreased excretion by the 
kidneys, thereby increasing the vehicle bioavailability during circulation, but it did 
not promote increased bioavailability at the cellular level. Polymer design 
strategies other than simply increasing colloidal stability must be applied to 
increase cellular bioavailability and gene expression. 
Another way of increasing bioavailability is to design polyplexes that reach 
and are retained in a specific tissue, and are even taken up by select cell types in 
that tissue.70 Generally acknowledged to be the most difficult functionality to 
achieve in vivo, tissue targeting is important for not only increasing the dose that 
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target tissues receive, which would make nonviral gene therapy less expensive 
and more effective, but it also prevents negative off-target effects.55, 85-90 While 
many of the same polymer structure motifs that promote colloidal stability also 
increase bioavailability through increased circulation time, the true “holy grail” of 
nonviral gene delivery is the ability to deliver the vehicles to specific tissues and 
cells.1, 21, 91 The polymer vehicle that increases both colloidal circulation time as 
well as tissue/cell targeting would almost certainly succeed in a clinical setting. 
Before a polymeric gene delivery vehicle could be introduced to human 
patients, it is necessary to test their immunogenicity, or ability to trigger an 
immune response. There are two general branches of the innate immune 
system: the innate and the adaptive systems. Each of those two branches can be 
further divided into a humorally- or a cell-mediated response. Humorally-
mediated responses rely primarily on proteins to help identify and eliminate 
antigens, while the other response relies primarily on cells to perform the work. 
Therefore, polymer gene delivery vehicles must avoid activating both cells and 
proteins involved in the immune response for both the innate and adaptive 
immune branches. This is a tall order, but some polymer structures have avoided 
triggering an immune response under some circumstances.66, 92 The immune 
system is complex and can vary slightly from person to person. This is yet 
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another reason that structure-function studies should be conducted in 
increasingly complex environments using ex vivo and in vivo studies.93 
Many polymeric gene delivery vehicles have been designed to promote 
colloidal stability and increased circulation time in vivo,30, 88 however, the type of 
structure-functions needed to achieve tissue targeting and non-antigenicity are 
less clear.88, 91 The field continues to push for a better understanding of these 
functionalities, and improving study design could improve vehicle structure-
function understanding in more complex environments. 
1.1.4 Structure-Function Study Design 
To probe polymer structure-function for gene delivery, the study must be 
designed in such a way that the function results can be related back to a specific 
aspect of the polymer function. Due to the complexity of both the experimental 
environments of interest as well as the complexity of the polyplex system, the 
study was designed to test the same polyplex systems in both complex and 
simplified environments. Studying novel carbohydrate polymer vehicles in vitro, 
ex vivo, and in vivo helps identify structure-function trends that hold up in multiple 
circumstances. Furthermore, the novel glycopolymers will be studied alongside 
well-understood PEG and PEI controls, helping link the function results to a 
specific structural aspect of the glycopolymers. 
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Carbohydrate-based polymers are hydrophilic, nontoxic, and possess many 
hydroxyl groups for changing chemical and biological functionality.31, 70 We 
previously designed carbohydrate-based polymers that overcame intracellular 
barriers and also demonstrated potential to overcome extracellular barriers.33 
Multiple sugars were modified into monomers for polymerization by Reversible 
Addition Fragmentation Chain-Transfer (RAFT) to allow controlled polymerization 
of polymer that could be clearly characterized in situ.31, 94, 95 The polymers were 
complexed with pDNA expressing various reporter genes such as green 
fluorescent protein (GFP) and luciferase, and polyplexes were characterized in 
vitro, ex vivo, and in vivo (Figure 1.3). In addition to studies on gene delivery 
vehicles, one in vitro study was also conducted on glycomaterials used to make 
epoxy thermoset films. This additional study illustrates that cross-state screens 
can efficiently identify important structure-function relationships for many different 
novel materials. 
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1.1.4.1 In Vitro Structure-Function Studies 
Over the past three decades, in vitro studies have been the standard for 
assessing the toxicity, efficacy, and mechanism of gene delivery vehicles.20 In 
vitro experiments use cells grown exclusively on culture dishes or other artificial 
scaffolds. Most in vitro experiments are conducted on immortalized (often 
cancerous) cell lines that are easy to grow and provide relatively reproducible 
 
Figure 1.3. Scheme of glycopolyplex study in vitro, ex vivo, and in vivo using 
glucose- and trehalose-based polymer delivery vehicles complexed with 
pT2/CAL plasmid DNA (pDNA). Abbreviations in plasmid scheme represent 
specific sequences discussed in Chapter 3. 
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results. The relatively simplistic cellular environment enabled the field of non-viral 
gene delivery to answer many important fundamental questions such as how 
cationic charge affects mitochondrial and cell membrane function,24, 96 and how 
polyplex physical characteristics such as charge and colloidal stability affect 
uptake and gene expression.31, 80 In addition to these basic screens, cell culture 
has helped answer more complicated questions such as whether different non-
viral vehicles prefer one cell uptake mechanism over another.35, 41, 97 Cells in 
culture can be easily observed without disrupting their function, and many studies 
have used this imaging methods to probe how polyplexes and their cargo are 
intracellularly trafficked.40, 98 The practicality and usefulness of cellular assays 
can hardly be debated, but the simplicity of cell culture limits the application of 
results. In vitro studies alone cannot capture the whole picture. 
1.1.4.2 Ex Vivo Structure-Function Studies 
Instead of immortalized cells cultured exclusively in dishes, ex vivo studies 
use tissues freshly removed from a human or animal donor. This type of study is 
useful for relating in vitro assay results to observations made with materials in 
vivo. The tissue more closely approximates a complete in vivo environment, but 
is easier to manipulate and observe removed from the host. Studies ex vivo 
helped researchers observe polyplex effects on coagulation and hemolysis.92, 99 
Another study found that, although their surface-modified material prevented 
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protein aggregation, which is a generally accepted mechanism to increase 
biocompatibility, the surface still induced coagulation upon exposure to whole 
blood ex vivo.100 One study was prompted after researchers witnessed severe in 
vivo toxicity that suggested issues with coagulation. They used ex vivo platelet 
studies to pinpoint how their poly(amidoamine) dendrimer particles altered 
platelet morphology and function.101 This example illustrates that in vitro, ex vivo, 
and in vivo studies do not need to be conducted unidirectionally, but that the 
characterization process can fluidly move between experimental states. 
For some applications, ex vivo studies are sufficient for characterizing the 
materials, but for vehicles to be administered directly to patients, it is necessary 
to push towards in vivo preclinical testing. 
1.1.4.3 In Vivo Structure-Function Studies 
The most complicated and arguably the most valuable type of study is 
conducted in vivo. In vivo studies conduct experiments using whole living 
organisms. The complex environment most closely approximates what the 
delivery vehicles would encounter in a living patient, but it also makes observing 
vehicle structure-function characteristics more difficult. Often in vivo studies will 
use complementary ex vivo methods such as organ imaging and histology to 
make more quantitative observation about material distribution.27 Other times it is 
possible to measure the gene delivery outcome directly by quantifying protein 
 24 
 
production or observing animal host health improvement.102 Still other methods 
have been develop to observe vehicle distribution in real time in vivo, although 
they are usually limited to observing carbon nanotubes,103 heavy metal-based 
nanoparticles,104 or fluorescently tagged moities.105 In vivo experiments usually 
take longer and environmental control is limited, which in turn limits which 
questions can be answered with these studies. Taken in context with in vitro and 
ex vivo results, however, these studies provide a more complete characterization 
picture than studies from only one category. It was our objective to use all three 
study-states to identify and characterize the structure-function relationships of 
cationic glycopolyplex gene delivery vehicles. 
1.1.4.4 Thesis Statement and Dissertation Summary 
Thesis statement: Studies in vitro, ex vivo, and in vivo elucidate structure-
function relationships characterizing glycopolymer materials for gene delivery 
and other applications more thoroughly than studies isolated to only one or two of 
those categories. 
Non-viral vehicle design is typically iterative and therefore relies heavily on 
clear structure-function relationship studies to inform design of the next vehicle 
generation. It was our hypothesis that using a combination of in vitro, ex vivo, 
and in vivo studies would more clearly characterize glycomaterial structure-
function than studies isolated to only one or two study categories. Previously, a 
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multitude of in-depth cell culture studies led to the design of two block copolymer 
vehicles derived from trehalose and glucose. Chapter 2 in this dissertation 
characterizes these vehicles in vitro, demonstrating that the type of cell culture 
media can affect polyplex uptake, and that polyplex cell uptake and gene 
expression don’t necessarily correlate. After thorough study in cell culture, 
Chapter 3 pushes characterization into ex vivo and in vivo environments, 
confirming polyplex stability as a key characteristic for hemocompatibility and 
widespread biodistribution. However, stability against protein aggregation is not 
sufficient to clear the immune response hurdle. Chapter 4 cycles back to in vitro 
study by characterizing the cytocompatibility and cell proliferation ability of a 
novel carbohydrate-derived epoxy film, identifying potential antifouling 
characteristics. Similarly, work included in the appendix uses in vitro testing to 
screen several glycopolyplex vehicles’ delivery capacity against immortalized 
human B cells. Screening vehicles in immortalized non-cancer cells 
demonstrated that vehicle design fed by in vitro data collected from cancer cell 
lines would not translate to similar results in immortalized cells. These chapters 
in combination demonstrate that studies from all three experimental states (in 
vitro, ex vivo, and in vivo) elucidated new structure-function relationships more 
clearly than studies from each category would have individually.  
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CHAPTER 2: CARBOHYDRATE-BASED BLOCK 
COPOLYCATIONS PROMOTE POLYPLEX STABILIZATION 
AND IN VITRO NUCLEIC ACID DELIVERY 
Synopsis 
The development and thorough characterization of non-viral delivery agents 
for gene and genome editing therapies are of high interest to the field of 
nanomedicine. Indeed, this vehicle class offers the ability to tune chemical 
architecture/biological activity and readily package nucleic acids of various sizes 
and morphologies for a variety of applications. Herein, we present the synthesis 
and characterization polymer vehicles derived from two carbohydrates. 
Trehalose-based and glucose-based block copolycations were designed to 
stabilize polyplex formulations for transfection in cell culture. Polymer structure 
affected polyplex cytotoxicity, cell uptake, and gene expression results. The 
trehalose-based vehicles provided an additional lyoprotectant property that 
stabilized polyplexes through several cycles of freeze drying and reconstitution. 
Lastly, hydrodynamic injections of P(MAT-b-AEMA) polyplexes verified that in 
vivo polyplex delivery could lead to gene expression. 
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2.1 INTRODUCTION 
Gene therapy offers new avenues for the treatment of genetic diseases 
characterized by deficiency of a protein that can be treated by the delivery of 
DNA encoding the required polypeptide.6-13 Viral vectors are often used for DNA 
delivery;14-16 however, the most commonly used viruses have limited DNA cargo 
space and many elicit strong immunological responses. In contrast, non-viral 
vectors can package any length of nucleic acid; however, delivery of non-viral 
vectors into cells is generally very difficult to achieve at levels that have 
therapeutic efficacy.19 
Cationic polymers that form an inter-polyelectrolyte complex with the 
negatively charged phosphodiester backbone of DNA or RNA,106 termed 
polyplexes, are an attractive choice for non-viral gene delivery agents as their 
chemical structure, functionality, and molecular weight can be tailored in a 
controlled fashion. Typically, polyplexes contain an excess of polymer, which 
yields a complex that has a net positive charge. However, when such polyplexes 
are introduced into the blood stream they aggregate with various negatively 
charged proteins, which hinders their ability to penetrate the plasma membranes 
of cells in tissues.107 Therefore, non-charged “stealth” coatings such as 
polyethylene glycol (PEG) have been used to help shield these particles from 
aggregation.108 PEGylated complexes generally have decreased immunogenicity 
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and increased lifetimes in the blood when compared with their unmodified 
counterparts.109-17 However, PEG is non-biodegradable and has been implicated 
in antibody formation,110 hypersensitivity reactions111, 112 and accelerated blood 
clearance upon repeated dosage.113-115 Accordingly, we have focused on building 
novel carbohydrate-based polymers to create a hydrophilic polyplex shell as an 
alternative to PEG. This study presents the first systematic investigation of these 
glycopolymers in vivo. 
Previously, we polymerized the glucose-based monomer, 2-deoxy-2-
methacrylamido glucopyranose (MAG), to form a block copolymer with N-(2-
aminoethyl) methacrylamide (AEMA).116 Tests in vitro suggest that the cationic 
glycopolymers have superior solution stability and lower cell toxicity in cell culture 
compared to PEI complexes. In addition to glucose, trehalose has also been 
explored as a PEG alternative.117 Trehalose is an α-α-linked dimer of glucose 
that is synthesized by bacteria, fungi, plants, and invertebrate animals118, 119 and 
is used by living systems to survive in extreme conditions.120, 121 Trehalose has 
long been used as a stabilizing agent in drug formulations such as Herceptin™ 
and Lucentis™.122 Step-growth polymers have been synthesized using a 
modified trehalose as one of the monomers. Polyplexes formed with these 
polymers displayed lower toxicity, high cellular uptake, and similar gene 
expression when compared to the commercially available gene delivery polymer 
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jetPEI.77, 78, 123 Polytrehalose imparted thermal stability to proteins: lysozyme 
enzymatic activity was retained upon extreme heating and cooling when 
polytrehalose was covalently attached.124 Our lab has reported polyplexes 
formulated with short interfering RNA (siRNA) and a trehalose block co-
polycation 6-methacrylamido-6-deoxy trehalose-b-N-(2-aminoethyl) 
methacrylamide [P(MAT-b-AEMA)].117 Polyplexes formulated with P(MAT-b-
AEMA) polymers displayed high uptake efficiency and powerful gene knockdown 
in U87 cells.117 
 
Herein, we investigated the use of P(MAT-b-AEMA) and a series of P(MAG-
b-methacrylate) block copolymers in the formulation of polyplexes containing 
A)
B)
 
Figure 2.1. Polymer structures for (A) P(MAGm-b-methacrylaten) and (B) 
P(EGm-b-AEMAn). 
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plasmid DNA (pDNA) for gene delivery in vitro and in vivo. Nine poly(2-deoxy-2-
methacrylamido glucopyranose)-b-poly(polymethacrylate amine) diblock 
copolycations [P(MAG-b-methacrylate)] were synthesized with varied pendant 
amine methylation (secondary, tertiary, quaternary) to optimize the structure and 
activity for plasmid DNA delivery,125 while the P(MAT-b-AEMA) polymers kept the 
same polymer composition and varied only the cationic polymer block length.58 
The plasmids contained either a firefly luciferase or a green fluorescent (GFP) 
reporter gene under the regulation of a strong synthetic promoter (CAGGS) that 
is highly active in vertebrate cells.126 Delivery experiments were first performed in 
human liver carcinoma (HepG2) cell lines and found to be highly efficacious. The 
trehalose polymers were then examined for the ability to stabilize polyplex 
formulations through lyophilization and reconstitution. We reveal that these 
trehalose-coated polyplexes retain pDNA delivery and gene expression activity 
after lyophilization and reconstitution, an important metric to improve the 
consistency of gene delivery and increase shelf life of nanomedicines. We also 
reveal the first examination of these trehalose block copolycations for in vivo 
pDNA administration. Polyplex formulations were administered to mice using two 
different injection techniques to observe toxicity, biodistribution, and efficacy of 
gene delivery in vivo. We reveal that these trehalose-coated polyplexes shield 
the formulations from nonspecific tissue internalization under slow tail vein 
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infusion, yet also retain stability in vivo following rapid hydrodynamic injection, 
resulting in the promotion of highly specific and excellent gene expression in the 
mouse liver (compared to jetPEI and pDNA only controls).  Indeed, this study 
demonstrates that trehalose-coated nanomedines offer a new stealth design 
motif that could provide an alternative to PEGylation for stabilizing formulations 
for in vivo administration. 
2.2 EXPERIMENTAL 
2.2.1 Materials and Reagents 
All reagents were obtained at the highest available purity from Thermo 
Fisher Scientific, Inc. (Pittsburgh, PA) or Sigma-Aldrich Co. LLC. (St. Louis, MO) 
and used as received unless noted otherwise. JetPEI was obtained from 
Polyplus-transfection SA (Illkirch, France).  Glycofect was obtained from 
Techulon, Inc. via donation. 6-Methacrylamido-6-deoxy trehalose (MAT) was 
synthesized as described previously.24 Propidium iodide, UltraPureTM Agarose-
1000, trypsin, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT), phosphate-buffered saline (PBS), Minimum Essential Medium with 
reduced serum (Opti-MEM) and Dulbecco’s Modified Eagle Medium (DMEM) 
were purchased from Life Technologies – Thermo Fisher Scientific (Carlsbad, 
CA). The pT2/CAL plasmid was prepared as described previously.35 The 
Luciferase Assay Kit and cell lysis buffer were obtained from Promega 
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Corporation (Madison, WI). Bio-Rad DC Protein Assay Reagent A, Reagent B 
and Reagent S were obtained from Bio-Rad Laboratories, Inc. (Hercules, CA). 
HepG2 and U87 cells were obtained from the American Type Culture Collection 
(ATCC) (Manassas, VA). The cells were grown in complete DMEM 
[supplemented with 10% (v:v) fetal bovine serum and 1% antibiotic-antimycotic 
solution (containing penicillin, streptomycin, and amphotericin B)] at 37 ºC and 
5% CO2 in a humidified incubator. 
Monomeric aminoethylmethacrylate (AEMt) was purchased from 
Polysciences (Warrington, PA). N-methyl-aminoethylmethacrylate (MAEMt), N,N-
dimethyl aminoethylmethacrylate (DMAEMt) and N,N,N-
trimethylammoniumethylmethacrylate (TMAEMt) was prepared with procedures 
shown in later chapters. 4-cyano-4-(propylsulfanylthiocarbonyl) sulfanylpentanoic 
acid (CPP) was synthesized according to a previous procedure.127 4,4’-Azobis(4-
cyanopentanoic acid) (V-501) was purchased from Aldrich and was crystalized 
from MeOH prior to use. Methacryloyl chloride was distilled to remove the free 
radical stabilizer. 2-Deoxy-2-methacrylamido glucopyranose (MAG) was 
prepared according to a previous publication.116 All other chemicals were 
purchased from Aldrich and used without further purification.  
Wild-type (WT) C57BL/6J 6wk-old mice were purchased from Jackson 
Laboratories (Sacramento, CA). All mice were maintained under AAALAC-
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accredited (Association for Assessment and Accreditation of Laboratory Animal 
Care) specific pathogen-free conditions.   
2.2.2 Instrumentation 
NMR spectra of P(MAT-b-AEMA) polymers and components were recorded 
using a Bruker Avance III HD 500 MHz spectrometer in D2O purchased from 
Cambridge Isotope Laboratories, Inc. (Andover, MA). NMR data was analyzed 
using Bruker Top Spin version 3.1. H NMR spectra of P(MAG-b-methacrylates) 
were recorded on a Varian INOVA-300 or Varian INOVA-500 NMR Spectrometer 
with D2O or CHCl3-d solvents. UV-Vis data was collected with an Ocean Optics 
Inc. CUV 1 cm cuvette holder powered by a Mikropack DH-2000 Deuterium/ 
Halogen open-close TTC lamp, and data was analyzed by Ocean Optics Inc. 
Basic Acquisition Software. 
Size exclusion chromatography (SEC) was conducted using an Agilent 
1260 High Performance Liquid Chromatograph running 1.0 wt% acetic acid/0.1 M 
Na2SO4 as the eluent at a flow rate of 0.4 mL/min. on size exclusion 
chromatography columns [CATSEC1000 (7 μ, 50×4.6), CATSEC100 (5 μ, 
250×4.6), CATSEC300 (5 μ, 250×4.6), and CATSEC1000 (7 μ, 250×4.6)] 
obtained from Eprogen Inc. (Downers Grove, IL). Signals were acquired using 
Wyatt HELEOS II light scattering detector (λ = 662 nm), and an Optilab rEX 
refractometer (λ = 658 nm). SEC trace analysis was performed using Astra VI 
 34 
 
software (version 5.3.4.18), Wyatt Technologies (Santa Barbara, CA). The 
hydrodynamic diameters of the polyplexes were recorded via dynamic light 
scattering measurements (DLS) with a Malvern Zetasizer Nano ZA. MTT, protein, 
and luciferase assay plates were analyzed using a Biotek Synergy H1 plate 
reader (BioTek Instruments, Inc., Winooski, VT). Cy5-uptake was measured on a 
FACSVerse (Becton Dickinson Biosciences, San Jose, CA) flow cytometer. TEM 
images were obtained with a FEI Tecnai G2 Spirit BioTWIN (FEI, Hillsboro, OR) 
transmission electron microscope, operated at 120 kV. 
Live animal and animal tissue imaging were performed on an IVIS 
Spectrum In Vivo Imaging system and data was analyzed with the Living Image 
software (PerkinElmer Inc., Waltham, MA). RT-qPCR was performed using an 
Eppendorf Mastercycler (software version 2.2; Eppendorf). 
2.2.3 Polymer Synthesis 
In the study focused on glucose-based materials, all synthesis and polymer 
characterization was conducted by Dr. Haibo Li. N,N-dimethylaminoethyl 
methacrylate hydrochloride (DMAEMt) was prepared by treatment of the neutral 
monomer (11.52 g, 73.28 mmol) with hydrochloride solution (9.5%, 27.40 mL) at 
0 oC, followed by removal of the solvent in vacuo and washed by mixed solvent 
of ethyl acetate and methanol (80:20 v:v) to give 12.07 g product. N,N,N-
trimethylammonium ethylmethacrylate iodide (TMAEMt) was prepared by 
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treatment of the N,N-dimethylaminoethyl methacrylate (12.39 g, 78.81 mmol) 
with MeI (5.90 mL, 94.57 mmol) in chloroform (60 mL), followed by removal of 
the solvent in vacuo to give 23.38 g product.  
MAEMt was prepared through a three-step reaction (Figure 2.2). First, 2-N-
methyl ethanol was protected by cooling a solution of methyl-2-aminoethanol 
(7.50 g, 100.12 mmol) in chloroform (50 mL) in an ice bath for 10 minutes. A 
solution of di-tert-butyl dicarbonate (BOC2O) (21.87 g, 100.12 mmol) in 
chloroform (50 mL) was added dropwise to the mixture over 30 minutes. The 
reaction was further stirred at 0 °C for 1 hour, after which, it was allowed to warm 
up to room temperature. The solvent was then removed in vacuo. After vacuum 
distillation, 16.29 g of product (93% yield) was obtained. For the second step, a 
solution of the product obtained from the previous step (BOC protected 2-N-
methyl ethanol, 15.73 g, 89.77 mmol) in chloroform (150 mL) was cooled in an 
ice bath for 10 minutes. Triethyl amine (16.00 mL, 115.07 mmol) was then added 
to the solution in one portion. After which, methacryloyl chloride (8.92 mL, 92.01 
mmol) was added dropwise over 10 minutes. The reaction was allowed to warm 
up to room temperature and was further stirred overnight. The reaction solution 
was then washed with water (150 mL) and dried over MgSO4. The desiccant was 
filtered off and the solution was concentrated in vacuo. The final product, BOC 
protected N-methylaminoethylmethacrylate, was obtained after purification with 
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column chromatography (with a mobile phase containing 25% ethyl acetate and 
75% hexane as the mobile phase (Yield: 16.74 g 74%).  
To deprotect, a solution of the product obtained from the previous step 
(16.16 g, 64.38 mmol) in HCl solution in MeOH (1.25 M, 180 mL) was cooled in 
ice bath for 1 hour and stirred at room temperature overnight. The solution was 
then concentrated in vacuo. 150 mL ethyl acetate was added to the residue to 
wash. The ethyl acetate was filtered off and the product was obtained as a white 
solid, which dried under vacuum to yield a white solid (Yield: 10.86 g, 94%). 
 
The P(MAG) macroCTA was prepared according to a procedure in one of 
our recent publications.116 To a 250 mL round bottom flask charged with nitrogen 
gas, MAG (6.00 g, 24.27 mmol), V501 (5.8 mg, 0.02023 mmol), CPP (56 mg, 
0.2023 mmol), acetate buffer (0.1 M, pH =5.2) (72 mL) and ethanol (18 mL) were 
added and stirred.  Nitrogen gas was allowed to purge the solution for 2.5 hours 
at room temperature.  After which, the solution (still under a nitrogen 
 
Figure 2.2. Synthesis scheme for methylaminoethylmethacrylate (MAEMT). 
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atmosphere) was heated to 70 oC and stirred for an additional 280 minutes. The 
reaction solution was quenched by via rapidly freezing the solution with liquid 
nitrogen and then exposing the contents to air. The solution was then transferred 
to dialysis tubing (MWCO 3500) and allowed to dialyze against ultra high purity 
water for three days (water was changed twice a day. The final solution was then 
lyophilized to dryness yielding 1.68 g of product. Yield: 28%.  
The following is a typical procedure used to prepare the diblock 
glycopolymers with the various cationic monomers.  The PolyMAG macroCTA 
(0.20 g, 0.01418 mmol), methacrylate chloride monomer (0.278 g, 1.5479 mmol), 
V501 (0.87 mg, 0.003096 mmol), and acetate buffer (1.0 M, pH=5.2) (2.40 mL) 
were added to a 5 mL vial charged with nitrogen gas and a mechanical stirring 
bar. The mixture was stirred to dissolve the reactants and the solution was 
purged with nitrogen gas for 30 minutes at room temperature.  Next, the reaction 
mixture was heated to 70 oC, and the reaction was stirred for 26 minutes. The 
solution was then dialyzed against water for three days and lyophilized to yielding 
0.23 g of the final glycopolycation final product.   
P(MAT)43 was synthesized as previously described.117 In the study focused 
on trehalose-based materials, all synthesis and polymer characterization was 
conducted by Dr. Zachary Tolstyka. Briefly, MAT monomer was polymerized via 
RAFT in acetate buffer. 4-cyano-4-(propylthiocarbonothioylthio)-pentanoic acid 
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was dissolved in 645 μL of MeOD and added to the MAT solution, followed by 
4,4’-azobis(4-cyanovaleric acid) (V-501) Finally, 861 μL of MeOD was added and 
oxygen was removed by bubbling nitrogen through the system for 45 min. The 
flask was heated to 70 °C for 6 h and the reaction was stopped by removing the 
septum and cooling the reaction mixture on ice. The polymer solution was 
dialyzed against ultra-pure water (3500 Da MWCO) acidified to pH 4-5 with HCl. 
After 3 d of dialysis, the polymer solution was freeze dried on a VirTis benchtopK 
lyophilizer at 62 mT with the condenser at -57.4 °C to yield 454 mg of white solid. 
See the appendix for an P(MAT)43 H NMR spectrum.   
Cationic diblock copolymers were synthesized as previously reported.117 
Briefly, P(MAT)43 and V-501 were dissolved in 1.0 M acetate buffer (pH = 5.5) 
and added to a Schlenk tube containing aminoethylmethacrylamide 
hydrochloride (AEMA). Deoxygenation was achieved via bubbling nitrogen gas 
for 45 min. The tube was heated to 70 °C. Aliquots (1.25 mL) were removed via 
syringe at 30 min [P(MAT-b-AEMA)-1] and 60 min [P(MAT-b-AEMA)-2]. Each 
aliquot was exposed to air and cooled in liquid nitrogen to stop polymerization. 
After 90 min [P(MAT-b-AEMA)-3], the reaction was halted by septum removal 
and submerging the Schlenk tube in liquid nitrogen. All three copolymers were 
dialyzed (3500 Da MWCO) against 0.5 M NaCl solution, followed by 0.1 M NaCl 
and finally ultra-pure water. All dialysis media were acidified with HCl to pH 4-5. 
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Polymer solutions were lyophilized as described above to yield white, flocculent 
powders. All experiments were completed using polymers P(MAT-b-AEMA)-1, -2, 
and -3. Polymer 1H NMR and SEC characterization results can be found in the 
appendix. 
 P(MAT-b-AEMA)-2 was labeled using an NHS-Cy7 fluorophore by 
dissolving it in H2O. Cy7 functionalized with N-hydroxysuccinamide (NHS-Cy7) in 
DMF was added followed by DMF to target 1 fluorophore/50 amine residues. The 
mixture was vortexed for 30 s and allowed to proceed at room temperature for 4 
h in the dark. The labeled polymer was purified via dialysis (3500 MWCO) 
against H2O (acidified to pH ~5.5 with HCl) for 2 days and lyophilized using the 
same conditions listed before to yield a blue flocculent solid. The extent of Cy7 
tagging was quantified measuring the absorbance of a 0.2 mg/ mL of labeled 
polymer in H2O at 750 nm via UV-Vis (ε = 199000 at 750 nm, Abs = 0.16, Figure 
2.3) giving approximately 1 Cy7 fluorophore / 10 polymer chains. 
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2.2.4 Polyplex Characteristics 
Polymer solution at an appropriate concentration in water was added to a 
400 μM solution of pDNA in DNase/RNase-free distilled water in an equal volume 
to yield polyplexes of (nitrogen to phosphate ratios) N/P = 5, 7, 14,15, and 21 at a 
final concentration of 200 µM pDNA. The nitrogen ratios were calculated based 
on the concentrations of amines (either pendant from the cationic blocks or within 
the backbone of jetPEI or Glycofect). The solutions were incubated at 23 °C for 1 
h before further use. 
2.2.5 Gel Electrophoresis 
A gel electrophoresis mobility shift assay was run to determine the minimal 
amount of polymer needed to achieve complete binding of the pDNA. 10 μL of 
 
Figure 2.3. Absorbance of P(MAT-b-AEMA)-2-Cy7 in H2O used to calculate 
labeling efficiency (~1 Cy7 per 10 polymer chains) from the extinction 
coefficient for NHS-Cy7 (provided by the manufacturer, Lumiprobe Corp.). 
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each polyplex solution formulated at various N/P ratios were diluted with 10 μL of 
water to achieve a concentration of 100 μM and were incubated at 25 °C for 1 h 
to allow polymer-pDNA binding. The polyplex suspensions were run on agarose 
gels (0.6%) containing 6 µg ethidium bromide at 60 volts for 80 min. Images were 
obtained using 312 nm UV light. 
2.2.6 Dynamic Light Scattering (DLS) 
To measure polyplex size in a protein environment over time, DLS 
experiments were run in DMEM containing 10% FBS. The DLS measurements of 
all P(MAG-b-methacrylate) formulations were collected by Dr. Haibo Li. 
Polyplexes were formulated at N/P = 7, 14, and 21 in H2O and incubated for 1 h 
at a concentration of 200 μM pDNA (to allow complexation) before being diluted 
with DMEM containing 10% FBS by volume. For DLS studies prior to 
lyophilization, the polyplexes were diluted to a final concentration of 100 μM (T = 
0 h). For the post-lyophilization DLS, polyplexes were prepared and lyophilized 
as previously described, reconstituted with water for 1 hour, then diluted with 
DMEM with 10% FBS to 133 μM. Size measurements were taken at 25 °C using 
a 173° detection angle at times of 0 h, 1 h, 2 h, and 4 h. 
2.2.7 Transmission Electron Microscopy (TEM) Imaging 
3 µL of polyplex solution (formulated with pDNA and polymers P(MAT-b-
AEMA)-1, -2, or -3) prepared at N/P = 10 were applied to a 300-mesh carbon 
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coated copper grid (Ted Pella, Inc., Redding, CA). Excess polyplex solution was 
blotted off with filter paper after 60 s, and 3 µL of 1% uranyl acetate was applied, 
left for 60 s, then blotted off. The negative staining process was repeated twice 
more. Images were recorded using an EagleTM CCD camera (up to 4 mega 
pixels), and phase contrast was enhanced at 6-12 µm underfocus. Images were 
saved as TIFF files and polyplex size was analyzed by using ImageJ (see 
appendix for quantified data). All TEM images were captured by Dr. Yaoying Wu. 
2.2.8 Cell Viability Studies 
MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) was 
used to estimate the cytotoxicity of the polyplexes. HepG2 cells were seeded at 
50,000 cells/well in 24-well plates 24 h prior to transfection. Polyplexes were 
formulated as described previously, then 100 µL polyplex solution was diluted 
with 200 µL DMEM containing 10% FBS. 300 µL of that mixture was added to 
each well. The transfection was ended 4 h later by diluting polyplexes with 1 mL 
of complete DMEM containing 10% FBS.  48 h after polyplexes were added to 
the cells, 0.5 mg/mL of MTT was added to each well and incubated for 1 h. Cells 
were lysed using DMSO and 200 µL aliquots were transferred to a 96-well plate 
for analysis using the plate reader (absorbance was measured at 570 nm). Non-
transfected cells were used for normalizing the data. 
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2.2.9 Cell Uptake Assay 
Flow cytometry experiments were performed to examine the cellular uptake 
of Cy5-labeled pDNA 4 h post-transfection. HepG2 cells were seeded at 300,000 
cells/well in 6-well plates 24 h prior to transfection. Polyplexes were prepared as 
described in the MTT assay protocol, except that the formulation was scaled up 
from 50,000 cells to 300,000 cells. After 4h, the polyplex media was removed 
and cells were detached from the plate surface using trypsin, centrifuged to 
remove polyplexes and trypsin, and then washed twice with PBS. Finally, 1 mL 
PBS was added and the cellular suspensions were kept on ice. Propidium iodide 
(1.0 mg/mL, 2.5 µL) was added prior to analysis. Each experiment was 
performed in triplicate. 
2.2.10 Gene Expression Assays 
Cells (HepG2) were seeded at 50,000 cells/well in 24-well plates 24 h prior 
to transfection. Polyplexes were prepared, diluted, and applied to the cells as 
described in the cytotoxicity section above. After 48 h, the cells were washed 
with PBS and treated with cell lysis buffer.  Aliquots (5 µL) of cell lysate combined 
with 100 µL luciferase substrate were examined in 96-well plates using a 
luminometer to determine relative light units (RLUs). Data were measured in 
triplicate and normalized for the amount of protein in each sample. Sample 
averages were plotted with error bars representing standard deviations. 
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2.2.11 Mouse Injections 
Appropriate amounts of polyplexes (10 µg or 25 µg of pDNA/dose at 
desired N/P of polymer) were prepared in a 5% by weight aqueous dextrose 
solution (D5W, Hospira, Inc.). For a standard tail vein injection, a 200 µL dose of 
polyplexes was injected through the tail vein of experimental animals. For 
hydrodynamic injections, a previously published procedure was used. Briefly, 
animals to be injected were weighed.  A polyplex solution with a volume 
equivalent to 10% of the weight of the mouse was injected in 3 to 4 s. After 
injection, animals were placed on a heating pad to recover, then returned to their 
colony. Mice were either imaged for luciferase transgene expression about 24 
and 48 h after transfection or imaged immediately after injection for Cy7 polymer 
fluorescence. After fluorescence imaging, mice were euthanized and their organs 
were imaged ex vivo. 
2.2.12 Mouse Imaging 
For luciferase imaging, 100 μL of luciferin substrate solution (28.5 mg/mL) 
was injected intraperitoneally to each mouse. 3 to 5 min later, mice were imaged 
for 1 min using a Xenogen Spectrum CCD camera system (Xenogen, Alameda, 
CA) according to the manufacturer’s instructions.  Each experiment was 
performed in triplicate.   
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After imaging mice for Cy7 fluorescence (data not shown for 
hydrodynamically injected animals), mice were euthanized by carbon dioxide 
(CO2) inhalation, perfused with saline, and selected organs were resected and 
preserved for analyses. Plasma and tissues were stored at –80 C.  Frozen 
tissues were homogenized by mortar and pestle, and ~100 mg of each tissue 
sample was removed for DNA processing. DNA was pulled from the organs 
using a phenol-chloroform extraction and ethanol precipitation. DNA purity and 
concentration were determined by using a NanoDrop instrument. 
2.2.13 qPCR 
DNA samples were normalized to 100 ng/μL.  500 ng of DNA was used with 
TaqMan Gene Expression Master Mix (Life Technologies – Thermo Fisher 
Scientific, Carlsbad, CA). TaqMan primers were designed and manufactured by 
Life Technologies – Thermo Fisher Scientific (Carlsbad, CA), Custom Plus 
TaqMan Assay, Assay ID – AJ6RNJ4.  A standard curve was prepared by 
serially diluting pT2/CAL plasmid into WT C57BL/6 DNA.  Samples were run 
using the impulse setting. The following conditions were used for the qPCR 
experiments: 95 °C for 10 min and 40 cycles of 90 °C for 15 s then 60 °C for 1 
min. QPCR experiments were performed by Jason Bell. 
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2.2.14 Statistical Analysis 
Statistical analysis was performed using JMP Pro Software (SAS Institute, 
Cary, NC) through the University of Minnesota Supercomputing Institute. 
2.3 RESULTS 
2.3.1 Polymer Synthesis and Characterization 
Trehalose is a carbohydrate with unique cryo- and lyo-protectant properties, 
which have prompted the use of this carbohydrate in materials synthesis to both 
retain and enhance these protective abilities.117-121, 128 Previously, we have 
shown that trehalose-containing block copolymers are effective in the formulation 
of polyplexes and efficient delivery of siRNA.117 Herein, we sought to examine 
these trehalose-based polycations for delivery of plasmids to cells in culture and 
in organs of living animals. Trehalose-based polymers were synthesized via 
reversible-addition-fragmentation chain-transfer (RAFT) polymerization with a 
65:1 monomer: chain-transfer agent (CTA) ratio of 6-methacrylamido-6-deoxy 
methacrylamido trehalose (MAT) and 4-cyano-4-(propylthiocarbonothioylthio)-
pentanoic acid (CPP) with 4,4′-azobis(4-cyanovaleric acid) (V-501) as the initiator 
to yield P(MAT) with 43 repeats. This 43-repeat unit P(MAT) was used as a 
macro CTA and chain-extended via RAFT polymerization with 125 equivalents of 
N-(2-aminoethyl) methacrylamide (AEMA) and V-501 as the initiator to yield three 
cationic block copolymers (Table 2.1),117 P(MAT-b-AEMA)-1 (21 repeats), -2 (44 
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repeats), and -3 (57 repeats), with each having the same length of MAT block but 
increasing lengths of the AEMA block. 
 
2.3.2 Polyplex Formation and Characterization 
These polymers were combined with pDNA encoding for the luciferase 
reporter gene to form polyplexes. The amount of polymer needed to fully bind the 
pDNA was first determined via gel electrophoresis. Polymers and pDNA were 
mixed at nitrogen-to-phosphate (N/P) ratios of 1, 2, 3, 4, 5, and 10, mixed with 1 
µL of running buffer and electrophoresed through a 0.6% w/w agarose gel 
containing ethidium bromide in TAE buffer. The gel was imaged under UV light to 
confirm binding (Figure 2.4). Anionic plasmid that remains uncomplexed by the 
Table 2.1. Summary of Polymer Molecular Weight and Composition 
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cationic polymer migrates through the gel toward the positively charged anode 
whereas fully complexed DNA does not. All polymers fully bound the DNA at 
N/P=5.  
 
A)
+
-
1234510 1234510 1234510
B)
 
Figure 2.4. Gel electrophoresis shift assay to measure pDNA binding by A) 
P(MAG-b-MAEMT) and B) P(MAT-b-AEMA) polymers. All P(MAG-b-MAEMT) 
polymers completely bound pDNA by N/P of 3, while P(MAT-b-AEMA) 
polymers bound pDNA at N/P = 5.  
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For further studies, each polymer was combined with DNA at three different 
N/P ratios: 7, 14, and 21, yielding nine polyplex formulations. Polyplex size and 
stability from aggregation in biological media containing serum (10% by volume 
fetal bovine serum, FBS) were examined via dynamic light scattering (DLS). We 
have previously shown that polyplexes formed from this polymer and siRNA have 
a positive ζ–potential in H2O. Polyplexes were formulated at 200 µM pDNA and 
allowed to complex for 1 h at 23 ˚C in water. The polyplexes were then diluted 
with Dulbecco's Modified Eagle Medium (DMEM) containing 10% by volume fetal 
bovine serum (FBS) solution to a final concentration of 100 µM in pDNA, and the 
polyplex size was monitored over 4 h (Figure 2.4). ζ–potential of these 
polyplexes was not collected as the presence of FBS disrupts the measurement. 
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Figure 2.5. Polyplex size monitored by dynamic light scattering (DLS) over 
time. 0 h measured initial polyplex formulation (at 200 µM pDNA 
concentration) in water followed by dilution to 100 µM pDNA in A) OptiMEM, 
B) OptiMEM, or C) DMEM containing 10% FBS from 1 to 4 hours post-dilution. 
The error bars represent standard deviation of triplicate measurements. 
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Trehalose polyplex size (~50-100 nm in diameter) remained consistent over 
the course of this experiment relative to the control polyplexes, jetPEI (N/P=5) 
and Glycofect (N/P=20), which increased in diameter with time. It is proposed 
that the jetPEI and Glycofect polyplexes aggregate with amino acids, buffer salts, 
and FBS proteins found in DMEM, which neutralizes their surface charge and 
causes aggregation. The trehalose polyplexes neither aggregate nor swell 
compared to the control complexes. This result mirrors what has been observed 
previously with carbohydrate-based block-co-polycations: poly 2-deoxy-2-
methacrylamido glucopyranose-b-N-(2-aminoethyl) methacrylamide [P(MAG-b-
AEMA)] polyplexes formulated with pDNA116 and P(MAT-b-AEMA) polyplexes 
formulated with siRNA.117 Polyplexes formed with cationic polymers containing a 
carbohydrate block are protected from aggregation. The pendant trehalose units 
of the MAT portion of the block copolymer likely form a shell around the outside 
of the polymer-pDNA polyplex, providing a highly hydrophilic layer and facilitating 
steric stabilization of the polyplexes in biological media. 
2.3.3 Cell Viability 
Examination of the polyplex function was performed on two human cell lines 
with differing physiological function to assess the general biologic activity of the 
polyplex formulations. Cell culture studies of polyplex internalization and 
luciferase gene expression were performed in both HepG2 liver carcinoma and 
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U87 glioblastoma human cell lines. We chose to examine two cell lines as we 
have found polyplex behavior to vary substantially in different cell lines. This 
behavior is difficult to predict and must be determined experimentally. These 
assays were run in DMEM containing 10% FBS to understand the role of serum 
in the transfection conditions. First, a colorimetric live-dead cell study was 
performed to assess the cytotoxicity of polyplexes formed from the P(MAT-b-
AEMA) and control polymers with pDNA. The 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide MTT assay is a commonly used viability assay that 
measures mitochondrial activity.129 Cells were exposed to polyplexes in DMEM 
containing 10% FBS for 4 h then incubated for 48 h prior to running an MTT 
toxicity assay. Survival of each sample was normalized to a negative control of 
cells that were exposed to neither pDNA nor polymer (Figure 2.6). 
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With HepG2 cells, most samples did not differ in value from the negative 
control of naïve cells for either the glucose- or trehalose-based polymers. No 
P(MAG-b-MAEMt) sample statistically decreased cell viability below the cells only 
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Figure 2.6. Cell viability as measured via MTT assay with HepG2 cells in 
DMEM + 10% FBS with A) P(MAG-b-methacrylate) polymers of varying length 
and N/P ratio and B) P(MAT-b-AEMA) of increasing length and N/P ratio. Error 
bars represent the standard deviation from three replicates. All measurements 
found to be statistically different (Student’s t test p < 0.05) as compared to 
cells only are marked with an asterisk.  
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control. Only the P(AEMA) and P(MAT-b-AEMA)-3 polyplexes formulated at an 
N/P=7 showed cell survival rates of less than 100%. None of the P(MAT-b-
AEMA)-1 formulations were found to cause a significant decrease in cell survival 
when compared to naïve cells grown without polyplexes present via the Student’s 
t-test (p = 0.05).77, 130, 131 Neither jetPEI nor Glycofect were toxic to HepG2 cells. 
The P(MAT-b-AEMA) with shorter AEMA block lengths had equal or higher levels 
of cell survivability than any of the controls, which also reflects previous work 
showing the biocompatibility of trehalose polymers.77, 78, 132 
2.3.4 Gene Expression 
The effectiveness of polyplex transfection and plasmid cargo uptake was 
assessed by measuring expression of a luciferase reporter gene. Polyplexes 
were formed and incubated with cells for 4 h in DMEM containing 10% FBS, 
followed by an additional incubation period of 48 h to allow for protein 
expression. Cells were washed, lysed, and the lysate analyzed for luminescence 
intensity after treatment with luciferin. In Figure 2.7, luminescence was plotted as 
relative light units (RLUs) per protein (mg) in each sample to normalize for the 
number of cells in each well, thus negating differences in expression due to cell 
death. It was observed in Figure 2.7A that an increase in the N/P ratio for most 
polymers did not show a significant increase in luciferase gene expression. 
However, the luciferase expression results did show a general trend when 
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considering the amine type. The transfection efficiency decreased slightly as the 
amount of methyl groups on the amine increased (secondary > tertiary > 
quaternary), suggesting that the P(MAEMt)-containing polymers should be 
further optimized and examined for nucleic acid delivery. 
In Figure 2.7B, jetPEI polyplexes yielded the highest levels of luciferase 
expression and were statistically higher than the other formulations. Therefore, 
statistical comparison was recorded against the cells only and the P(AEMA) 
homopolymer controls. Mirroring the cell uptake data, P(MAT-b-AEMA)-2 
samples had the highest level of expression, with lower expression for the 
shorter and longer cationic block polymers. This further supports that hypothesis 
that the amount of cationic charge can help transfection to a point before it starts 
to hinder uptake and expression. 
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Figure 2.7. Gene expression as measured by the luminescence of HepG2 cell 
lysate following the addition of luciferin reagent. Cells were transfected using 
A) P(MAG-b-methacrylates) and B) P(MAT-b-AEMA) in DMEM + 10% FBS. 
Data were normalized for cell death. Error bas represent the standard 
deviation from three replicates. All measurements found to be statistically 
different (Student’s t test p < 0.05) as compared to cells only are marked with 
an *. Samples found to be significantly higher than the positive control 
p(AEMA) are marked with a +, and samples found to be statistically equivalent 
to P(AEMA) are marked with an = (Student’s t-test p < 0.05). 
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In previous work, we have found that polyplexes formed with glucose-
containing P(MAG-b-AEMA) exhibited higher transfection efficiency with a 
shorter length of AEMA when made with siRNA and a longer AEMA block when 
formulated with plasmid DNA (pDNA).116 Polyplexes formulated with trehalose-
block copolycations, P(MAT-b-AEMA) and siRNA also displayed better 
transfection with a shorter AEMA block than with longer blocks.117 Among the 
trehalose polyplex formulations studied herein from N/P=7 to N/P=21, luciferase 
expression increased 8 fold in HepG2 cells for P(MAT-b-AEMA)-1 and decreased 
with N/P with P(MAT-b-AEMA)-3. For P(MAT-b-AEMA)-2 polyplexes, luciferase 
expression was statistically equivalent from N/P = 7 – 21 to expression values 
from P(AEMA) polyplexes in HepG2 cells. Gene expression with P(MAT-b-
AEMA)-2 polyplexes was also statistically equivalent to that yielded by P(AEMA) 
at N/P = 7. 
The P(MAT-b-AEMA)-2 formulations were the only P(MAT-b-AEMA)-based 
polyplexes to exhibit luciferase expression at the same level as any of the control 
polymers. This trend was similar to the cellular uptake data, again supporting the 
hypothesis that AEMA (and therefore positive charge) does aid cellular 
internalization and expression to a point. However, with a further increase in the 
N/P ratio, expression values start to decrease. The decrease could be due to two 
factors: i) prevention of the release and transcription of DNA cargo116 or ii) by 
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increasing cell membrane permeability to the point of toxicity.24, 129 Because 
luminescence RLUs are normalized to the amount of cell protein in each sample, 
cytotoxicity is not enough to account for low expression in either cell line. It is 
more likely that polyplexes with large AEMA blocks and high polymer-to-plasmid 
ratios have higher charge densities that prevent cargo release and 
transcription,116, 133 while complexes with too little AEMA or too small an N/P ratio 
could prematurely release DNA prior to nuclear entry.134 We were not as 
concerned with this latter issue due to the stability of the polyplexes that was 
observed in the DLS data. It should be noted that differences between some 
samples are not statistically significant, but the general trend that appears in the 
uptake assays as well as gene expression studies for both cells lines correlates 
with previous work in the field.116, 125, 130, 133  
After the large luciferase screen, a smaller group of P(MAG-b-methacrylate) 
polymers was chosen to further test for transfection efficiency and cellular 
internalization (vide infra) via flow cytometry analysis. This smaller group of 
polymers was designed to be an orthogonal study to include the three different 
amine types containing comparable charge block lengths, P(MAG-b-MAEMt)-3, 
P(MAG-b-DMAEMt)-3, and P(MAG-b-TMAEMt)-3. As the secondary amine 
derivatives yielded the highest gene expression in the preliminary screen, 
P(MAG-b-MAEMt)-1 and -2 were also included to further investigate the effect of 
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amine length on transfection efficiency.  All additional tests were performed by 
formulating the polyplexes at an N/P ratio of 15. To further probe transfection 
efficiency in a quantitative manner, green fluorescent protein (GFP) was used as 
the reporter gene and analyzed using flow cytometry (P(MAT-b-AEMA) was not 
tested using the GFP method). In DMEM containing 10% (by volume) fetal 
bovine serum, transfection efficiency decreased as methyl substitution of the 
amine increased (Figure 2.8, horizontal striped bars), which agreed with the 
luciferase expression data. When examining the effect of amine length (Figure 
2.8, green bars), P(MAG-b-MAEMT)-1 and -2 showed similar transfection 
efficiency, while the longest of that polymer series, P(MAG-b-MAEMT)-3, 
exhibited significantly lower GFP expression (p value < 0.05) than the shorter 
polymers. 
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2.3.5 Cell Uptake 
To quantify the amount of plasmid cargo taken up by cells, pDNA was 
fluorescently labeled with cyanine 5 (Cy5) prior to transfection. Polyplexes were 
formulated and exposed to the cells as previously described for the MTT assay. 
After transfection, cells were washed, collected, and centrifuged to concentrate 
the cells in solution and analyzed via flow cytometry. After the first run, 2.5 µL of 
propidium iodide (PI) was added to the remaining samples in each tube and left 
to sit for 30 min at room temperature prior to re-analysis. Cells positive for PI 
were assumed to be dead or dying and were removed from gating. Data were 
plotted as a percentage of live cells positive for Cy5 (Figure 2.9). 
N/P = 15 15 15 155 15
 
Figure 2.8. Total GFP fluorescence (number of events measured multiplied by 
mean GFP fluorescence intensity) of HepG2 cells analyzed by flow cytometry. 
Cells were transfected using P(MAG-b-methacrylate) polymers in DMEM + 
10% FBS. Error bas represent the standard deviation from three replicates. All 
measurements found to be statistically different (Student’s t test p < 0.05) as 
compared to cells only are marked with an asterisk. 
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For the cellular internalization results, all samples were statistically 
compared to the negative control cells exposed to non-complexed pDNA. For 
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Figure 2.9. Flow cytometry analysis of pDNA-Cy5 cargo carried by A) P(MAG-
b-methacrylates) and B) P(MAT-b-AEMA) into HepG2 cells. Cells were 
transfected using A) P(MAG-b-methacrylate) polymers and B) P(MAT-b-
AEMA) in DMEM + 10% FBS. Error bas represent the standard deviation from 
three replicates. All measurements found to be statistically different (Student’s 
t test p<0.05) as compared to cells only are marked with an *. Samples found 
to be significantly higher than the positive control jetPEI are marked with a +, 
and samples found to be statistically equivalent to jetPEI are marked with an = 
(according to Student’s t-test with p < 0.05). 
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uptake of P(MAG-b-methacrylate) polyplexes (Figure 2.9A), P(MAG-b-MAEMt)-1 
and -3 showed the highest uptake, while P(MAG-b-MAEMt)-2 uptake levels 
tapered off to about the same uptake as P(MAG-b-DMAEMt)-3 and P(MAG-b-
TMAEMt)-3. P(MAG-b-TMAEMt)-3 showed the lowest Cy5 intensity among the 
polymers, but still showed significantly higher Cy5 intensity than both cells only 
and jetPEI. Although jetPEI usually demonstrates relatively high cell uptake, it is 
known that the presence of serum hampers jetPEI cell uptake.125 This illustrates 
that polyplex interactions with transfection media plays an important role in gene 
delivery. 
In Figure 2.9B, all but one polyplex formulation had higher Cy5 percentages 
than DNA alone, with P(AEMA) having the highest uptake, followed by P(MAT-b-
AEMA)-2, then P(EG-b-AEMA) and jetPEI. P(MAT-b-AEMA)-2 at all three N/P 
ratios tested had the highest level of polyplex uptake when compared to the other 
trehalose block-co-polycations formulations (and were statistically superior to the 
positive control jetPEI in HepG2 cells), which correlates with the high gene 
expression seen in Figure 2.11 (vide infra). P(MAT-b-AEMA)-1 and -3 polyplexes 
have lower uptake compared with either P(MAT-b-AEMA)-2 with some 
formulations barely exceeding background levels. This trend suggests that more 
positive charge promotes uptake to a point, then begins to limit uptake. While it 
was expected that P(AEMA) polyplexes would have very high uptake due to its 
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high amount of positive charge, it was also predicted to be the most toxic. 
Surprisingly, we did not observe any effects of cell death with P(AEMA) 
polyplexes (at N/P = 7) and thus, this did not impact uptake values. Also, it 
should be noted that both P(MAT-b-AEMA)-2 and- 3 polyplex formulations at 
N/P=7 had cell uptake comparable to that of P(EG-b-AEMA).116, 125 
2.3.6 Lyoprotectant Properties 
To examine the polyplex formulations further, transmission electron 
microscopy (TEM) was used to image the formulations before and after 
lyophilization. Each of the polymers [P(MAT-b-AEMA)-1, -2, or -3] were mixed 
and allowed to complex with pDNA at N/P=10 in water for 1 h at 23 ˚C, then the 
sample was divided into two portions. The unlyophilized portions were imaged by 
TEM immediately (Figure 2.10a-c), and the lyophilized samples were imaged 
after reconstitution and resuspension (Figure 2.10d-f). For comparison, TEM 
images of P(MAG-b-MAEMt)-3 and P(MAG-b-DMAEMt)-3 both at N/P=15 are 
shown in Figure 2.10g-h.83 Image analysis was used to quantify the polyplexes in 
the TEM images (Figure 7.21, Appendix). In addition, the lyophilized polyplexes 
hydrodynamic diameters were measured by DLS after one round of lyophilization 
(Figure 7.22A, Appendix) as well as an additional second round of lyophilization 
(Figure 7.22B, Appendix).  
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No significant size or shape differences were observed between the fresh 
polyplexes and those reconstituted following lyophilization. We have recently 
reported that polyplexes formed with P(MAT-b-AEMA) and siRNA maintained 
size and biological activity following lyophilization and resuspension. The 
particles appear slightly smaller in the TEM images than via DLS, likely due to a 
combination of dehydration of the particles during TEM sample preparation135 
and the preference of the negative stain for the highly-charged core of the 
particle.136 
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Luciferase expression assays were completed as previously described 
except the assay was performed on U87 cells instead of HepG2 cells. The 
expression for each lyophilized polyplex sample was normalized to samples 
made with the same polymer that had not been lyophilized. Figure 2.11 shows 
this data as a percentage of gene expression retained for each round of 
lyophilization. 
g h
 
Figure 2.10. TEM images of polyplexes formulated with P(MAT-b-AEMA)-1 (a 
and d), -2 (b and e), and -3 (c and f), respectively, at N/P=10, as well as 
P(MAG-b-MAEMt)-3 (g) and P(MAG-b-DMAEMt)-3 (h) polyplexes at N/P=15. 
Polyplexes from (a, b, c) were imaged prior to lyophilization, with images (d-f) 
taken after lyophilization and reconstitution to original concentration in water. 
Polyplex samples (g-h) were prepared as usual in water with no lyophilization. 
Samples were negatively stained with uranyl acetate and all scale bars 
represent 100 nm. 
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Following a single round of lyophilization and reconstitution, only the two 
polymers containing a sugar moiety, P(MAT-b-AEMA)-2 and Glycofect, retained 
any ability to transfect U87 cells. P(MAT-b-AEMA)-2 exhibited expression equal 
to 69% of its initial level while Glycofect was reduced to 4%. It is hypothesized 
that the P(MAT-b-AEMA) polyplexes form a core-shell structure with the 
trehalose-containing block coating the external surface of the polyplex, aiding 
polyplex stability during the lyophilization process. Neither Glycofect nor jetPEI 
polyplexes contain stabilization layers leaving these formulations susceptible to 
aggregation via the lyophilization procedure. Interestingly, the P(EG-b-AEMA) 
was expected to have a similar polyplex structure (containing a hydrophilic PEG 
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Figure 2.11. Luciferase expression in U87 cells following transfection with 
lyophilized polyplexes. Luciferase expression from lyophilized samples was 
normalized to the expression data from non-lyophilized polyplexes for each 
polymer. Error bars mark the standard deviation from triplicate measurements. 
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shell coating) to the P(MAT-b-AEMA)-2, however it did not retain transfection 
capability following lyophilization. The trehalose blocks appear to impart a unique 
protective property to polyplexes for potential lyophilization and storage.  
2.3.7 In Vivo 
Polyplexes formed from P(MAT-b-AEMA)-2 and pDNA had the highest level 
of gene expression in cultured cells in vitro and low toxicity at the three tested 
N/P ratios; these promising properties led to the selection and examination of this 
formulation in vivo. Murine studies with P(MAT-b-AEMA)-2 were explored for 
delivering luciferase-encoding pDNA with C57 black 6 (C57BL/6) mice. Tail vein 
injection was used to probe for biodistribution, toxicity, and transfection of the 
polyplexes in a living organism.  
Mice treated via standard tail vein injections were administered with one of 
four polyplex formulations in 5% dextrose (D5W, Figure 2.12) and a fifth control 
sample of D5W only. Importantly, with all formulations, all mice survived to the 48 
h endpoint of the study with no noticeable health deterioration. All mice were 
active and showed no signs of lethargy nor ill health effects after being dosed 
with up to 490 μg of polymer per mouse (the equivalent of 19.6 mg/kg of 
polymer/mouse). Following tail vein injection, the mice were then injected 
peritoneally with luciferin at 24 and 48 h after polyplex injection and imaged using 
a bioluminescence Xenogen Spectrum CCD camera system (data not shown). 
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Luciferase gene expression could not be detected either 24 or 48 h after the 
infusion of polymers. Following the 48 h imaging, all mice were euthanized and 
the heart, liver, lung, spleen, kidneys, and brain were harvested for analysis by 
qPCR to determine biodistribution of the pDNA cargo (Figure 2.12).137 QPCR 
analysis of the DNA extracted from those tissues revealed a nearly uniform 
distribution of genetic material throughout the organs. On a per-cell basis, pDNA 
was found at a range of 1.1 - 10 plasmid copies per cell in each organ (values 
less than or equal to 1.0 copies/cell cannot be resolved from the background). 
Hydrodynamic injection of 25 µg of pDNA, discussed in further detail below, 
typically achieves delivery of ~100 plasmids per cell in the liver, leading to 
significant gene expression.138, 139 The lower level of genetic material delivered to 
each of these organs following tail vein injection was insufficient to achieve 
observable gene expression. 
Multiple cyanine fluorophores, including Cy7, have been used successfully 
to tag DNA cargos for in vivo imaging.140-142 Using cyanine-3 labeled siRNA, 
Davis and coworkers have shown that tail vein-injected polyplexes begin urinary 
clearance within six min.142  Here, to determine if the polymer and pDNA reached 
the tissues with similar distributions (indicative of intact polyplexes), P(MAT-b-
AEMA)-2 was fluorescently labeled with Cy7 via amine-NHS coupling chemistry. 
Polyplexes were then formulated with P(MAT-b-AEMA)-2-Cy7 polymer and 25 μg 
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of pDNA at an N/P=7 and administered to mice via tail vein injections. Animals 
were imaged 15 min post-injection, euthanized, and the organs were harvested 
and imaged (Figure 2.12).  
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Figure 2.12. Representative fluorescence images of organs harvested from a) 
a mouse injected via the tail vein with P(MAT-b-AEMA)-2-Cy7 polyplexes and 
b) a naïve mouse measured with a Xenogen Spectrum CCD camera system. 
Excised tissues: 1, liver; 2, kidney; 3, heart; 4, lung; 5, spleen; 6, brain; 7, 
blood. Part c) shows the injection parameters and calculates the average 
number of delivered pDNA copies per genome equivalent (i.e. per cell) as 
measured by qPCR of DNA from the imaged organs. 
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Fluorescence was observed in the liver, spleen, kidneys, and lungs of the 
mice injected with the P(MAT-b-AEMA)-2-Cy7 (Figure 2.12). Fluorescence was 
not observed in the blood, indicating that the polymers/polyplexes had fully 
cleared the blood stream (at the detectable level). As expected, the organs from 
the naïve mouse also did not show fluorescence, indicating that the fluorescence 
visualized in the experimental mice arose from the Cy7-labeled polymer and not 
from background fluorescence from the tissues. 
Collectively, these data show that the concentration of plasmid delivered to 
each organ was insufficient to observe significant gene expression in the mice 
when delivered through a standard tail vein injection. Thus, a hydrodynamic 
injection technique was then examined to promote plasmid delivery specifically to 
the liver, wherein a large volume of DNA solution, typically 2 mL in a 20g mouse, 
is infused in 4-8 seconds.139 More than 99% of the gene can be localized to the 
liver143 as the high pressure appears to expand the liver endothelium promoting 
liver cell internalization and gene expression.143-145 Typically, naked plasmid DNA 
is used with this injection technique and results in high signals of gene 
expression, ~ 1010-1011 RLUs, in the liver when the firefly luciferase gene is 
placed behind a strong promoter such as the hybrid b-actin/cytomegalovirus 
(CAGGS) synthetic promoter (Scheme 1). The large volume injected combined 
with the high pressure has been found to strain the mouse, especially the cardiac 
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system146, 147 and the liver; it takes 24 to 48 h for the liver to recover from the 
injection.1, 4-5 However, while direct scale up of systemic hydrodynamic injection 
to larger mammals resulting in sustained transgene expression has yet to be 
achieved,148  it may be potentially translatable if the high pressure injection is 
isolated only to the organ of interest and formulation of DNA into polyplexes 
could improve delivery and gene expression. For example, Itaka and coworkers 
were able to perform a hydrodynamic injection directed to skeletal muscle by 
injecting into a limb isolated with a tourniquet.149 DNA delivered as a polyplex 
formulated from a PEG-poly-L-lysine cationic block copolymer showed increased 
expression and DNA lifetime in the tissue when compared to similar injections 
performed with naked pDNA.149 Nakamura and coworkers performed 
hydrodynamic injection followed by a luciferase assay on excised liver tissue and 
found that polyplexes formed with jetPEI yielded higher luminescence than naked 
pDNA.150 
Glycofect, jetPEI, and P(MAT-b-AEMA)-2 were used to deliver 10 µg of 
pDNA via hydrodynamic injection and compared to naked pDNA as a control 
(Figure 2.13e). All mice survived the high-pressure injections. To analyze gene 
expression, the mice were injected peritoneally with luciferin at 24 and 48 h and 
imaged with a Xenogen system (Figure 2.13c, d). Interestingly, jetPEI, despite 
being the most effective delivery vehicle in tissue culture, showed the lowest 
 73 
 
level of luciferase expression in the liver of all tested formulations via live-animal 
imaging. The luminescence level was found to be 2-3 orders of magnitude below 
that of the naked pDNA. Even when the amount of DNA was more than doubled 
to 25 µg, the luminescence level was still 1 to 2 orders of magnitude below that of 
the control. Glycofect was the more effective of the commercially available 
transfection agents but still performed an order of magnitude below the control. 
Polyplexes formed with P(MAT-b-AEMA)-2 transfected at a higher level than 
either of the commercially available polymers and maintained the same level of 
gene expression as the naked pDNA control. Taken together, these results show 
that P(MAT-b-AEMA)-2 polyplexes are capable of delivering DNA that can 
subsequently be expressed in vivo with minor toxicity. 
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Figure 2.13. Representative (N = 3) fluorescence images of organs harvested 
from a) a mouse hydrodynamically injected with P(MAT-b-AEMA)-2-Cy7 and 
b) a naïve mouse measured with a Xenogen Spectrum CCD camera system. 
Tissues: 1, liver; 2, kidney; 3, heart; 4, lung; 5, spleen; 6, brain; 7, blood. 
Luminescence mouse images c) after hydrodynamic injection with P(MAT-b-
AEMA)-2 and subsequent treatment with luciferin and d) a naive control 
mouse measured with Xenogen Spectrum CCD camera system. The 
luminescence images are representative to that observed for N = 3 replicates. 
Table e) summarizes luminescence data over 48 hours with corresponding 
polyplex formulation. Luminescence levels were averaged from the values 
obtained from 3 mice in each data set and are reported in photons/second (s). 
Samples found to be statistically different (Student’s t test) from P(MAT-b-
AEMA)-2 were marked with an asterisk. 
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It appears that the majority of the pDNA was delivered to the liver due to the 
high levels of gene expression observed. Polyplexes were again formed using 
the Cy7-labeled P(MAT-b-AEMA)-2 and injected hydrodynamically for further 
verification the delivery of intact polyplexes to the liver. Animals were injected, 
imaged 15 min post-injection, euthanized, and the organs were harvested and 
imaged (Figure 2.13a,b). The liver was the only organ to show significant 
fluorescence, indicating that the polyplexes stay intact during the hydrodynamic 
experiment as polymer and pDNA are localized to the liver and are responsible 
for yielding high levels of gene expression.  
2.4 CONCLUSION 
Glucose- and trehalose-containing cationic block copolymers were 
synthesized and their colloidal stabilization and gene delivery properties were 
examined in detail in vitro and in vivo. The block copolymers bound pDNA and 
remained stable over time even in the presence of serum. Studies in tissue-
cultured cells, however, indicated that both the cationic block length and polymer-
pDNA ratio are important factors in determining toxicity, cellular uptake, and gene 
expression. 
A comparable series of P(MAG-b-methacrylate) polymers was created to 
test the degree of pendant amine methylation as well as cationic block length. All 
polymers maintained a hydrodynamic diameter < 100 nm in serum solution as 
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well as a low toxicity profile. The P(MAG-b-MAEMT) polymers generally exhibited 
increased delivery efficiency as compared to polymers with more highly 
substituted amines. The P(MAT-b-AEMA) polymers also demonstrated high 
serum stability, low toxicity, and high levels of luciferase expression. In addition, 
they were also able to harness the unique property of trehalose as a 
lyoprotectant upon freeze-drying and resuspension, prompting in vivo studies of 
these formulations.117  
To test the biodistribution and toxicity of these trehalose-stabilized 
polyplexes in vivo P(MAT-b-AEMA)-2 was selected for murine studies. The mice 
appeared to suffer no ill health effects after being dosed with up to 490 μg of 
polymer per mouse (the equivalent of 19.6 mg/kg of polymer/mouse). 
Quantitative PCR studies were conducted to measure the plasmid amount in six 
major organs. The amount of plasmid present was very low, especially when 
compared to plasmid levels in the liver following hydrodynamic infusion.138, 139 
The low level of polyplex uptake by all tissues was insufficient to achieve 
detectable levels of luciferase gene expression. The widespread and roughly 
equal distribution of the polyplexed plasmid suggested that the trehalose 
polyplexes were colloidally stable during circulation and offer an excellent design 
motif for further in vivo delivery experiments. To determine the in vivo stability of 
the polyplexes (whether the polymer retained its cargo upon delivery), the 
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polymer was fluorescently tagged and the mice and their organs were imaged. 
After 15 min of polyplex circulation, fluorescence was detected in the organs 
where pDNA was found but not in the blood, which was consistent with results 
that injected polyplexes are cleared into the urine within 6 min.142  
A second injection method was then used to bypass extended circulation in 
the blood as a physical means to target polyplex delivery to a specific tissue. 
Accordingly, we performed a hydrodynamic infusion to force the majority of 
polyplexes to the liver,143-145 which resulted in significant luciferase expression. 
Indeed, gene expression was comparable to that seen in previous work with 
diseased mouse models,144 suggesting that genes coding for therapeutic proteins 
would also be expressed at high levels when complexed with P(MAT-b-AEMA)-2. 
Due to the large volumes required to perform hydrodynamic injection, it is difficult 
to expand the use of this delivery technique into higher mammal models.148-150 
Catheters are being explored to localize the high pressure to targeted tissues of 
interest, yet, it is still difficult to achieve sufficient pressure levels needed to 
promote successful naked plasmid delivery and gene expression in vivo. 
Polyplexing plasmids could offer a method to reduce the injection volume and 
pressure needed to maintain significant gene expression. To this end, we show 
that polyplexing pDNA does not appear to prohibit its delivery/expression through 
in vivo hydrodynamic delivery methods (in fact, higher gene expression was 
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observed) and shows promise to offer a way to formulate plasmids for direct 
catheter-based tissue administration. Overall, this work demonstrates the unique 
properties of trehalose for stabilizing polyplex formulations for lyophilization and 
delivery in vivo, important metrics for advancing new vehicles for clinical gene 
therapy applications. Additionally, these results illustrate that polyplex structure-
function relies not only on how the polymer and pDNA interact, but can also be 
affected by the solution environment whether in vitro or in vivo. Future work is 
aimed at applying these biodistribution and expression methods to further study 
the P(MAG-b-MAEMt) polymers for in vivo gene therapy applications as well as 
to probe how carbohydrate-based block copolymer polyplexes function in the 
blood stream. 
2.4.1 Appendix includes: 
Polymer 1H NMR spectra, polymer SEC chromatograms, P(MAG-b-
methacrylate) kinetic studies, P(MAG-b-methacrylate) cell viability, cell uptake, 
and gene expression studies conducted in OptiMEM, quantitative analysis of 
TEM images, and DLS of lyophilized P(MAT-b-AEMA) polyplexes.  
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CHAPTER 3: GLYCOPOLYCATION-DNA POLYPLEXES ARE 
HEMOCOMPATIBLE, STABLE, AND AVOID NONSPECIFIC 
ORGAN INTERNALIZATION IN VIVO 
Synopsis  
Gene therapy via genome editing holds great promise for the cure of 
monogenic diseases; however, nonspecific tissue distribution limits the 
bioavailability and application of nonviral delivery methods. Herein, we 
characterize the hemocompatibility and biodistribution of three block 
copolycations containing a hydrophilic and neutral glucose block chain extended 
with cationic secondary amines of three lengths, poly(methacrylamido 
glucopyranose-block-2-methylaminoethylmethacrylate) [P(MAG-b-MAEMt)-1, -2, 
-3]. One block copolycation control, P(EG-b-MAEMt), and a second 
homopolymer control, P(MAEMt), were synthesized and the ex vivo 
hemocompatibility and in vivo biodistribution of the formulations were examined 
in detail. The block copolymer vehicles avoided hemolysis, but activated 
complement protein. In vivo distribution results suggest P(MAG-b-MAEMt)-2 
polyplexes (N/P=5, 15) remained intact during circulation and avoided 
accumulation in six major organs, while P(EG-b-MAEMt) polyplexes were filtered 
out by mononuclear phagocytic organs. Avoiding non-specific organ capture can 
improve gene therapy efficacy by increasing genetic cargo bioavailability as well 
as decreasing expression in undesirable tissues. 
This chapter was adapted with permission from the reference below:  
1. Phillips, H. R.; Tolstyka, Z. P.; Hall, B. C.; Hackett, P. B.; Reineke, T. M. 
Glycopolycation-DNA Polyplexes are Hemocompatible, Stable, and Avoid 
Nonspecific Organ Internalization In Vivo. In preparation. 
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3.1 INTRODUCTION 
Genome editing holds great promise for the cure of monogenic diseases 
such as cystic fibrosis, Duchenne muscular dystrophy, hemophilia A and B, and 
epidermolysis bullosa.3-5, 151 However, tissue non-specificity limits the application 
of genetic therapeutics.4, 20, 21, 152, 153 Viral vectors provide efficient delivery of 
genetic cargo. However, packaging limitations, occasional safety issues such as 
immune response, and the high costs associated with mass production of 
clinical-grade viruses for treating large patient populations are major issues.17, 18, 
154 Polymers with the ability to condense and protect genetic material offer a 
promising alternative to viral vectors. They are relatively easy to produce 
compared to viral vehicles, can safely package various plasmid sizes, and have 
shown significant uptake in a wide variety of human cell lines.4, 17, 18, 20-22, 155 
Nonviral vehicles, however, generally struggle to deliver therapeutic amounts of 
genetic material in vivo due to various systemic and intracellular transfection 
barriers.20  
 Colloidal stability is an important delivery vehicle characteristic for 
preserving cargo bioavailability. Additionally, the vehicle diameters must fall 
within a range of approximately 50-500 nm to avoid renal filtration and to achieve 
cellular endocytosis.49 Vehicles must avoid swelling or aggregation, which can 
lead to disassembly or precipitation. Swollen vehicles expose their cargo to 
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nucleases that can digest the genetic payload as well as target the complexes for 
kidney filtration.27 Aggregation also enhances trapping of enlarged particles in 
lung capillary beds.4, 27, 29, 30 Opsonization, a particular aggregation process with 
blood serum proteins, also results in particles that are actively removed by the 
body’s mononuclear phagocyte system (also called the reticuloendothelial 
system).4, 26, 28 
Strategic polymer design can aid refinement of delivery vehicles that avoid 
aggregation and contribute other desirable properties such as stable DNA 
loading and protection, increased circulation time, low cytotoxicity, and high 
cellular uptake and consequently elevated gene expression.20, 49 To condense 
and protect DNA, most polymer vehicles are cationic and bind anionic DNA via 
electrostatic interactions to form interpolyelectrolyte complexes (polyplexes).156, 
157 When polyplexes are formulated at an N/P ratio (ratio of charged nitrogen to 
charged phosphate units) greater than 1, there is a net positive charge, which 
increases association with negatively charged cell membranes and promotes 
endocytosis.4 However, this positive charge can also lead to nonspecific protein 
interactions and aggregation.2 In addition, higher N/P ratios often lead to 
increased cellular toxicity.96, 158 Adding an uncharged hydrophilic block to a 
polycationic block forms a neutral and steric shell-like barrier around the cationic 
polyplex core to further protect the genetic material from degradation by 
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nucleases, decrease cell exposure to positive charge and nonspecific uptake, 
and prevent polyplex aggregation and premature blood clearance.20, 31, 159 
Through strategic polymer design, we created polyplexes that avoid aggregation, 
blood interaction, and non-specific tissue uptake. 
 Polyethylene glycol (PEG) is the most common neutral hydrophilic moiety 
used to increase polyplex biocompatibility, stability, and circulation time in 
vivo.160-162 PEG “brushes” as small as 2 kDa can block electrostatic interactions 
between negatively charged proteins and positively charged surfaces, and 
attachment of PEG (i.e., PEGylation) to cationic polymers can prevent red blood 
cell hemolysis and decrease interaction with blood proteins such as fibrinogen 
and albumin.161, 163, 164 PEGylation of polymer-DNA complexes generally 
improves biocompatibility compared to their non-PEGylated counterparts; 
however, it has made liposomes susceptible to accelerated blood clearance 
(ABC) after multiple doses.165-167 The clearance is not likely due to autoantibody 
activity, but may be a result of either complement activation due to blood serum 
binding or IgM production against the PEGylated liposomes.165, 167 Our lab 
specializes in developing biocompatible carbohydrate-based polymers that form 
colloidally stable, safe, and effective nonviral gene delivery vehicles.31, 58, 70, 83, 94  
 Carbohydrate-based polymers are often hydrophilic, nontoxic, and 
possess many hydroxyl groups for changing chemical and biological 
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functionality.31, 70 We previously designed carbohydrate-based polymers able to 
overcome intracellular barriers that have also demonstrated the potential to 
overcome extracellular barriers83 and have modified multiple sugars into 
monomers for Reversible Addition Fragmentation Chain-Transfer (RAFT) 
polymerization.31, 94, 95 Gene delivery vehicles composed of 
poly(methacrylamidoglucopyranose-block-2-methylaminoethylmethacrylate) 
(P(MAG-b-MAEMt)) displayed colloidal stability in serum and avoided nonspecific 
cell interaction with blood in vitro.159 By design, the sugar moieties are pendant to 
the polymer backbone, offering both hydroxyl groups for further chemical 
modification, such as the addition of targeting motifs, and accessible 
carbohydrate groups for cell surface receptor interaction.70 We chain extended 
the glucose-based polymers using cationic monomers with secondary, tertiary, or 
quaternary pendant amines in order to test the effect of the degree of methylation 
on polyplex cytotoxicity and efficiency of gene delivery.83 The glucose block, 
poly(methacrylamido glucopyranose) (P(MAG)), was shown to stabilize 
polyplexes in cell culture media. Polyplexes made with P(MAG) polymer 
containing secondary amine moieties, 2-methylaminoethylmethacrylate (P(MAG-
b-MAEMt)), displayed the highest gene expression in both cell lines, and was 
selected for further study herein.  
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 To further examine P(MAG-b-MAEMt) polyplex biocompatibility in more 
complex and relevant environments, this study aims to quantify the stability, 
hemocompatibility, and in vivo biodistribution of glycopolycation-DNA complexes 
in mice. Using P(MAG-b-MAEMt) polyplexes with increasing lengths of cationic 
MAEMt block denoted by a -1, -2, -3 suffix that previously demonstrated serum-
stability and gene-delivery capacity, we measured polyplex interactions with 
blood components and observed the biodistribution of polymer and pDNA cargos 
in mice after intravenous injection. We were unable to detect any differences in 
hemocompatibility with varying cationic block length, although P(MAG-b-MAEMt)-
1, -2, -3 polymer vehicles overall showed superior ex vivo hemocompatibility 
compared to analogous polycations containing PEG-based hydrophilic blocks 
(Figure 3.1). P(MAG-b-MAEMt)-2 polyplexes at N/P=15 also demonstrated 
stealth properties in vivo by avoiding capture by major organs in contrast to 
P(EG-b-MAEMt) polyplexes, which were trapped in the lungs, liver, and kidney 
(Figure 3.1). The results of this work generally support the importance of 
hemocompatibility studies and the ability for glucose-based vehicles to widely 
distribute in vivo; thus, offering a useful alternative to PEGylation for improving 
serum stability and systemic circulation for drug and nucleic acid delivery. 
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3.2 EXPERIMENTAL 
3.2.1 Materials and Methods 
All chemicals or reagents were purchased from Sigma Aldrich (St. Louis, 
MO) unless specified. Cyanine7 NHS ester (Cy7) was purchased from 
P(MAG-b-MAEMt)
P(EG-b-MAEMt)
 
Figure 3.1. P(MAG-b-MAEMt) polymers and P(EG-b-MAEMt) polymers are 
complexed with pDNA to form their respective polyplexes. Polyplex blood interaction 
was tested ex vivo and biodistribution patterns were determined in vivo. P(EG-b-
MAEMt) polyplexes at N/P=5  lysed red blood cells and were primarily trapped in the 
lungs, liver, and kidneys, whereas the P(MAG-b-MAEMT)-2 N/P=15 polyplexes did 
not lyse cells and distributed at low levels to all major organs. 
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Lumiprobe (Hallandale Beach, FL). The control polymer jetPEI was purchased 
from Polyplus Transfection Inc. (Illikirch, France) and Glycofect was donated by 
Techulon (Blacksburg, VA). Dulbecco’s Modified Eagle’s Medium (DMEM), fetal 
bovine serum (FBS), phosphate buffered saline (PBS), and nuclease-free water 
were purchased from Gibco (Carlsbad, CA), and a sterile 5% dextrose by weight 
in water (D5W) solution was purchased through DME Supply Group (Augusta, 
GA). Agarose powder and 10X tris-acetate-ethylenediaminetetraacetic acid 
(TAE) gel supplies were obtained from Fisher BioReagents (Hampton, NH). 
Plasmids (pT2/Cal) were prepared as previously described.87 
3.2.2 Blood, Biological Reagents, and Animals 
Human whole blood with and without 3.2% sodium citrate anticoagulant 
was purchased from Memorial Blood Centers (St. Paul, MN). Protamine sulfate 
was obtained from MP Biomedicals (Santa Ana, CA). Partial thromboplastin time-
Lupus anticoagulant reagent (PTT-LA), Neoplastin Plus, and 25 mM CaCl2 
solution was purchased through Diagnostica Stago (Parsippany, NJ). The MBL 
oligomer kit (kit no. 029), the MicroVue C4d (kit no. A008) and the MicroVue Bb 
Plus (kit no. A027) kits were all purchased from Quidel (San Diego, CA), and the 
preactivated zymosan positive control was obtained through Complement 
Technology, Inc. (Tyler, TX). Ten week-old C57BL/6 mice were obtained through 
the National Cancer Institute (NCI, Frederick, MD) and housed in pathogen free 
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conditions according to the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) requirements and fed a normal diet. Mice 
were handled per the Institutional Animal Care and Use Committee (IACUC) 
using an Institutional Biosafety Committee (IBC) approved protocol 
(1202A09921). Lysis buffer was purchased from Qiagen (Hilden, Germany), and 
proteinase K was obtained through Roche (Basel, Switzerland). 
3.2.3 Instrumentation 
1H NMR spectra were obtained in D2O at 23 °C using a Bruker Avance III 
HD 500 MHz spectrometer from Cambridge Isotope Laboratories, Inc. (Andover, 
MA), and analyzed the data on Bruker Top Spin 3.1 software. Polymer dispersity 
was analyzed using size exclusion chromatography (SEC) on an Agilent 1260 
High Performance Liquid Chromatography instrument (Santa Clara, CA) with 1.0 
wt% acetic acid/0.1 M Na2SO4 eluent at a 0.4 mL/min flow rate. The system used 
Eprogen (Downers Grove, IL) size exclusion columns, [CATSEC1000 (7 μ, 
50×4.6), CATSEC100 (5 μ, 250×4.6), CATSEC300 (5 μ, 250×4.6), and 
CATSEC1000 (7 μ, 250×4.6)], a Wyatt Dawn Heleos-II light scattering module (λ 
= 662 nm), and an Optilab T-rEX refractometer (λ = 658 nm). Data were 
analyzed with Wyatt Technologies Astra VI software version 5.3.4.18 (Santa 
Barbara, CA). Fluorescent polymer tagging was quantified on a CUV 1 cm 
cuvette holder with a Mikropack DH-2000 Deuterium/Halogen TTC lamp from 
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Ocean Optics Inc. (Dunedin, FL), and data were analyzed using Ocean Optics 
Inc. Basic Acquisition Software.  
DNA gels were visualized with a Spectroline BI-O-VISION Transilluminator 
(Westbury, NY) under the UV setting (312 nm) and imaged with a Samsung 
Galaxy S3 camera phone. Polyplex size over time was determined using a 
Brookhaven BI-200SM DLS system. The system included a Brookhaven Mini L-
30 HeNe laser (637 nm), a Brookhaven BI-NDO detector, a Brookhaven 
TurboCorr correlator, and a decalin bath. 
Hemoglobin absorbance was measured on a BioTek Synergy H1 hybrid 
plate reader (Winooski, VT) at 380 nm, 415 nm, and 450 nm. Morphology images 
were captured with differential interference contrast on an EVOS FL digital 
inverted microscope (Fisher Scientific, Pittsburg, PA), while all animal and tissue 
imaging was conducted on an IVIS Spectrum with an excitation wavelength of 
710 nm, an exposure time of 3 sec, and absorbance wavelength at 780 nm. 
Images were captured using Living Image software (PerkinElmer Inc., Waltham, 
MA). Animal tissue was bead milled with a BulletBlender from Laboratory Supply 
Network, Inc. (Atkinson, NH). Quantitative polymerase chain reaction (qPCR) 
experiments were performed using an Eppendorf Mastercycler (Hamburg, 
Germany). 
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3.2.4 Synthesis and Characterization of Polymers 
 The MAG and MAEMt monomers and the P(MAG-b-MAEMt) polymers 
were synthesized and characterized previously (Figure 3.2A, new MAEMt 
monomer 1H NMR in Figure 7.29, Appendix).83, 95, 168 The P(MAG-b-MAEMt)-1, -
2, and -3 polymers were synthesized using radical addition-fragmentation chain-
transfer (RAFT) polymerization for increasing lengths of time to generate 
increasing lengths of MAEMt blocks of 31, 42, 76 repeat units. The polymers 
were dialyzed for 4 days in water (MWCO 3500) and characterized by 1H NMR 
and size exclusion chromatography with static light scattering analysis. 
To synthesize the new P(EG-b-MAEMt) control for this study, we first 
synthesized a PEG chain transfer agent (CTA) by coupling a 2000 Da linear 
poly(ethylene glycol) methyl ether (mPEG, 4120 mg, 2.05 mmol, 1 eq) to a 
molecule of 4-cyano-4-(propylsulfanylthiocarbonyl) sulfanylpentanoic acid (CPP, 
1130 mg, 4.07 mmol, 2 eq) in the presence of 4-dimethylaminopyridine (DMAP, 
263 mg, 2.15 mmol, 1 eq) and N,N’-dicyclohexylcarbodiimide (DIC, 505 mg, 4.0 
mmol, 2 eq). The reaction was solvated by 50 mL methylene chloride + 80 mL 
toluene and run at 0 °C for 12 h, then warmed to room temperature for another 
20 h (Figure 3.2B). A crystalline byproduct, was filtered off and the golden yellow 
product was vacuum dried at 35 °C overnight (yield: 2219 mg, 42.3%).169 The 
PEG-CTA was characterized by 1H NMR (see Figure 7.30 Appendix). To chain 
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extend off the PEG macroCTA, 1 eq CTA (764 mg, 34 mmol) was mixed with 0.1 
eq 4,4′-azobis(4-cyanopentanoic acid) (V501, 12.2 mg, 44 × 10-3 mmol) and 56 
eq MAEMt monomer (2000 mg, 12 mmol) in 4:1 acetate buffer:ethanol at 70 °C 
for 14 hours under nitrogen atmosphere (Figure 3.2B-C). The polymer was 
purified by dialysis (3500 MWCO) in deionized water that was pH adjusted to 5-6 
with 12.1 M HCl for 3 days, followed by lyophilization to dryness (yield: 0.9 g, 
56%). The light yellow, flakey product was characterized by 1H NMR and SEC 
(see Figure 7.31 and Figure 7.32, Appendix). 
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 The same reaction conditions used to prepare P(EG-b-MAEMt) were used 
to polymerize the homopolymer control, except that CPP was used in place of 
the PEG macroCTA (Figure 3.2D). CPP (1 eq.; 30.7 mg, 111 × 10-3 mmol) plus 
 
Figure 3.2. Synthesis of (A) MAEMt monomer and (B) PEG macroCTA. 
Polymerization of (C) P(EG-b-MAEMt) and (D) P(MAEMt). 
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0.1 eq. V501 (4.04 mg, 14.4 × 10-3 mmol) and 56 eq MAEMt monomer (1000 mg, 
6.24 mmol) were dissolved in 4:1 acetate buffer:ethanol and reacted at 70 °C for 
14 h under nitrogen atmosphere. The polymer was dialyzed (300-500 MWCO) in 
deionized water adjusted to pH 5-6 with HCl for three days. After dialysis, the 
product was lyophilized to dryness and characterized by SEC and 1H NMR 
(Figure 7.32, Appendix). 
3.2.5 Fluorescent tagging of Polymers 
For in vivo studies, P(MAG-b-MAEMt)-2 and P(EG-b-MAEMt) were 
fluorescently labeled with a near infrared fluorescent tag, Cyanine7-N-
hydroxysuccinamide (Cy7-NHS), via amidation of the NHS ester to a pendant 
amine. The ratio of Cy7 to MAEMt functionality was 1:50 for both polymers 
(P(MAG-b-MAEMt)-2: 0.00018 mmol Cy7, 0.0098 mmol N+; P(EG-b-MAEMt): 
0.00070 mmol Cy7, 0.035 mmol N+). The reaction was carried out in a solution 
containing a 9:1 ratio of 0.1 M sodium acetate buffer to dimethylformamide 
(DMF). The mixture was vortexed and incubated for 4 h at 23 °C in the dark. The 
solutions containing the Cy7-labeled polymers were dialyzed exhaustively into DI 
water (3500 MWCO, pH adjusted to ~5 with 1 M HCl) for 48 h and lyophilized, 
yielding a blue powder. The degree of labeling with Cy7 was measured by UV-
Vis (Ocean Optics, Inc.) absorbance at 750 nm using a solution of 0.2 mg/mL 
labeled polymer in water (Figure 7.33A, Appendix, P(MAG-b-MAEMt-2-Cy7): ε = 
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199000, A750=0.166; P(EG-b-MAEMt)-Cy7: ε = 199000, A750=0.355). Based on 
the absorbance measurements, the polymers were labeled at an efficiency of 1 
Cy7 tag per 12.3 P(MAG-b-MAEMt)-2 polymer chains and 1 Cy7 to 9.7 P(EG-b-
MAEMt) polymer chains. To verify that the fluorescence of the Cy7-tagged 
polymers is not quenched during polyplex formation, we compared the Cy7 
fluorophore absorption of polyplexes to free Cy7-polymer (Figure 7.33B, 
Appendix). 
3.2.6 Polyplex Preparation, Binding, and Size Studies 
  All polyplexes were formulated with pT2/CAL plasmid DNA (pDNA, 7537 
bp) containing the firefly luciferase reporter gene.170, 171 This plasmid design also 
included a Sleeping Beauty transposon and a CAGGS promoter known to 
promote high gene expression in vertebrate cells.171 
  To formulate polyplexes, pDNA was diluted to 0.02 μg/μL in D5W. The 
overall volume varied based on the sample size needed for each experiment. 
The polymers were separately diluted with D5W to the same total volume as the 
pDNA. However, to achieve the appropriate N/P, which is the molar ratio of 
ionizable amines to ionizable phosphates in the polyplex system, the 
concentration of polymer in solution varied according to the polymer molecular 
weight; the higher the N/P, the higher the concentration of cationic block in 
solution. P(MAG-b-MAEMt)-1, -2, -3 and P(EG-b-MAEMt) were each formulated 
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at N/P=5 and 15. Commercial controls, jetPEI and Glycofect, were formulated at 
N/P=5 and 20, respectively. Following dilution, polymer and pDNA solutions were 
filtered separately through a 0.2 µm sterile syringe filter and then polymer 
solution was added to an equal volume of pDNA solution. Polyplexes were 
incubated at room temperature for 1 h before use.  
 P(MAG-b-MAEMt)-1, -2, -3 polyplexes showed complete DNA complex 
formation at N/P=5 according to a previous gel electrophoresis shift assay 
(results summarized in Figure S4, Supporting Information).83 This gel-shift assay 
was performed with the P(EG-b-MAEMt) polyplexes as well as the complexes 
made with the Cy7-tagged polymers using P(MAG-b-MAEMt)-2 as a control. A 
1.2% agarose gel was prepared by dissolving 1.2 g of agarose in 100 mL of 1x 
TAE buffer and the solution was heated for 30 minutes. The solution was then 
removed from the heat and 10 µL of ethidium bromide (EtBr) was mixed into the 
solution, which was cooled for 5 min. The gel was poured and allowed to solidify 
for 1 h. While the gel set, polyplex solutions in D5W were made for: pDNA only, 
jetPEI N/P=5, Glycofect N/P=20, P(EG-b-MAEMt) and P(MAG-b-MAEMt)-2 each 
at N/P= 5 and 15, P(EG-b-MAEMt)-Cy7 at N/P=5, and P(MAG-b-MAEMt)-2-Cy7 
at N/P=5 and 15. The polyplex solutions prepared at 0.02 μg/μL pDNA in D5W 
were allowed to complex for 1 h, then 45 μL of each sample was loaded into the 
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gel. The gel was submerged in 1x TAE buffer and run at 125 mV for 1.5 h and 
then visualized with the transilluminator (Figure 7.34, Appendix). 
For size and stability analysis, polyplexes were made in D5W solution. EtBr 
was added to solution and the EtBr fluorescence was measured at 526 nm 
(Figure 7.35, Appendix). To further assess polyplex stability in the prescence of 
protein, polyplexes were made in D5W. After an intitial DLS measurement, phenol 
red-free Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal 
bovine serum (FBS) by volume (both at room temperature) was added. Polyplex 
hydrodynamic diameters (HD) were measured by dynamic light scattering (DLS) 
over 2 h to determine if the polyplex sizes changed in this media.2,16,19 200 µL of 
each sample in D5W were analyzed for 10 min with a 637 nm laser at 20 mW 
using 90° backscatter detection, then 400 µL of DMEM/10% FBS was added to 
the polyplex solution. A measurement was taken 10 min after serum addition, 
and recorded as t=0. Measurements were repeated once each at 60 and 120 
min. The correlation functions were processed into size distribution curves using 
REPES analysis, and further discussion on data fitting and analysis can be found 
in the supporting information (Figure 7.36-Figure 7.48, Appendix). Peaks 
belonging to FBS protein were disregarded, and the polyplex peak in each 
sample was plotted. 
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3.2.7 Red Blood Cell Lysis and Morphology Analysis 
Whole human blood in 3.2% sodium citrate anticoagulant was used to 
measure hemolysis. The whole blood was spun on an Eppendorf centrifuge 5810 
R at 2400 x g for 20 min, and the plasma supernatant was transferred to a 15 mL 
centrifuge tube and flash frozen for use in the coagulation assays. Once 
separated from the plasma, red blood cell concentrate (RCC) was either used 
fresh or stored at 4 °C for up to 30 days.172 The RCC was washed four times with 
~2 mL of PBS at room temperature, then diluted 1:9 in PBS (700 µl RC: 6300 µl 
PBS). Aliquots (900 µL) of 0.1X RCC were mixed with 100 µL of each polyplex 
sample in triplicate: jetPEI N/P=5; Glycofect N/P=20; P(EG-b-MAEMt) at N/P=5 
and 15; and P(MAG-b-MAEMt)-1, -2, and -3 each at N/P= 5 and 15. RCC was 
mixed with 100 µL of D5W solution as a negative control since D5W is isotonic 
with blood ex vivo, and one aliquot of 5 µL was added to 495 µL of sterile water 
as a 100% lysis positive control. All samples were incubated at 37 °C for 1 h. 
Following centrifugation at 3200 x g for 3 min at room temperature, 150 µL of the 
water sample was pipetted into a clear 96-well plate. 100 µL of each polyplex or 
D5W sample was aliquoted and 50 µL of PBS was added. Absorbance was 
measured on a BioTek Synergy H1 hybrid plate reader at 380 nm, 415 nm, and 
450 nm and the hemoglobin (Hb) concentration was calculated using the Harboe 
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method (Eqn. 1).172, 173 Eqn. 2 was used to calculate percent hemolysis, and the 
data were normalized to the 100% lysis control.  
 
 To observe changes in red blood cell morphology with polyplex addition, 
naïve washed RCC was compared to RCC samples incubated with polyplexes. 
All samples sat for 1 h at 37 ˚C, allowing cells to settle into three layers, and 1.25 
µL of cells were drawn from the opaque, cherry-red middle layer, diluted into 3 µL 
PBS on a glass microscope slide, and topped with a coverslip. All images were 
collected using the differential interference contrast setting on an EVOS FL digital 
inverted microscope.  
3.2.8 PT and aPTT Coagulation Assays 
Platelet poor plasma, hereon referred to as plasma, was separated from 
whole blood in 3.2% sodium citrate-coated collection tubes following 
centrifugation at 2400 x g for 20 min at room temperature. Plasma was either 
used immediately or flash frozen in liquid nitrogen and stored at -80 °C for up to 
30 days. Polyplex solutions (100 μL) in D5W were incubated with 900 µL of 
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plasma for 1 h at 37 °C. D5W (100 µL) was used as a negative control for both 
the activated partial thromboplastin time (aPTT) and the prothrombin time (PT) 
assays. Data from either assay is a measure of the time it took for the sample 
plasma to coagulate, and is reported in seconds.  
To observe coagulation in the aPTT assay, partial thromboplastin time-
Lupus anticoagulant reagent (PTT-LA) reagent was prepared following the 
manufacturer’s instructions. 100 µL of reagent was added to 100 µL of plasma 
sample mixture in a 35 mm Pyrex test tube in triplicate. Plasma incubated with 
D5W was the negative control, while the positive control was made by incubating 
plasma with protamine sulfate (3 mg/mL in PBS). While protamine sulfate is 
normally used to trigger coagulation, in this case we used it at high concentration 
to induce coagulation factor dilution, which delays coagulation.174 The tubes were 
warmed for 3-4 min in a 37 °C water bath. In a separate tube, 25 mM CaCl2 
solution was warmed to 37 °C. Once all samples and reagents equilibrated to 37 
°C, 100 µL of warm CaCl2 was added to one sample tube. The bottom of the tube 
was held in the 37 °C water bath to maintain consistent temperature, briefly lifted 
and tipped sideways for observation, then resubmerged into the bath. Time was 
kept from the moment CaCl2 was added until a clot was seen in the tipped 
solution.  
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To test whether normal aPTT coagulation time could be restored, we ran a 
mixing assay where 50% more coagulation factor (via PPP) is added to the 
system. The original mixture of 100 µL PPP plus sample mixture, 100 µL PTT-LA 
reagent was divided in half, and 25 µL extra PPP was added to one of the test 
tubes. In addition, we also tested whether the addition of more contact factor, 
which is supplied by the PTT-LA reagent as particulate silica, would reduce the 
coagulation time back to normal range by adding 2x more reagent (50 µL) to the 
other test tube. 50 µL CaCl2 was added to start coagulation, and clotting times 
were collected using the tipping method outlined above. 
PT was measured using the same manual tube tipping method, but with 
different reagents. Instead of CaCl2, Neoplastin reagent was prepared per 
manufacturer instructions, then warmed to 37 °C. Plasma samples were 
prewarmed in the water bath for 1 min without any additional reagent. To start 
coagulation, 200 µL of warm neoplastin was added to each sample tube, and PT 
was measured from time of reagent addition until visible clot formation. D5W in 
plasma was again the negative control, but the positive control was made by 
diluting plasma with 3X the normal amount of neoplastin reagent. This effectively 
delayed clotting by diluting the protein that forms clots, plasma fibrin, without 
completely preventing clot formation. 
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3.2.9 Complement ELISA Assays 
To screen the polyplex vehicles against complement activation, polyplexes 
were formulated in D5W as described before and allowed to incubate on hour at 
room temperature. Normal human serum was collected from human donors 
through the Memorial Blood Center (St. Paul, MN) as whole blood in tubes 
lacking anticoagulant. The blood was allowed to clot at room temperature for 30 
min, and the tubes were centrifuged at 1500 g for 10 min. The serum was 
pipetted off the clot into 15 mL centrifuge tubes. Because it is projected that 
>10% of the general human population is mannose-binding lectin (MBL) 
deficient, it was important to weed out serum samples lacking MBL prior to 
screening MBL activation with our samples.175 5 uL of serum from each donor 
was pre-screened using an MBL oligomer ELISA kit purchased through Quidel, 
and all donor serum contained normal levels of MBL (data not shown). 10 uL of 
each polyplex sample was then incubated in 90 uL human serum for 1 h at 37 °C 
while gently rocking. Two additional control samples were prepared by incubating 
90 uL serum with either 10 uL D5W or 10 uL zymosan (10.0 mg/mL). The serum 
+ polyplex samples were then screened for C4 and Bb protein content using the 
respective ELISA kits (Quidel) following the instructions provided with each kit. 
The ELISA absorbance values were converted to protein content (ug/mL) and 
plotted thusly.  
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3.2.10 In Vivo Biodistribution Studies 
To observe biodistribution, one of the glucose polymers and the control 
P(EG-b-MAEMt) polymer were fluorescently tagged with Cy7 as described 
above. These Cy7-tagged polymers formed Cy7-tagged polyplexes with 
pT2/CAL, which we used to fluorescently image whole mice and in extracted 
organs. To avoid subjecting the mice to undue stress and hemotoxicity, we 
tested the P(EG-b-MAEMt) control only at N/P=5, as the N/P=15 formulation 
aggregated in serum and lysed RBCs significantly. Control mice were dosed with 
D5W only. For the glucose polymer, we observed that all the polymers regardless 
of cationic block length behaved similarly with blood components, so we chose 
the mid-length MAEMt block polymer, P(MAG-b-MAEMt)-2 to represent the 
glucose polymer series. We also knew from previous work that P(MAG-b-
MAEMt)-2 gave the highest gene expression in HepG2 liver cells in vitro.83 
To perform the biodistribution study, we formed polyplexes in D5W, 
allowed them to complex for 1 h at room temperature as before, and injected 200 
µL of the formulations into mice tail veins(pDNA concentration= 0.01 µg/µL). After 
euthanasia by CO2, all organ imaging was conducted on an IVIS Spectrum with 
an excitation wavelength of 710 nm, an exposure time of 3 sec, and an 
absorbance wavelength of 780 nm. Measured fluorescence (Cy7) was expressed 
as radiant efficiency (p/cm2/s/sr)/(µW/cm2). Mice were euthanized approximately 
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30 min post-injection, and blood samples were drawn by cardiac puncture. 
Mouse vasculatures were then perfused with at least 20 mL of D5W. Mouse 
organs were collected, imaged 1 h post-injection, and stored in liquid nitrogen. 
Fluorescent heat maps were generated using IVIS Living Image Software. All 
images were simultaneously loaded with the Living Image Browser and regions 
of interest (ROI), in this case individual organs, isolated via the “Free Draw 
Method”.  Each organ consisted of its own ROI where fluorescence is measured 
and reported in radiant efficiency/ROI pixel area. Radiant efficiency is defined as 
the ratio of emission light over excitation light. Plotting the fluorescence using 
radiant efficiency over ROI pixel area accounts for differences in both sample 
area and how the imager excitation light interacts with the irregular surface of the 
samples. 
To determine the biological location of the second polyplex component, 
the pDNA, we purified DNA from mouse organs and measured the amount of 
cargo plasmid delivered using quantitative polymerase chain reaction (qPCR). 
First, organs were homogenized using the Next Advance Bullet Blender™ 
according to an adaptation of the instrument manufacturer’s protocol for liver 
homogenization. Briefly, we placed the whole organ (or both organs, in the case 
of the lungs and kidneys) into an Eppendorf tube. Then we added 2-3 large 
stainless steel beads (1.6 mm diameter), about 20 smaller beads (0.9-2.0 mm 
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blend), and 500 µL of lysis buffer (Qiagen) and ran the blender for 1 min.  To 
extract the DNA, 20 µL (about 3 µg) of tissue homogenate from each organ 
sample was placed in a separate microcentrifuge tube with 665 µL lysis buffer 
and 15 µL proteinase K (Roche) (20 µg/µL) and digested overnight at 55 ºC on 
an elliptical rocker. DNA was isolated using a phenol chloroform protein 
extraction followed by ethanol DNA precipitation. Samples in a range of 200 – 
1000 ng/µL of DNA were submitted to the University of Minnesota Genomics 
Core for qPCR analysis. The measurements were conducted using primers luc-
F1 (sequence: TGAGTACTTCGAAATGTCCGTTC) and luc-R1 (sequence: 
GTATTCAGCCCATATCGTTTCAT). The fold increase in pDNA over background 
tissue readings was plotted.   
 
3.2.11 Statistical Analysis 
All values reported are the mean ± the standard deviation of 
measurements made in triplicate unless noted otherwise. All means were 
compared to a specified control with the Student’s t-test using JMP Pro Software 
(SAS Institute, Cary, NC) through the University of Minnesota Supercomputing 
Institute. Results were considered statistically different from the indicated control 
if p < 0.05. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Polymer Synthesis and Characterization  
The MAG and MAEMt monomers and the P(MAG-b-MAEMt) polymers 
were previously synthesized via RAFT polymerization according to our published 
method.83 The P(EG-b-MAEMt) control polymer was also synthesized via RAFT 
polymerization by using a PEG45-CTA and chain extending with MAEMt 
monomers using the same reaction conditions used to make the P(MAG-b-
MAEMt) polymers. The polymers were characterized via GPC, 1H NMR, and 
SEC (Figures S1-S4, Supporting Information). Figure 3.3 summarizes the 
characterization data obtained for the diblock copolymers investigated in this 
study. P(MAG-b-MAEMt) polymers consisted of a constant MAG block length 
and the length of the MAEMt cationic block was systematically increased from 30 
to 76 repeat units.  
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After Cy7-labeling P(EG-b-MAEMt) and P(MAG-b-MAEMt)-2, the degree 
of labeling was assessed by measuring the fluorophore absorbance using UV-Vis 
(Figure 7.33A, Appendix). The degree of labeling came to 1 Cy7 tag per 12.3 
P(MAG-b-MAEMt)-2 polymer chains and 1 Cy7 to 9.7 P(EG-b-MAEMt) polymers. 
To ensure the polymer complexation process did not quench the Cy7 signal, 
fluorophore absorbance between free polymer and polyplexes were compared 
using UV-Vis (Figure 7.33B, Appendix). There was no significant difference in 
D)
A) B)
C)
 
Figure 3.3. Characterization summary for the polymers used in this study. (A) 
Structure of P(MAEMtn). (B) Polymer structure of P(EGm-b-MAEMTn). (C) General 
structure of all P(MAGm-b-MAEMTn) polymers. (D) Polymer block degree of 
polymerization (DP) values for P(MAG-b-MAEMT)-1, -2, -3 and P(MAEMt) were 
determined using GPC while the P(EG-b-MAEMT) block lengths were determined 
using 1H NMR. Mn and Ð for all polymers were measured by GPC/light scattering.  
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absorbance between any polyplex formulation and the same concentration of 
free polymer in D5W, so polymer complexation does not quench the Cy7 signal. 
3.3.2 Polyplex Formation and Characterization 
 A gel electrophoresis shift assay was performed on all the Cy7-tagged 
polymers at the N/P ratios used for the animal study as well as the new P(EG-b-
MAEMt) polymer at both N/P=5 and 15. The P(MAG-b-MAEMt)-1, -2, and -3 
binding shift assay was previously published, but P(MAG-b-MAEMt)-2 at N/P=5 
and 15, jetPEI N/P=5, Glycofect N/P=20, and pT2/CAL only samples were 
included as controls.33 The binding shift assay confirmed that the P(EG-b-
MAEMt) polymer as well as P(EG-b-MAEMt)-Cy7 and P(MAG-b-MAEMt)-2-Cy7 
completely bound pT2/CAL plasmids even as low as N/P=5 (Figure 7.34, 
Appendix). The polymers bound pT2/CAL plasmids at both N/P= 5 and 15 ratios 
and those formulations were used for further characterization.33 To further assess 
polyplex binding capability, an ethidium bromide (EtBr) exclusion study was 
performed (Figure 7.35, Appendix). All polyplexes prevented EtBr from 
intercalating the pDNA cargo as compared to a D5W only negative control. 
 For effective delivery to tissues in vivo, polyplexes should maintain a 
consistent size over time in the presence of serum proteins in the blood and 
physiological salt concentrations. Polyplex aggregation and opsonization can 
cause premature clearance from the blood stream, immune response, and/or 
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cause polyplexes to collect in the lung capillaries.4, 20, 26-28, 160 Polyplex size was 
measured in the presence of DMEM/10% FBS solution over 2 hours using DLS 
(Figure 3.4). Raw DLS traces are shown in Figure 7.36-Figure 7.48 included in 
the Appendix. Both jetPEI and Glycofect, cationic polymers not containing a 
protective neutral block, were found to aggregate upon incubation in the DMEM + 
10% FBS solution. Once protein was introduced to the system, polyplexes made 
with P(MAEMt) and P(EG-b-MAEMt) aggregated at both N/P=5 and 15. In 
contrast, all polyplexes with a P(MAG) block maintained a relatively consistent 
hydrodynamic diameter of approximately 125 nm even upon addition of serum. 
All of the P(MAG-b-MAEMt) polyplex formulations were found to be colloidally 
stable, despite changes in N/P ratio and MAEMt block length, suggesting 
P(MAG) is able to shield polyplexes from aggregation.31, 176 
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3.3.3 Hemolysis and Red Blood Cells Morphology 
Red blood cells (RBCs) compose the largest portion of whole blood and 
act as reliable in vivo toxicity indicators.177 Accordingly, hemolysis and RBC 
morphology were examined to determine if polyplexes compromised RBC 
integrity. Polyplexes were formed in D5W as described above. 100 µL of polyplex 
 
Figure 3.4. Polyplex hydrodynamic diameter in D5W initially, then in DMEM + 10% 
FBS over time. The x-axis specifies polyplex polymer and N/P formulation. Peak end 
points were recorded at t=0, 1, and 2 h after addition of DMEM + 10% FBS to the 
samples. Each data point represents one ten-minute measurement. Note: The 
P(MAEMt) N/P=5 measurements at t= 1 and 2 h are of the particles remaining in 
solution after macroscopic particles settled out (based on visual observation). 
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solution in D5W was incubated with 900 µL 0.1X RCC for 1 h at 37 ºC, and the 
supernatant from each sample was measured for hemoglobin release, which is 
proportional to the amount of RBCs lysed.172, 173 Polyplexes formed with all three 
P(MAG-b-MAEMt) N/P=5 formulations, jetPEI, and Glycofect, did not lyse more 
cells than the negative control of RBCs incubated with D5W (Figure 3.5A). The 
shorter of the three P(MAG-b-MAEMt) polymers at N/P=15 also failed to lyse red 
blood cells, but the polymer with the longest cationic block, P(MAG-b-MAEMt)-3, 
lysed cells at N/P=15. This formulation has the highest ratio of cationic 
charge:neutral glucose block, and it is known that particles with a net positive 
charge can disrupt cell membranes.24, 25 P(EG-b-MAEMt) and P(MAEMt) 
polyplexes at both N/P=5 and 15 demonstrated statistically significant RBC lysis 
compared to the D5W negative control.  
To observe possible changes in RBC morphology, visual observations 
were made for all samples diluted into PBS and imaged under a digital 
microscope (Figure 3.5B, Figure 7.49, Appendix). No significant morphology 
changes were noticeable, and all cells had a normal disc-like shape with a dark 
central dimple. No lysed cells were visible using this method. 
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Figure 3.5. RBC lysis and morphology. (A) RBC lysis after one hour of incubation 
with polyplexes. Hemolysis is proportional to supernatant hemoglobin absorbance 
and is presented as the percent of RBCs lysed (based on a 100% lysis sample by 
incubating RBCs in water). Data are the mean of three replicates ± standard deviation 
with the polymer abbreviation and N/P values on the x-axis. An asterisk indicates a 
statistical difference between the sample and the D5W negative control according to 
a Student’s t-test with p < 0.05. (B) Representative morphology microscopy images of 
RBCs incubated with select polyplex samples. No distinctive differences in 
morphology can be seen. 
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RBC lysis was likely caused by loss of cell membrane integrity after 
contact with the charged polyplexes, followed by an influx of solution. Neither 
jetPEI nor Glycofect visually altered RBC morphology or caused lysis, nor did 
any of the P(MAG-b-MAEMt) polymers at either low N/P ratio. Commercially 
available jetPEI is normally thought to be membrane lytic due to its high density 
of positive charge. However, Godbey et al. showed that that while free linear PEI 
polymer can permeabilize membranes, the lytic effect decreases when the 
polymer is complexed with DNA.178 In a related study, Lambert and coworkers 
transfected human neural cells with PEI and confirmed that neural cell 
electrophysiological function was not affected, and thus the plasma membrane 
should be intact.179 While the PEI dose was toxic to cells, this did not coincide 
with increased membrane permeability. Their lack of observed hemolysis further 
supports the conclusion that linear PEI did not lyse cell membranes when 
complexed to DNA at low concentrations. These results combined with the DLS 
study demonstrate that P(MAG-b-MAEMt) polymers do not cause destructive 
interactions with blood serum or cells at least at lower N/P ratios. 
3.3.4 Coagulation 
Plasma coagulation is an important blood function that can be altered 
even by polymers considered biocompatible. Heparin, for instance, is a common 
polyanion used to prevent coagulation and the formation of blood clots.180 Other 
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polymers that are more structurally similar to our glycopolymer diblocks such as 
poly(amidoamine) (PAMAM) have been found to induce plasma clotting, while 
nanoparticles with a cationic galactose shell greatly delay coagulation.92, 99, 101 
Furthermore, glycoproteins naturally activate coagulation through two different 
enzymatic pathways - the partial thromboplastin and the prothrombin 
pathways.181 Plasma coagulation was tested following 1 h polyplex incubation to 
ensure the delivery vehicles did not alter clot formation time. There are two 
pathways through which plasma may clot, the common, or intrinsic, pathway and 
the extrinsic pathway. As the pathway names suggest, the extrinsic pathway 
activates from external trauma that allows blood to escape the vascular system, 
while trauma internal to the vascular system triggers the intrinsic coagulation 
pathway through activation of platelets, collagen, and other biomarkers.181 An 
aPTT test measures coagulation through the intrinsic pathway, and the PT assay 
tests the extrinsic pathway. Figure 3.6 compiles clot formation PT and aPTT from 
plasma incubated with our polyplexes.  
The PT for all samples occurred within 12.5-14.5 sec, a normal range by 
comparison to the D5W negative control, hence the polyplexes did not affect 
extrinsic coagulation (Figure 3.6A). In the aPTT assay, all diblock polyplexes at 
N/P=5 as well as jetPEI and Glycofect polyplexes presented normal coagulation 
times of about 40.0 sec (Figure 3.6B). Interestingly, the polyplexes made with the 
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P(MAG-b-MAEMt) polymers at N/P=15 significantly delayed coagulation time, 
while the block copolymer control, P(EG-b-MAEMt), did not affect coagulation. 
The homopolymer, P(MAEMt), likewise did not alter aPTT coagulation. There are 
several known causes of aPTT delay: antibody production, unfractionated 
heparin treatment (UFH), coagulation factor deficiency, and contact factor 
deficiency.182 Indeed, antibodies are not a factor in these assays as all platelet 
poor plasma (plasma) samples were prescreened before use to ensure they 
clotted in a normal time frame. For the same reason, plasma samples that may 
have been exposed to UFH were not used in these experiments. In this case, 
depletion of clotting factors in the plasma or depletion of contact factor in the 
thromboplastin reagent (Neoplastin Plus from Diagnostic Stago) are the two 
potential causes of coagulation delay. Others have shown that addition of PEG to 
surfaces that normally trigger coagulation on contact can prevent contact factor 
activation.100 It is likely that polyplexes at higher N/P ratios delay coagulation by 
capturing either coagulation factor from the plasma or the negatively charged 
contact factor included with the PTT-LA reagent (particulate silica, in this case).  
To test this hypothesis, a mixing study was run where key coagulation 
components were added back to plasma samples showing poor coagulation 
ability. Plasma samples incubated with block glycopolymers at N/P=15 were split 
in half, either more plasma or more reagent (containing silica contact factor) was 
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added to the test tube, and coagulation times were recorded. If the polyplexes 
depleted coagulation factors or contact factors in the aPTT, the re-addition of that 
component should return coagulation time to normal. Adding twice as much 
reagent to the samples decreased coagulation time for all samples, but only the 
addition of more plasma completely restored a normal aPTT (Figure 7.50, 
Appendix). This suggests that P(MAG-b-MAEMT) N/P=15 polyplexes deplete 
both coagulation and contact factors. It should be noted that while the PT and 
aPTT assays are valuable measures of biomaterial effects on coagulation, these 
conditions do not exactly mimic in vivo conditions, and thus this assay serves as 
a model system only that should be coupled with further in vivo studies (vide 
infra).100  
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Figure 3.6. Determination of polyplex effects on blood coagulation. (A) The effect of 
polyplex incubation as a function of N/P ratio (numbers on x-axis) on coagulation 
through the PT extrinsic pathway. (B) Coagulation time (sec) of blood plasma 
samples via the aPTT intrinsic pathway after incubation with each polyplex sample for 
1 h as a function of N/P ratio (numbers on x-axis). All data are presented as the mean 
number of seconds ± standard deviation with an asterisk denoting and variation from 
the negative control according to the Student’s t-test with p < 0.05. 
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3.3.5 Complement Activation 
The complement system is a form of innate immunity in which 
complement proteins found in the blood can be activated by contact with foreign 
material and initiate an enzymatic cascade to remove that material. Complement 
activation can lead to material rejection, inflammation, antibody mediated injuries, 
and even cardiovascular distress due to hypersensitivity reactions.183-185 It is 
crucial to test whether biomaterials activate complement pathways as a safety 
measure. Complement activation of the formulations was tested by incubating 
polyplexes with complement protein found in human serum and then exposed the 
serum to animal erythrocytes (red blood cells). If complement proteins were 
activated, they would lyse the red blood cells. Because there are three different 
pathways through which activation can occur, activation of each pathway was 
measured separately using experimental conditions unique to each pathway. The 
results of the complement screen are presented in Figure 3.7. 
The three different pathways through which complement activation can 
occur are the classical pathway (CP), the mannan-binding lectin pathway 
(MBLP), and the alternative pathway (AP).186, 187 These pathways converge with 
the activation of complement component 3 (C3). The CP is typically activated 
through contact with immune complexes such as immunoglobulins or with 
lipopolysaccharides.186, 187 The MBLP can be activated by mannose 
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polysaccharides displayed in certain patterns.186 Since it is possible for activation 
to occur through any pathway, the polyplexes were screened against all three 
pathways.188  
CP and MBLP activation initiate through the same processes before 
diverging to their final forms. Figure 3.7A show the amount of complement 
component 4d (C4) protein produced by serum incubation with all the polyplex 
samples as well as a D5W negative control, and a positive control made by 
incubating serum with zymosan, a polysaccharide derived from yeast known to 
activate all three complement pathways.189, 190 Since C4 protein is common to 
both the CP and the MBLP, we cannot determine which pathway the polyplex 
vehicles activate. Future work could repeat the screen using C1q-depleted 
serum, which would prevent any activation through the CP.190 If polyplexes still 
generate C4 protein, then they would be activating the MBLP.  
AP activation is known to occur through non-specific covalent binding 
through nucleophilic groups such as pathogen-associated molecular patterns 
(PAMPs) normally found on microorganisms to C3.187 Compared to the D5W 
negative control, all tested polyplex formulations significantly activated 
complement via the AP (Figure 3.7B), although the sample activity levels did not 
approach the level of complement Bb protein (Bb) produced by the positive 
control, zymosan. This suggests that complement activation exists on a 
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spectrum, and that complement activation could be mitigated by cellular and 
humoral inhibitors in vivo.186 It is known that hydroxyl groups on the surface of 
biomaterials amplify AP activity.191 Toda et al. demonstrated that amino groups 
can only activate the AP indirectly through proteins adsorbed on the material 
surface.188 This could be a possible activation mechanism for polyplexes that do 
not contain –OH groups available for covalent binding to C3 such as jetPEI and 
P(EG-b-MAEMt). Indeed, while the PEG block has an hydroxyl group at the 
terminus of the polymer, work by Hamad et al. has shown that PEG still activates 
the AP by binding ficolin protein even if the terminal alcohol is acetylated.190  
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Figure 3.7. Complement activation as assessed using ELISA screens for the 
production of pathway activation marker proteins. (A) C4 protein is a marker for CP 
and MBLP activation. Samples that significantly differ from D5W are marked with an 
(*). Samples that exceed the positive control, zymosan, are marked with a (+), and 
samples that statistically equal zymosaon are marked with an (=). (B) Bb protein is an 
activation marker for the AP. No sample statistically rivaled the positive control, and 
samples that significantly exceeded the D5W sample are marked with an (*). Each 
sample was run in duplicate and the error bars represent the standard deviation. 
Statistical markers were determined using a Student’s t test (p < 0.05). 
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3.3.6 Biodistribution 
To understand the biodistribution of polyplexes in vivo, P(MAG-b-MAEMt)-
2 was selected as the most promising formulation due to its stability in biological 
media and compatibility with human blood. For comparison, the control polymer, 
P(EG-b-MAEMt) was also selected to further understand vehicle stability and 
compatibility for tail vein administration in mice. Vehicle distribution through the 
blood is a passive process, so polyplexes must circulate unobstructed through 
the organism vasculature to reach tissues of interest.4, 28, 29 During circulation, 
they must also avoid nonspecific protein aggregation, opsonization, disassembly, 
or immune system activation.4, 27, 29, 30, 49, 192 Only after avoiding all these 
mechanisms the body uses to identify and remove foreign material can the 
vehicles reach their intended target tissues. Examining every possible polyplex 
fate is outside the scope of this study, but future studies to further understand the 
causes of P(MAG-b-MAEMt) polyplex distribution and their effect on genetic 
cargo expression may prove useful. For the current study, vehicle distribution to 
six major organs were assessed; a lack of polyplex (polymer and pDNA) 
aggregation in specific organs is a strong indicator of stability, biocompatibility, 
and stealth nature in vivo. 
One general strategy for avoiding nonspecific uptake and prolonging 
circulation, which increases the chance of target tissue uptake, is to incorporate 
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hydrophilic block copolymers into delivery vehicles.193-195 The lack of P(MAG-b-
MAEMt) interaction with blood components suggests the complexes would 
remain intact during circulation, but because the polymer and genetic cargo are 
not covalently linked, the biodistribution of both the polymer and pDNA were 
measured individually. Both P(MAG-b-MAEMt)-2 formulations were selected for 
further study in vivo as the mid-length MAEMt block gave the highest gene 
expression in previous cell studies.83 P(EG-b-MAEMt) at N/P=5 was chosen as 
the negative polymer control. Both P(MAG-b-MAEMt)-2 and P(EG-b-MAEMt) 
polymers were tagged with a Cy7 fluorophore to allow deep tissue imaging in 
organs, as Cy7 is a near-infrared emitter, and then were complexed with pDNA 
and injected into mouse tail veins. Following tail vein injection, the mice were 
imaged for Cy7 fluorescence, and then were euthanized after 30 min. Their major 
organs were excised and imaged ex vivo as a measure of polymer biodistribution 
and PCR analysis was performed to analyze for the amount of plasmid in the 
tissues.  
Six major organs in addition to blood were collected: the heart, brain, liver, 
lungs, kidneys, and spleen. Organs were imaged ex vivo (Figure 3.8A and Figure 
7.51, Appendix), and radiant efficiency was quantified for each organ (Figure 
3.8B). Background autofluorescence in the negative control (D5W only) mice was 
measured at approximately 5.0×108 for all organs (blood was not plotted due to 
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low fluorescence in all samples). P(EG-b-MAEMt) polymers were found at high 
levels in the liver, which is the most active organs in the mononuclear 
phagocytosis system.16 It has been shown that PEGylation using linear 
molecules of at least 2000 Da help nanoparticles avoid macrophage capture,26, 
196 but it is likely some polyplexes were still captured by macrophages in the liver. 
P(EG-b-MAEMt) polyplexes were also found in the lungs and kidneys, which 
suggests they were not totally stable against protein opsonization, so they 
aggregated and were either trapped in the lung capillaries or filtered out by the 
kidneys.27, 197 
The fluorescent polymer data shows that P(MAG-b-MAEMt)-2 at N/P=5 
and 15 distributed evenly in all organs except the liver. P(MAG-b-MAEMt)-2 at 
N/P=15 was the only formulation to successfully avoid capture by any one organ. 
P(MAG-b-MAEMt)-2 N/P=5 distributed in the same way as the higher N/P 
formulation except with much higher polymer fluorescence in the liver. Although 
the liver is a mononuclear phagocytosis organ, the lack of signal in the spleen, 
which is also rich in macrophages, for this polyplex formulation suggests a 
separate mechanism of capture not solely related to phagocytosis by 
macrophages.187 It is possible that the P(MAG-b-MAEMt) N/P=5 polyplexes 
disassociated in the liver and were unable to circulate further, as has been 
demonstrated with PEGylated polyplexes previously.197 In fact, increasing the 
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amount of polymer in the formulation to an N/P ratio of 15 decreases liver uptake 
to near-background levels. . It is striking that simply increasing the amount of 
polymer in the formulation leads to a drastically different polyplex distribution 
pattern. The reason for the specific differences in tissue uptake cannot be fully 
explained from these data, but is worth further exploration. 
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Figure 3.8. Summary of biodistribution data. (A) Representative fluorescent mouse organ 
images for each sample exhumed at one hour post-injection: 1) kidneys 2) spleen 3) liver 4) 
lungs 5) brain 6) heart 7) blood. (B) Organ fluorescence in radiance efficiency was plotted by 
organ and polyplex sample. Each data point is the average of n=5 samples (D5W samples 
have an n=3) and error bars represent the standard deviation. (C) DNA was extracted from 
the harvested organs and analyzed by qPCR. Each data point is the average of an n=5 (D5W 
samples have an n=3). The amount of plasmid delivered to each organ was normalized to 
the amount of genomic background level to normalize for organ mass. Error bars represent 
the standard deviation. 
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The amount of genetic material delivered to each organ was measured by 
qPCR (Figure 3.8C). The relative distribution of pDNA with the P(EG-b-MAEMt) 
and P(MAG-b-MAEMt)-2 N/P=5 samples do not correlate with the polymer 
distribution seen in Figure 5B. Figure 5C shows that with the P(EG-b-MAEMT) 
carrier, high levels of pDNA were found in the spleen and lungs, and moderate 
levels in the liver. The localization of pDNA in the lungs after delivery by P(EG-b-
MAEMt) is likely due to polyplexes becoming trapped in the capillaries.27, 197 With 
P(MAG-b-MAEMt)-2 N/P=5 delivery, there was no pDNA detected in any of the 
organs. This supports our hypothesis that these polyplexes disassociate in the 
liver and/or kidneys, leaving the pDNA to be cleared by the kidneys (the pDNA 
was likely excreted by the urine, but no urine samples were taken to support that 
theory).142, 197 The distribution of pDNA with P(MAG-b-MAEMt)-2 N/P=15 shows 
some uptake into all six organs with slightly higher uptake in the liver, spleen, 
and lungs. To reach all the organs, P(MAG-b-MAEMt)-2 N/P=15 must have more 
stable during circulation than the N/P=5 formulation with the same polymer. This 
agrees with previous hemocharacterization and DLS data showing P(MAG-b-
MAEMt)-2 N/P=15 to be stable against protein aggregation and relatively benign 
in human blood, which are both good functions for promoting stealth circulation in 
vivo. 
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Together, the data in Figure 5 suggest that P(MAG-b-MAEMt)-2 polymer 
at higher N/P formulations is a useful stealth material to promote pDNA delivery 
in vivo.  P(MAG-b-MAEMt)-2 N/P=15 appears to be the best polyplex formulation 
for stable circulation and avoiding organ capture. Further studies are necessary 
to better understand these distribution patterns and the glycopolyplex 
physiochemical parameters necessary to achieve desired biodistribution, 
particularly for future targeting endeavors. 
3.4 CONCLUSION 
 In this work, the contribution of a hydrophilic glucose block to the 
hemocompatibility and biodistribution pattern of the cationic polymer gene 
delivery vehicles ex vivo and in vivo was assessed. The glucose block 
copolycations, P(MAG-b-MAEMt)-1, -2, and -3, formed polyplex formulations with 
pDNA that were colloidally stable from aggregation in physiological salt and 
serum conditions as determined by DLS. P(MAEMt) and P(EG-b-MAEMt) were 
synthesized as controls, and unlike the glucose systems, aggregated (according 
to DLS measurements) under the same physiological salt and serum conditions. 
P(MAG-b-MAEMt)-1, -2, and -3 polyplex samples were exposed to human blood 
and did not cause red blood cell lysis (except for P(MAG-b-MAEMt) N/P=15) nor 
a visible effect on cell morphology, indicating formulation hemocompatibility. In 
contrast, the P(MAEMt) and P(EG-b-MAEMt) control polyplex formulations lysed 
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cells even at a lower N/P ratio of 5. Some aPTT coagulation interference was 
detected for all glucose block copolymers at N/P=15, and all polyplex 
formulations activated the complement system via the CP/MBLP. Cy7-tagged 
polyplexes were administered to mice via the tail vein, and biodistribution of the 
polymer and pDNA was measured by fluorescent imaging and qPCR, 
respectively. P(MAG-b-MAEMt)-2 (N/P=15) polyplexes (polymer and pDNA) 
avoided capture by any particular organ (low distribution in all organs), while the 
control vehicles consisting of P(EG-b-MAEMt) and P(MAG-b-MAEMt)-2 at N/P=5 
localized to the spleen, kidneys, lungs. This supports our hypothesis that the 
lower N/P formulations disassembled in either the liver or kidneys.142, 197 The 
P(EG-b-MAEMt) pDNA cargo found in the lungs is possibly due to the polyplexes 
being trapped in the lung capillaries.4, 27, 29, 30 
 Collectively, these results support our hypothesis that P(MAG-b-MAEMT)-
2 (N/P=15) is a stable, hemocompatible, and stealthy vehicle formulation that 
avoids nonspecific lung and liver capture and shows promise compared to 
PEGylated alternatives such as P(EG-b-MAEMt). This work increases the 
understanding of nonviral gene delivery vehicle structure-function relationships 
and supports that carbohydrate-based blocks offer a more stable and functional 
alternative for stealth properties than linear PEG derivatives. Indeed, fine-tuning 
the formulation could allow for passive targeting of these stable formulations to 
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tumors or the addition of targeting moieties may facilitate tissue delivery 
specificity. Further work to measure circulation time, the effects of repeated 
dosing, and the unique distribution patterns of these vehicles is underway. 
3.4.1 Appendix includes: 
Supplemental synthetic and characterization procedures; 1H NMR spectra, 
UV-Vis, SEC chromatograms, gel electrophoresis shift assays, dynamic light 
scattering; additional information about coagulation studies and biodistribution.  
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CHAPTER 4: CARBOHYDRATE-BASED BIOCOMPATIBILE 
EPOXY RESIN THERMOSETS FOR FIBROBLAST CELL 
PROLIFERATION 
Synopsis 
Chapter 4 covers the synthesis and characterization of two new carboxylic 
acid hardener materials and the polymer thermoset films they form after curing 
with epoxidized soybean oil. The hardeners, derived from trehalose (TR) and 
beta-cyclodetrin (CD), were functionalized with heptanoyl chloride (HP) and 
succinic anhydride (SA) and then homogenously formulated with epoxidized soy 
bean oil (ESO) in different carboxyl-epoxide ratios. The cured resins were 
thermally stable up to 300 °C and degraded into water soluble components under 
basic aqueous conditions. The surfaces of the resulting epoxy polymers films 
were homogeneous and hydrophilic. Neonatal human dermal fibroblast (HDFn) 
cell adhesion and proliferation experiments on films made of CD-based epoxy 
resin with a 50/50 ratio of -COOH/ESO presented comparable biocompatibility to 
the well-studied poly(DL-lactide-co-glycolide) (PLG) copolymer, while TR-based 
epoxy polymers prevented cell adhesion and growth. The starkly different cell 
adhesion results and favorable physical characteristics support the further in situ 
and in vitro testing of these fully sustainable epoxy polymer materials as potential 
tissue engineering or antifouling coatings. 
This chapter is adapted with permission from the references below. Copyright 
(2017) American Chemical Society: 
1. Zhang, Q.; Phillips, H. R.; Purchel, A.; Reineke, T. M. In preparation. 
2017. 
 
This chapter is adapted with permission from the references below. Copyright 
(2017) American Chemical Society: 
2. Zhang, Q.; Phillips, H. R.; Purchel, A.; Reineke, T. M. In preparation. 
2017. 
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4.1 INTRODUCTION 
The use of polymeric materials in our daily life is widespread due to their 
versatile mechanical performance, durability, and ease of processing.198 Millions 
of tons of conventional polymers are primarily sourced from the non-renewable 
and quickly depleting petroleum stock on the earth.199 What’s more, the disposal 
of those polymer materials after use brings up more severe challenges, such as 
the ever-growing environmental pollution issue as well as human health 
concerns.200-202 To address those severe ecological challenges, sustainably 
sourced polymers have drawn substantial worldwide interest in recent years.203-
205 Sourcing polymers and their precursors from renewable feedstocks is a safe 
and strategic approach to fulfill the exponentially increasing demand for polymers 
and composites while reducing negative environmental impact.206 Bio-based 
polymers from natural feedstocks are promising materials with similar and 
sometimes improved properties. Various bio-based polymers have been 
prepared from renewable resources, such as bio-based paints from vegetable 
oils,207-209 soybean and corn protein-based biopolymers,210 glucose- and Castor 
Oil-based polyesters,211 thermosetting acrylic resins212 and polyolefins,213 and 
cyanate ester resins.214 
Carbohydrates offer great opportunities to create new renewable polymers 
because of their sustainability, biodegradability, and natural abundance at low 
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cost. They are naturally derived and have numerous hydroxyl groups for creating 
highly functionalized monomers and crosslinked thermosetting polymers.215, 216 
The polymer properties can be adjusted by changing the crosslinking density and 
chemical compositions.217 Trehalose and β-cyclodextrin are naturally-occurring 
carbohydrates obtained by enzymatic fermentation of starch,218, 219 and they have 
been used to prepare various polymers with considerable biocompatibility.220 
Recent efforts have been made to crosslink and incorporate trehalose and β-
cyclodextrin to exploit their unique properties. Nagashima and coworkers have 
studied the mechanical strength of an allyl-etherified trehalose-based polymer 
network formed via thiol-ene photo-polymerization.221 Trehalose based hydrogels 
were also prepared by thiol-ene and redox radical polymerization, and the 
synthesized polymers effectively stabilized a wide variety of enzymes against 
heat and also controlled protein release behavior.222-224 Yano et al. has photo-
polymerized trehalose-based cinnamoyl esters, and the crosslinked polymer films 
exhibited high transparency and biocompatibility for fibroblast cell adhesion and 
proliferation.225 Crosslinked polymers containing β-cyclodextrin have also been 
extensively studied for inclusion-recognition applications, such as drug carrier 
systems and water pollutant adsorbents, making use of the cone-shaped cavities 
that capture organic molecules.226, 227 For example, Alsbaiee et al. recently 
reported a porous β-cyclodextrin-based crosslinked polymer that exhibited 
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exceptional removal efficiency of organic micropollutants from water with great 
regeneration ability.228 β-Cyclodextrin-based hydrogels were formed by free 
radical polymerization and the gels were able to sustain drug release for several 
days depending on the cyclodextrin content.229, 230 More recently, our group has 
prepared bio-based epoxy thermosets derived from Tr, Cd, succinic anhydride 
and trimethylolpropane triglycidyl ether, and studied their thermal curing behavior 
and mechanical properties. The prepared epoxy resins also exhibited excellent 
lap-shear strength indicating their great promise as renewable high performance 
epoxy resins.231 These results imply that both trehalose and β-cyclodextrin are 
promising components to use in preparing sustainable and biocompatible 
polymers for various applications. 
Due to the crosslinked chemical structure, sustainable thermosetting 
polymers do not melt when heated and do not dissolve in most solvents, which 
enables them to maintain their designed properties in various dynamic 
environments without degrading or breaking down.232 Hence, there is 
tremendous interest in studying the biocompatibility of sustainable thermosetting 
polymer materials that may persist in the environment long after their lifetime 
use. Bob Langer’s research group has prepared various crosslinked and 
biodegradable elastomers from sustainable sebacic acid and polyols including 
glycerol, xylitol, sorbitol, and mannitol, and the prepared polymer implants 
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displayed similar in vitro and in vivo biocompatibility to the well-studied poly(DL-
lactide-co-glycolide) (PLG) copolymer.233-235 More recently, photo-cured 
trehalose-based polymer films were also reported to promote fibroblast cell 
proliferation compared to a polystyrene control.225 Yang et al. has reported new 
renewable thermosets based on carvone from caraway seeds, and the rubbery 
polymers exhibited robust mechanical strength.236 The fibroblast cell adhesion, 
growth rate, and morphology on the polymer films were superior to PLG 
copolymers, indicating the material’s potential for engineering various soft 
tissues. More recently, natural sunflower oil-derived thermosets was prepared via 
thiol-ene Michael addition under mild conditions.237 The thermosetting polymers 
were reinforced by the addition of different content of cellulose nanocrystals and 
the noticeable adsorption of bovine serum albumin indicates their promise 
biosensors and cell growing supports.  
Bio-based soy bean oil is a safe and green alternative chemical feedstock 
to prepare sustainable thermosets. Besides its long history in food applications, it 
is the most inexpensive plant oil-based chemical in the world and can be 
epoxidized in large volumes.238 Epoxidized soy bean oil has been widely utilized 
for various applications, such as bio-based plasticizers and stabilizers to improve 
the toughness of epoxy resins.239, 240 In this study, we report the synthesis of 
thermosetting epoxy polymers from renewable starting materials including 
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trehalose (TR) or β-cyclodextrin (CD), heptanoic acid, succinic anhydride (SA), 
and epoxidized soybean oil (ESO). We assessed the thermal curing behavior, 
thermal properties, mechanical performance, degradation, and the cell adhesion 
and proliferation properties of the resulting thermoset films. The TR-based epoxy 
thermosets were elastomeric and did not allow HDFn cell adhesion or growth, 
while the CD-based films were typical plastic materials that promoted HDFn 
adherence and growth to a level comparable with the PLG copolymer control 
films. These results implying their potential applications as tissue engineering or 
antifouling materials.241-243 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
All chemicals and solvents were purchased from Aldrich and used without 
further purification unless otherwise noted. Anhydrous trehalose (TR) was 
purchased from Acros Organics. Food grade β-cyclodextrin (CD) was supplied by 
Wacker Chemie AG. Succinic anhydride (SA) and heptanoyl chloride (HP) was 
purchased from Alfa Aesar and used without further purification. Epoxidized soy 
bean oil (ESO) was obtained from Scientific Polymer Products, Inc. and used as 
received. Poly(DL-lactide-co-glycolide) (PLG) copolymer with a lactide/glycolide 
ratio of 50/50 (with inherent viscosity range of 0.26-0.54, ester terminated) was 
purchased from LACTEL Absorbable Polymers. Dry dimethylformamide (DMF) 
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was obtained using an MBRAUN MB solvent purification system manufactured 
by M. Braun Inert Gas-System GmbH (Garching, Germany) using HPLC grade 
solvent. The biological reagents Dulbecco’s Modified Eagle’s Medium (DMEM), 
fetal bovine serum (FBS), phosphate buffered saline (PBS), OptiMEM, trypsin, 
nuclease-free sterile water, and penicillin-streptomycin (pen-strep) were 
purchased from Gibco (Carlsbad, CA). Calcein-AM was purchased through 
Affymetrix Inc. (Santa Clara, CA). The human dermal neonatal fibroblast cell line 
(HDFn) and dimethyl sulfoxide (DMSO) were obtained through ATCC 
(Manassas, VA). 
4.2.2 Instrumentation 
1H NMR spectroscopy experiments were performed on a Bruker Avance III 
HD 500 spectrometer at 500 MHz. FT-IR spectra were obtained using a Bruker 
Alpha Platinum ATR spectrometer. TGA was performed on a TA Instruments 
Q500 at a heating rate of 10 °C min-1 under a nitrogen flow of 60 mL min-1 in a 
temperature range from 25 to 520 °C. Differential scanning calorimetry (DSC) 
measurements were carried out using a TA Instruments Discovery DSC under a 
nitrogen atmosphere. Tg values were determined on the second heating at a 
heating rate of 10 °C min-1. The curing behavior was measured by DSC at 
heating rates of 2, 5, 10 and 20 °C min-1. Tensile testing was performed using a 
Minimat Tensile Tester on samples with a dog bone geometry (typical gauge 
 139 
 
dimensions 14 × 1.30 × 1.20 mm or 14 x 3.0 x 0.50 mm) with a free crosshead 
rate of 5 mm min-1. The dynamic mechanical analysis of the cure samples was 
conducted on a TA Instruments ARES-G2 rheometer with a rectangular torsion 
geometry with a temperature range of -80 - 150 °C or a frequency range of 0.1 - 
100 Hz. Scanning Electron Microscopy (SEM) images were taken using Hitachi 
S-900 field emission gun SEM. All samples were placed on a carbon tape on the 
SEM sample stubs (Ted Pella, Inc.) and sputter-coated with a conductive layer of 
platinum (~5 nm) using Denton DV-502A high vacuum deposition system. 
Imaging operations were performed using long working distances (10-20 mm) 
from a sample to the backscattering detector with Autrata modified YAG crystal, 
and at 5.0 kV of accelerating voltage. Cells were imaged with a Nikon A1RMP 
multiphoton confocal system connected to a Nikon FN1 microscope with a Plan 
Apo LWD 25x water-immersion, NA 1.1 objective (Melville, NY). The calcein 
images were excited at 488 nm and saved as a .TIFF file and exported to ImageJ 
where they were converted to 8-bit and analyzed for surface area and circularity. 
Analysis was limited to only isolated cells not in physical contact with any other 
cells. Cell counts were obtained on a FACSVerse flow cytometer and software 
from BD Biosciences (San Jose, CA) with a laser excitation wavelength of 488 
nm. Data were analyzed via the FlowJo software program (Ashland, OR).  
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4.2.3 Hardener Synthesis 
4.2.3.1 Synthesis of trehalose-based hardener (TR4HP3SA) 
In a 250 mL round bottom flask, anhydrous TR (7.04 g, 20.6 mmol) was 
stirred in 150 mL of anhydrous DMF at 90 C until completely dissolved to give a 
clear solution. The resulting solution was cooled in an ice bath, and pyridine 
(22.0 mL) and DMAP (0.500 g, 4.09 mmol) were added into the solution. Then 
heptanoyl chloride (H, 12.7 mL, 82.0 mmol) was added slowly to the mixture and 
the resulting solution was stirred for 48 h at room temperature. After SA (16.5 g, 
165 mmol) was added, the resulting solution was heated to 90 C and stirred for 
another 48 h. The flask was taken out of the oil bath, and ~300 mL of ethyl 
acetate was added to dissolve the product. The resulting mixture was transferred 
to a 1 L separatory funnel, and extracted with 2 M HCl with brine (1 x 400 mL, 2 x 
100 mL) and deionized water (3 x 50 mL). The ethyl acetate layer was dried with 
anhydrous sodium sulfate and concentrated using a rotoavap system. The 
resulting viscous liquid was dissolved in 100 mL of CHCl3 followed by addition of 
5 mL of deionized water and stirred for another 24 h. The resulting mixture was 
washed with brine (6 x 50 mL) in a separatory funnel to remove all succinic acid. 
The organic layer was dried with anhydrous sodium sulfate and concentrated on 
rotavap. The resulting viscous liquid was re-dissolved in ~40 mL of CHCl3 and 
precipitated into ~ 1.1 L of pentane. The desired product was collected and dried 
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under high vacuum as a light yellow viscous liquid, 37.5 g, 89.7%. 1H NMR 
(CDCl3, 500 MHz) δppm: 5.72-4.81 (m, 7H), 4.56-3.43 (m, 7H), 2.85-2.47 (m, 
12H), 2.47-2.12 (m, 8H), 1.81-1.49 (m, 8H), 1.51-1.13 (m, 24H), 1.09-0.69 (m, 
12H).  
4.2.3.2 Synthesis of β-cyclodextrin-based hardener (CD6HP8SA) 
In a similar manner to the preparation of TR4HP3SA, anhydrous CD (8.80 
g, 7.75 mmol) was dissolved in 100 mL of anhydrous DMF at 90 C and the 
resulting solution was cooled in an ice bath. After pyridine (26.3 mL) and DMAP 
(0.500 g, 4.09 mmol) were added, heptanoyl chloride (H, 8.40 mL, 54.3 mmol) 
was slowly added dropwise and the resulting solution was stirred for 41 h at room 
temperature. Then the reaction mixture was stirred at 90 C for another 48 h after 
addition of SA (21.7 g, 217 mmol). After cooled to room temperature and addition 
of ethyl acetate (~400 mL), the resulting mixture was extracted with 2 M HCl with 
brine (1 x 400 mL, 2 x 100 mL) and deionized water (3 x 50 mL). The organic 
layer was dried with anhydrous sodium sulfate and concentrated on rotavap, and 
the resulting viscos liquid was stirred in a mixture of CHCl3 (100 mL) and 
deionized water (5 mL) for 24 h. The organic layer mixture was extracted with 
brine (3 x 50 mL), dried with anhydrous sodium sulfate and concentrated on 
rotavap. The resulting viscous liquid was re-dissolved in CHCl3 and precipitated 
into pentane to provide the desired product as a white solid, 20.1 g, 72.3%. 1H 
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NMR (acetone-d6, 500 MHz) δppm: 5.94-3.24 (m, 49H), 3.24-1.98 (m, 32H from 
CH2 of SA groups, 12H from COCH2 of H group, 5H from DMF residual), 1.81-
1.47 (m, 12H), 1.38-1.15 (m, 36H), 1.09-0.57 (m, 18H).  
4.2.4 Resin Formulation and Tensile Bar Preparation 
The synthesized hardeners were mixed with epoxidized soy bean oil (ESO, 
assuming 5 epoxide groups per molecule) in different molar ratios of -
COOH/epoxide (40/60, 50/50, and 60/40) by solvent blending. Briefly, accurately 
weighted hardeners and ESO were dissolved in acetone and stirred in a 20 mL 
scintillation glass vial followed by the removal of acetone on a rotovap system at 
30 °C. The resulting epoxy resins were dried under high vacuum as either 
viscous liquids or solids and stored in a freezer for later use. The thermal curing 
of the resins was conducted following two methods based on the physical form of 
the formulated resins. (1) The viscous liquid epoxy resins of TR4HP3SA/ESO 
were transferred into rubber silicone mold that contained a dog-bone shape, and 
then dried under high vacuum for 12 h at room temperature. Then, the epoxy 
resins were pre-cured at ~110 °C for 2h and post-cured at ~165 °C for 3 h for 
further mechanical testing. (2) The solid epoxy resins of CD6HP8SA/ESO were 
loaded into a stainless steel mold with a dog-bone shape and cured at ~165 °C 
for 2 h in a hot press under a pressure of 3000 psi. 
 143 
 
4.2.5 Hydrolytic Degradation 
To study the hydrolytic degradation of the epoxy resins, three parallel 
samples of polymer (~50 mg, dogbone shape) were immersed in the appropriate 
aqueous solution (5 mL) of deionized (DI) H2O, 1 M NaOH and 1 M HCl. The 
polymers were allowed to sit undisturbed at room temperature, and periodically 
removed, blotted dry, weighed, and re-immersed in the same solution. 
4.2.6 Swelling Ration and Gel Fraction 
Three parallel samples of cured polymers (∼50-70 mg, dogbone shape) 
were weighed (m1) and immersed into 5 mL of THF (48 h) to remove the 
solubilized fraction. The wet weight (m2) of the polymer samples was recorded for 
the swelling ratio calculation. After the wet samples were completely dried at 50 
°C under high vacuum for 24 h, the dry weight (m3) of polymer samples was 
recorded for the gel fraction calculation. The swelling ratio and gel fraction were 
calculated according equation (3) and (4). 
 
Swelling ratio = m2/m1    (3) 
Gel fraction = m3/m1    (4) 
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4.2.7 In Vitro Biocompatibility 
Glass Petri dishes (40 mm diameter, washed with concentrated sulfuric 
acid, DI water, acetone and CH2Cl2) were coated with a CH2Cl2 solution (1.5%) of 
the prepared epoxy resins (40 mg), and the Petri dishes were dried under high 
vacuum for 12h at room temperature after evaporation of the solvent in air. The 
coated dishes were transferred into a vacuum oven, and the epoxy resins were 
pre-cured at ~110 °C for 2 h and post-cured at ~165 °C for 3 h under nitrogen 
atmosphere. The PLG control dishes was coated with CH2Cl2 solution (1%) of 
PLG (25 mg), and the solvent was evaporated overnight in air before drying 
under high vacuum at room temperature.  
To sterilize the dishes prior to cell seeding, the dishes were lightly sprayed 
inside and out with 75% ethanol in water solution and left to air dry film side up 
for 10 min inside the biohood under UV light. Each dish containing the film was 
then filled with 4 mL of DMEM + 10% FBS by volume +1% pen-strep solution and 
left for 2 h in the biohood with the UV light off. After being soaked in DMEM + 
10% FBS, the dishes were rinsed 3 times with sterile water and left to air dry for 
2 h in the biohood without the presence of UV light. The dishes were stored away 
from UV light in sealed sterile glass jars. 
HDFn cells between passage # 5-15 were diluted to a concentration of 
6,000 cells/mL then aliquoted into each dish (24,000 cells per dish into 4 mL 
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DMEM + 10% FBS + 1% pen-strep total). The dishes were gently rocked a few 
seconds to evenly distribute cells, then incubated 24 h at 37 °C. The cell media 
was refreshed every 24 h for all samples. Cells were allowed growing from 1-5 
days. One hour before imaging, a calcein-in-OptiMEM solution was made by 
diluting 1 µL of calcein-AM (1 mg/mL in DMSO) per 1 mL of OptiMEM and 
warmed to 37 °C in a water bath. The dishes were aspirated to remove old 
media, washed 3 times with PBS, and filled with 3 mL of the calcein-OptiMEM 
solution. The dishes were incubated with the calcein at 37 °C for at least 30 min 
before imaging. After imaging, cells were trypsonized off the films, washed with 
PBS, re-dispersed in 200 µL of fresh PBS, and analyzed by flow cytometry using 
the λ=488 nm filter (N=3 for each assay).  The cell counts were collected over the 
course of 20 s. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Hardener Synthesis 
Via a one-pot two-step reaction in dimethylformamide (DMF), the hydroxyl 
groups of anhydrous TR and CD were first partially esterified in the presence of 4 
and 7 equivalents of heptanoyl chloride (HP), respectively. An excess of SA was 
further applied to functionalize the remaining hydroxyl groups of both TR and CD 
(Figure 4.1).231 The two hydrophobic carboxylic acid hardeners, TR4HP3SA and 
CD6HP8SA, were obtained in about 72% and 89% yields after purification, 
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respectively. As shown in Figure 7.24 (Appendix) the integration of protons from 
the trehalose moiety after functionalization (3.4-5.7 ppm) was defined as 14,231, 
244, 245 and the proton integrations of HP (2.47-2.12 ppm) and SA (2.85-2.47 ppm) 
were ~8 and ~12, respectively, indicating that TR4HP3SA had an average 
substitution degree of 4 and 3 for HP and SA groups per TR unit. Similarly, 
hardener CD6HP8SA had an average substitution degree of 6 and 8 for HP and 
SA groups, respectively, (Figure 7.25 Appendix) per CD unit. Both HP and SA 
can be obtained from natural feedstock via thermal degradation of castor oil246, 
247 or fermentation of glycerol.248-251 Therefore, it is reasonable to consider both 
epoxy resin hardeners to be fully bio-based curing agents. 
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Figure 4.1. Synthesis scheme of sugar-derived epoxy resin hardeners and 
bio-based thermosets (TR: trehalose; CD: β-cyclodextrin; HP: heptanoyl group 
SA: succinic anhydride; TR4HP3SA: trehalose based hardener with ~4 HP 
units and ~3 SA units; CD6HP8SA: β-cyclodextrin hardener with ~6 HP units 
and ~8 SA units; DMF: dimethyl formaldehyde; Py: pyridine). 
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4.3.2 Bulk Characterization 
The fully bio-based carboxylic acid hardeners, TR4HP3SA and CD6HP8SA, 
were formulated with plant-based ESO in three -COOH/epoxide ratios (40/60, 
50/50, and 60/40) and formed homogenous epoxy resins (Figure 4.2). Differential 
scanning calorimetry (DSC) was used to monitor the thermal curing behavior and 
Figure 4.2A shows the DSC curing curves of both two resin systems, 
TR4HP3SA/ESO and CD6HP8SA/ESO, at 50/50 ratios with a heating rate of 5 
°C/min. Both epoxy resin mixtures clearly display a single exothermic peak at 
around 172.5 and 171.2 °C for TR4HP3SA/ESO and CD6HP8SA/ESO, 
respectively. The existence of these exothermic peaks indicates the nucleophilic 
ring opening reaction of the epoxides in ESO by the -COOH groups of the 
hardeners upon heating. To confirm the crosslinking reactions, Fourier transform 
infrared (FT-IR) spectra of the monomers and resin mixtures (TR4HP3SA/ESO 
and CD6HP8SA/ESO at 50/50 ratios) before and after cure are shown in Figure 
4.2B. The spectra clearly showed that a shoulder adsorption band at ~1706 cm-1 
from the -COOH groups of hardeners, and the epoxide ring peaks at 900-750 
cm-1 disappeared after thermal curing. The presence of hydroxyl groups from 
epoxide ring opening after polymerization is represented by a broad peak at 3450 
cm-1. These results indicate the successful crosslinking of epoxides and -COOH 
groups to form polymers (Figure 7.26 and 7.27 Appendix), and the data agree 
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well with our previous report.231 The exotherm peaks of bulk polymerizations from 
DSC isothermal scans at 165 °C (Figure 7.28, Appendix) disappeared after ~25 
min, indicating the fast curing rate for the two epoxy resin systems. Therefore, 
the formulated epoxy resins were polymerized at ~165-170 °C. 
The very small difference between peak temperatures of TR4HP3SA/ESO 
and CD6HP8SA/ESO under the same conditions (Figure 4.2A and Figure 7.29 in 
the Appendix), indicate the similar thermal curing reactivity of hardeners 
TR4HP3SA and CD6HP8SA.231, 252 This is also supported by determining the 
activation energy of the thermal curing polymerizations using the peak 
temperatures at different heating rates of dynamic DSC scans by Kissinger’s 
method.231, 253 The Kissinger’s theory (Kissinger equation) is shown as below:  
-ln(q/Tp2) = Ea/RTp – ln(AR/Ea). 
The slope of the plot of −ln(q/Tp2) versus 1/Tp can provide us the apparent 
activation energy, where q is the heating rate of DSC thermal curing scans, Tp is 
the exothermic peak temperature, Ea is the activation energy, R is the gas 
constant (8.314 J mol−1 K−1), and A is the pre-exponential factor. As shown in 
Figure 4.2C, the Ea values of the thermal curing reactions for TR4HP3SA/ESO 
50/50 and CD6HP8SA/ESO 50/50 were calculated as 57.1 kJ mol-1 and 54.9 kJ 
mol-1, respectively, and the close values between the two hardeners demonstrate 
a similar curing reactivity. 
 150 
 
 
4.3.3 Thermal Properties 
The homogeneous resin mixtures at different -COOH/epoxide ratios were 
thermally cured, and the thermal properties and thermal stability of the resulting 
polymers under nitrogen atmosphere were investigated by DSC and 
 
 
Figure 4.2. DSC curing thermograms of (A) TR4HP3SA/ESO and 
CD6HP8SA/ESO (50/50) under nitrogen, 5 °C min-1; FT-IR spectra of (B) 
CD6HP8SA, ESO, CD6HP8SA/ESO (50/50) before and after curing (arrows 
denote peaks of interest to support crosslinking reaction); (C) linear plot of 
−ln(q/Tp2) versus 1000/Tp based on Kissinger's equation. 
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thermogravimetric analysis (TGA). Tuning the mixing ratio of the hardeners and 
epoxy in the resins can impact the cross-linking reaction and the properties of the 
resulting polymers. The Tg of each resulting polymer set (Table 4.1 and Figure 
4.3B) were very close to each other, ranging from -3 to 3 °C for TR4HP3SA/ESO 
polymers and from 28 to 36 °C for CD6HP8SA/ESO polymers, and the polymers 
at 50/50 ratios of -COOH/epoxide exhibited slightly higher Tg for each resin 
systems. As shown in Table 4.1and Figure 4.3B, the degradation temperatures at 
5% weight loss (Td5) of the cured polymers were from ~310 to ~230 °C. This is 
higher than the Td5 of both hardeners (Figure 7.30, Appendix), indicating the 
formation of the crosslinked networks within polymers and the higher thermal 
stability of the polymers. Similar to our previous report,231 the Td5 dramatically 
decreased when increasing the ratios of -COOH/epoxide, likely due to the excess 
hardener -COOH groups with lower thermal stability remaining in the polymers 
but not participating in the crosslinking reaction, lowering the crosslinking density 
of the polymers.254 The swelling ratio and gel fraction of the polymers were tested 
in tetrahydrofuran (THF) which is a good solvent for hardeners, ESO, and linear 
polyesters, and the ratios are listed in Table 4.1. 
The examined polymers maintained their polymer network upon immersing 
them in THF for 48 h, revealing that both monomers participated in 
polymerization and formed crosslinked polymer networks at all -COOH/epoxide 
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ratios. The CD6HP8SA/ESO resin polymers exhibited much lower swelling ratios 
and higher gel fractions than those of TR4HP3SA/ESO resins, indicating that the 
higher structural rigidity and the formation a network with higher crosslinking 
density for CD6HP8SA/ESO polymers than TR4HP3SA/ESO polymers.231 The 
swelling ratios of all polymers increased and their gel fractions decreased when 
increasing the -COOH/epoxide ratio from 40/60 to 60/40, possibly due to the fact 
that the excess of epoxide groups at lower -COOH/epoxide ratios could further 
participate in the crosslinking reaction and result in higher crosslinking density.231, 
254 
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Table 4.1. Crosslinked thermoset characterization data. 
 
a Determined by immersing the samples in THF for 48 h, the wet weight 
was measured for the swelling ratio calculation. The dry weight was measured 
for the gel fraction calculation after drying the samples at 50 °C under high 
vacuum. b Temperatures at 5% weight loss were determined using TGA. c 
Temperatures were determined by performing DSC at 10 °C min-1 under 
nitrogen. 
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4.3.4 Tensile Properties 
The tensile bars of TR4HP3SA/ESO and CD6HP8SA/ESO at different 
ratios were prepared and the tensile properties of the polymers were 
investigated. TR4HP3SA/ESO resins cured as slightly dark yellow tensile bars in 
a rubber mold after removing residual acetone under high vacuum followed by a 
pre-curing/post-curing process. And the solid CD6HP8SA/ESO resin mixtures 
were directly cured as light yellow tensile bars in a hot press for mechanical 
measurements. As shown in Table 4.2 and Figure 4.4, the thermosetting 
polymers displayed linear responses at low strains of 50% and 7% for 
TR4HP3SA/ESO and CD6HP8SA/ESO, respectively. While TR4HP3SA/ESO 
polymers showed tensile strength of between 0.5 and 1.3 MPa with a strain of 
66-186%, cured CD6HP8SA/ESO samples exhibited much a higher tensile 
 
Figure 4.3. (A) DSC thermograms (second heating) and (B) TGA curves for 
cured TR4HP3SA/ESO and CD6HP8SA/ESO at different ratios with a heating 
rate of 10 °C min-1 under nitrogen. 
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strength of around 10 MPa with a smaller strain of about 40%, probably due to 
the more rigid structure and higher cross-linking density of the CD hardeners. 
This is also supported by the fact that all CD6HP8SA/ESO polymers showed 
very typical plastic deformation in stress-strain curves (Figure 4.4B). Both epoxy 
resin systems have relatively low Young’s moduli of up to ~2.4 and 302 MPa for 
TR4HP3SA/ESO and CD6HP8SA/ESO polymers, indicating the flexible and soft 
nature of the epoxy polymers at room temperature. Both tensile strength and 
Young’s moduli of TR4HP3SA/ESO polymers decreased as the ratios of -
COOH/epoxide increased from 40/60 to 60/40. However, the tensile strength and 
Young’s moduli of CD6HP8SA/ESO polymers increased and then decreased as 
the ratios of -COOH/epoxide increased from 40/60 to 60/40, but with less obvious 
effect on the tensile strength. These results indicate that the chemical structure of 
the hardeners and epoxy can significantly influence the cross-linking density of 
the polymers and their mechanical properties. 
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Table 4.2. Crosslinked thermoset tensile and thermal mechanical 
characterization. 
 
a Determined from stress-strain tests and averaged from at least 5 tensile 
bars. b Determined from dynamic mechanical analysis (temperature sweep) at 
25 °C with torsion geometry. 
 
Figure 4.4. Representative stress-strain curves for cured (A) TR4HP3SA/ESO 
and (B) CD6HP8SA/ESO at different ratios by tensile testing from at least 5 
polymer tensile bars. 
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4.3.5 Dynamic Mechanical Properties 
Dynamic mechanic analysis (DMA) experiments of the cured polymers were 
recorded to study the effect of temperature on their mechanical properties, and 
the storage moduli of the polymers as a function of temperature are shown in 
Figure 4.5. All examined epoxy resin polymers were in a glassy state at low 
temperature (< -20 °C), and their storage moduli were almost constant at ~0.5-
0.9 GPa. As the temperature increased, their storage moduli exhibited a 
noticeable drop (-15 to 32 °C for TR4HP3SA/ESO and 0 to 70 °C 
CD6HP8SA/ESO polymers) due to the polymer chain relaxation at the glass 
transition. We observe that CD6HP8SA/ESO polymers had much higher storage 
moduli than TR4HP3SA/ESO polymers, especially in their rubbery state at 
elevated temperatures. And the storage moduli drop of CD6HP8SA/ESO epoxy 
resins was over a range of ~70 °C, which is much slower comparing to a range of 
only ~45 °C for the TR4HP3SA/ESO resins. This is consistent with our previous 
discussion that the CD moieties in the CD6HP8SA/ESO polymers enhanced 
polymer rigidity and cross-linking density which restricted and retarded the 
polymer chain mobility.231, 255, 256 The loss factor (tan δ) of epoxy resins (Figure 
7.31, Appendix) also showed that the CD6HP8SA/ESO polymers had much 
broader tan δ peaks and lower tan δ intensity, indicating the presence of a highly 
cross-linked polymer network.257 The ratios of -COOH/epoxide did not show 
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significant effect on the glass transition temperatures of the examined polymers, 
as indicated by the close peak values of tan δ (Figure 7.31, Appendix), which is 
consistent with the previous discussion on Tg obtained from DSC experiments 
(Table 4.1). 
 
4.3.6 Hydrolytic Degradation 
The hydrolytic stability of the cured epoxy resins was measured in neutral, 
acidic, and basic aqueous environments at room temperature by monitoring the 
weight loss of the examined polymers over time. As shown in Figure 4.6A and 
Figure 7.32A (Appendix), the cured TR4HP3SA/ESO and CD6HP8SA/ESO 
epoxy polymers swelled to different levels after day 1 under neutral aqueous 
conditions, and there was no further weight loss nor swelling behavior observed 
over the next 69 days. Similar to the neutral conditions, all epoxy resin polymers 
only swelled under acidic conditions without any weight loss during the hydrolytic 
 
Figure 4.5. Storage modulus versus temperature for the cured 
TR4HP3SA/ESO and CD6HP8SA/ESO thermosets at different ratios by DMA. 
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experiments (Figure 4.6B and Figure 7.32B, Appendix) This is different from our 
previous report where similar epoxy resin polymers completely degraded to 
water-soluble components after 50-90 days under acidic conditions.231 Clearly, 
the incorporation of hydrophobic HP and ESO moieties greatly enhanced the 
hydrophobicity of the resulting polymers which hampered their acidic 
degradation. However, both the solid TR4HP3SA/ESO and CD6HP8SA/ESO 
polymer samples quickly degraded over a varying time period of 1 hour to 1.5 
days in 1 M NaOH as gel mixtures due to the presence of amphiphilic fatty acid 
salts (Figure 4.6C and Figure 7.32C, Appendix). The polymers with higher -
COOH/epoxide ratios degraded much more quickly, probably due to the excess 
of -COOH groups in the polymer network allowing rapid water penetration to 
facilitate the hydrolysis under basic conditions. Based on our previous report on 
monitoring the hydrolytic degradation products of sustainable epoxy polymers 
using 1H NMR,231 we anticipate that the degradation products consisted of TR, 
CD, disodium succinate, and the ring-opened product of ESO (and/or its 
derivatives of glycerol and salts of fatty acids) which are environmentally benign. 
 160 
 
 
4.3.7 Surface Morphology and Wettability 
The TR4HP3SA/ESO 50/50 and CD6HP8SA/ESO 50/50 epoxy resin 
polymer films after thermal curing in glass petri dishes were selected to study 
their film surface morphology and wettability, which are two factors affecting cell 
adherence and proliferation.225, 258, 259 Shown in Figure 4.7 are the SEM surface 
morphologies of the surfaces of (A) a glass petri dish, (B) a PLG film (a positive 
control for cell proliferation study), and (C-D) the thermally cured epoxy polymer 
 
Figure 4.6. Hydrolytic degradation/stability profile of cured TR4HP3SA/ESO at 
different ratios in (A) water, (B) 1 M HCl, and (C) 1 M NaOH. The error bars 
represent the standard deviation from the mean of 3 measurements. 
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films. As shown, the PLG film, the TR4HP3SA/ESO 50/50 film, and the 
CD6HP8SA/ESO 50/50 film were smooth and homogeneous, and there was no 
cracking or phase separation observed, showing that the hardeners and soy 
bean oil were fully miscible during the curing process. The water contact angles 
of both cured TR4HP3SA/ESO 50/50 and CD6HP8SA/ESO 50/50 polymer films 
are shown in Figure 4.7, and are compared to a glass substrate and the positive 
control PLG film. The contact angle of the glass substrate was ~34.7°, and it 
increased to ~79.1° for PLG film. The contact angles of the TR4HP3SA/ESO 
50/50 and CD6HP8SA/ESO 50/50 polymers films were ~84.6° and ~88.6°, 
respectively. These results show that the examined epoxy resin polymers are 
more hydrophobic than PLG. 
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Figure 4.7. SEM images of (A) glass surface, (B) PLG, (C) TR4HP3SA/ESO 
50/50 and (D) CD6H8SA/ESO 50/50 (scale bar = 500 nm). 
 
Figure 4.8. Water contact angles of glass surface, PLG, TR4HP3SA/ESO 
50/50 and CD7HP8SA/ESO 50/50. 
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4.3.8 In Vitro Biocompatibility 
The TR4HP3SA/ESO 50/50 and CD6HP8SA/ESO 50/50 polymer films 
were prepared in glass petri dishes, and the cell adhesion and proliferation on 
the polymer film surfaces were investigated and quantified by confocal 
microscopy and flow cytometry using the human dermal neonatal fibroblast cell 
line (HDFn). HDFn cells were seeded and cultured on the TR4HP3SA/ESO 
50/50 and CD6HP8SA/ESO 50/50 polymer films. HDFn cells were also cultured 
on PLG films as positive control. Figure 4.8 and Figure 7.33 (Appendix) captured 
the cell growth characteristics on the polymer films of TR4HP3SA/ESO 50/50, 
CD6HP8SA/ESO 50/50, and control PLG over a 5-day culture period and the 
percentage of those cells that are alive (note the drastically different y-axis range 
when comparing Figure 4.9 and Figure 7.33). As seen in Figure 4.9A, HDFn cells 
adhered to CD6HP8SA/ESO 50/50 and to control PLG polymer films on day 1, 
and exponentially proliferated through day 4 and leveled out by day 5. Both 
CD6HP8SA/ESO 50/50 and control PLG polymer films exhibited high cell viability 
(Figure 4.9B) as indicated by the high percentage of cells that are alive on each 
sample. In conjunction, these results demonstrate the low toxicity and similar 
biocompatibility of the CD6HP8SA/ESO 50/50 polymer compared to that of PLG 
control copolymer. In contrast, the TR4HP3SA/ESO 50/50 polymer did not allow 
HDFn cells to adhere or grow on the film surface (Figure 7.33, Appendix). To 
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probe this lack of adherence, HDFn cells were seeded onto the TR4HP3SA/ESO 
50/50 polymer films, and both the supernatant above the film and the adhered 
cells on the film after 24 h cell culture were collected for cell count analysis by 
flow cytometry. The film did not allow cells to adhere, nor did many cells survive 
in the supernatant over the course of 24 h as shown in Figure 7.34 (Appendix). 
Representative raw flow cytometry data for the cell quantification is shown in 
Figures 7.35-7.38 (Appendix).  
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Currently, there is no data to support that the TR4HP3SA/ESO 50/50 film 
actively kills cells, and cells may simply be unable to adhere on the surface, 
which could affect their viability indirectly. As discussed earlier, the surface 
morphologies and wettability of the TR4HP3SA/ESO 50/50 and CD6HP8SA/ESO 
 
Figure 4.9. (A) Average number of cells and (B) the percentage of those cells 
that are alive on CD6HP8SA/ESO 50/50 and PLG films at day 1 through day 5 
by flow cytometry. N=4 for each assay, and the error bars represent the 
standard deviation from the mean. No CD6HP8SA/ESO samples were 
statistically different (p<0.05) from the PLG controls according to the Student’s 
t-test. 
 166 
 
50/50 polymer films did not significantly differ. A preliminary leaching screen 
study showed that neither polymers is leaching much material as indicated by the 
very similar gel fractions (by immersing the films in cell culture medium for 150 
days) of 94.8±0.5% and 92.0±1.3% for TR4HP3SA/ESO 50/50 and 
CD6HP8SA/ESO 50/50 polymer films, respectively. Therefore, further studies are 
needed to explain the cause of their starkly different cell adhesion/proliferation 
properties.  
Quantification of the cell surface area and circularity (Figure 4.10A and B) 
indicates that cells proliferated and spread on the CD6HP8SA/ESO 50/50 
polymer films, and the cells’ physical characteristics were comparable to those 
cultured on the control PLG films. The cellular morphology on CD6HP8SA and 
the control PLG films from day 1 to day 5 after seeding was visualized with a 
confocal fluorescence microscope (Figure 4.10C and Figures 7.39-43, 
Appendix). The cells on the cured CD6HP8SA/ESO 50/50 films showed no 
significant morphological difference compared to cells on the control PLG, further 
supporting that CD6HP8SA/ESO 50/50 polymer is at least as biocompatible as 
that of PLG in vitro. 
 
 167 
 
 
4.4 CONCLUSION 
We reported the synthesis and characterization of fully sustainable 
thermosetting epoxy polymers from renewable starting materials including 
trehalose or β-cyclodextrin, heptanoic acid, succinic anhydride and epoxidized 
soybean oil. Two new epoxy hardeners were prepared in high yields via a two-
 
Figure 4.10. (A) Average cell surface area in µm2, (B) average cell circularity 
(0-1.0), and (C) confocal micrographs of cells proliferated on the 
CD6HP8SA/ESO 50/50 and control PLG polymer films at day 1 to day 5 
culture. Cell morphology on films were measured by confocal microscopy of 
the calcein signal in living cells and processed by ImageJ. A minimum of N=80 
measurements (maximum N=225) were averaged for each data point, and the 
error bars represent the standard deviation from the mean. No samples were 
statistically different (p < 0.05) according to the Student’s t-test. 
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step one-pot reaction, and their thermal curing behavior with ESO was studied. 
The thermal properties, mechanical performance, hydrolytic degradation under 
various aqueous environment and the cell adhesion and proliferation properties 
of the resulting epoxy resin polymers were investigated. DSC experiments 
indicated that the formulated epoxy resins were thermally cured at ~165 °C and 
the resulting cured epoxy polymers had thermal stability up to ~300 °C. Both 
tensile testing and thermal mechanical analysis suggested that the 
TR4HP3SA/ESO 50/50 and CD6HP8SA/ESO 50/50 polymers were soft and 
flexible materials. The epoxy polymers are quickly degraded to water-soluble 
components in basic solution but formed gel-like mixtures, and the epoxy resins 
are resistant to degradation in both acidic and neutral aqueous conditions over a 
testing period of 69 days. Our results indicate that our TR-based epoxy polymers 
with ratio of -COOH/epoxide at 50/50 did not allow HDFn cells to adhere and 
proliferate, suggesting the potential anti-fouling applications of TR-based epoxy 
polymer film. However, CD-based polymer with a ratio of -COOH/epoxide at 
50/50 did promote cell adhesion and growth on the polymer surface, indicating its 
comparable biocompatibility to PLG control copolymers and its potential use in 
tissue engineering applications. The drastically different cell adherence 
properties of TR4HP3SA/ESO and CD6HP8SA/ESO may suggest an interesting 
mechanism behind the TR4HP3SA polymer’s ability to prevent cell growth. More 
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work is necessary to identify and understand the structure-property functions 
driving this phenomenon. 
4.4.1 Appendix Includes: 
1H NMR of the hardeners, DSC, isothemal DSC, TGA, FT-IR, tan δ vs 
temperature curves, hemolytic degradation profiles, fibroblast cell morphology 
confocal images, raw cell count data, and flow cytometry gating procedures are 
included in the Supplementary Information. 
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CHAPTER 5: CONCLUSION 
5.1 IN VITRO, EX VIVO, AND IN VIVO STRUCTURE-FUNCTION 
5.1.1 Improving Glycopolycation Polyplexes for Systemic Delivery 
Future work developing polyplex vehicles for systemic gene delivery should 
build on the structure-function relationships uncovered through studies in vitro, ex 
vivo, and in vivo. Ex vivo hemocompatibility and in vivo biodistribution supported 
the hypothesis that colloidal stability was an important polyplex function for 
achieving systemic delivery. However, complement activation results and the 
capture of P(MAG-b-MAEMt)-2 N/P=5 polymers by the liver indicate that colloidal 
stability is not sufficient for systemic delivery. While the bulkiness of the P(MAG) 
block demonstrated superior hemocompatibility compared to the P(EG) block in 
the hemolysis study, it may also play a role in delaying coagulation. Further 
protein-binding assays should be done to explore the extent of coagulation factor 
binding by the glycopolyplexes to determine if they are indeed interacting with 
those proteins, and if so, could P(MAG-b-MAEMt) polymers find a new 
application the field of anticoagulant medications. 
Now that widespread biodistribution has been achieved, it should be 
possible to add targeting moieties to the P(MAG-b-MAEMt) polyplexes such as 
N-acetal galactosamine. Acetylated sugars have been known to activate 
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complement systems, so any targeting additions should be thoroughly screened 
for hemocompatibility ex vivo.  
5.1.2 Continuing B Cell Transfection 
Future work for transfecting B cells with non-viral cationic polyplexes should 
focus on developing or obtaining a satisfactory positive control. B cells of the 
same line that are genome edited to constitutively express GFP or IDUA protein 
would improve the quantification of gene expression generated by polyplex 
transfection. After obtaining a control, future screens could widen the pool to try 
transfecting other lymphocytes, or even stem cell precursors to B cells. Lastly, it 
has been shown that B cells endocytosis at different rates based on their age. 
Syncing the cells and aiming transfection during mitosis stages or even obtaining 
younger B cells could dramatically increase transfection using the polymers 
already developed. If that fails, new polymers could be designed with B cell 
physiology specifically in mind. 
5.1.3 Continuing Glycofilm Studies 
The trehalose- and β-cyclodextrin-based epoxy films presented similar 
physical properties upon crosslinking, but had dramatically different 
biocompatibility profiles. Future work will focus on identifying the structure-
function relationships that contribute to those profiles. Initial tests should test both 
films for possible leachate that may kill cells or alter their physiology. Epoxide 
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functionality could be shuffled to probe the effects of different functional groups 
on the cell adhesion levels. 
5.2 SUMMARY 
Polymers contribute almost limitless chemistry, architecture, and 
functionality combination possibilities to the field of non-viral gene delivery. Many 
novel and creative vehicles have been made to overcome the intracellular and 
extracellular hurdles preventing these vehicles from effectively delivering their 
genetic payload, but not all vehicle functions are well understood in complex 
environments. The work discussed herein supports the trend that all polymeric 
gene delivery vehicles should be screened using a combination of experimental 
environments in addition to the standard in situ and in vitro screens. Screens ex 
vivo and in vivo supported previous in vitro work in highlighting the importance of 
polyplex colloidal stability, but also identified new structure-function relationships 
important to achieving system and cellular delivery. In time, ex vivo and in vivo 
screening methods will become easier to do, and will simultaneously become 
standard in the field just as in vitro screening methods did. Clarifying structure-
function in complex environments will pave the way for more effective vehicles to 
be developed, and advance the use of safe, effective gene therapy for patients 
awaiting relief. 
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CHAPTER 7: APPENDIX 
7.1 ABBREVIATIONS AND ACRONYMS 
AEMA N-(2-aminoethyl) methacrylamide 
AP Alternative pathway 
aPTT Activated partial thromboplastin time 
C3 Complement component 
C57BL/
6J  
Wild type black 6 mice 
CAGGS Strong synthetic DNA promoter 
CARPA Complement activation-related pseudoallergy 
CD Cyclodextrin 
CP Classical pathway 
CPP 4-cyano-4-(propylsulfanylthiocarbonyl) sulfanylpentanoic 
acid  
CT Cycle threshold 
CTA Chain transfer agent 
Cy5 Cyanine 5 
Cy7 Cyanine 7 
Đ Dispersity 
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D5W 5% by weight aqueous dextrose solution 
Da Daltons 
DLS Dynamic light scattering 
DMAEM
t 
N,N-dimethyl aminoethylmethacrylate 
DMEM Dulbecco’s Modified Eagle Medium 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acids 
DSC Differential scanning calorimetry 
ESO Epoxidized soybean oil 
FBS Fetal bovine serum 
FT-IR Fourier transform infrared 
GalNAc N-acetyl galactose 
GFP Green fluorescent protein 
GPC Gel permeation chromatography 
HP Heptanoyl chloride 
HD Hydrodynamic diameter 
HDFn Neonatal human dermal fibroblasts 
HepG2 Human liver carcinoma 
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Luc Luciferase 
MAEMt N-methyl aminoethylmethacrylate 
MAG 2-deoxy-2-methacrylamido glucopyranose 
MAT 6-Methacrylamido-6-deoxy trehalose 
MBLP Mannan-binding lectin pathway 
Mn Number average molecular weight 
MWCO Molecular weight cutoff 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide 
NMR Nuclear magnetic resonance 
N/P Charged nitrogen to charge phosphate ratio 
OptiME
M 
Minimum Essential Medium with reduced serum 
OptiMEM 
PAMAM Polyamidoamine 
PAMPs Pathogen-associated molecular patterns 
PBS Phosphate buffered saline 
pDNA Plasmid DNA 
PEI Polyethyleneimine 
PEG Polyethylene glycol 
PI Propidium iodide 
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PLG Poly(DL-lactide-co-glycolide) 
pT2/CA
L 
Plasmid DNA with CAGGs promotor 
PT Protothrombin time 
PTT-LA Partial thromboplastin time-Lupus anticoagulant reagent 
RAFT Reversible-addition-fragmentation chain-transfer 
Rh Hydrodynamic radius 
RLUs Relative light units 
RNA Ribonucleic acids 
RPMI Roswell Park Memorial Institute cell culture medium 
SA Succinic anhydride 
SEC Size exclusion chromatography 
SWNT Single-walled nanotube 
Tg Thermogravimetry 
THF Tetrahydrofuran 
TMAEM
t 
N,N,N-trimethylammoniumethylmethacrylate 
TR Trehalose 
U87 Human glioblastoma 
V501 4,4’-Azobis(4-cyanopentanoic acid) 
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WT Wild type 
λ Wavelength 
δ Loss factor 
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7.2 PRELIMINARY GLYCOPOLYCATION B CELL TRANSFECTION RESULTS 
Synopsis 
Gene therapy has the potential to improve treatment of MPS I compared 
to conventional treatment options by altering patients' cells to produce and 
secrete IDUA over time. To obtain long-term expression of a gene, it must be 
incorporated into the cell genome. Sleeping Beauty (SB) is a non-viral genome 
engineering system that makes an enzyme to "cut and paste” genes from 
plasmids DNA into the chromosomes of cells. A major limiting factor for gene 
integration is the amount of SB plasmid the cells take up. Rather than design and 
synthesize a new polymer to increase uptake into a specific cell line, a series of 
glycopolymers previously created in the Reineke Lab were screened for 
transfection against primary human B cells. These polymers differed in the type 
of sugar used as well as the amount of charge in the structure, but all four 
glycopolymers demonstrated biocompatibility and increased gene expression in 
human cell lines compared to other commercially available cationic polymer 
controls.  
 
This chapter was adapted with permission from the authors listed below. 
a) Haley R. Phillips 
b) Craig Van Bruggen 
c) Theresa M. Reineke 
 
This chapter was adapted with permission from the authors listed below. 
d) Haley R. Phillips 
e) Craig Van Bruggen 
f) Theresa M. Reineke 
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7.2.1 Introduction 
The goal of this proposal is to improve production of a therapeutic protein 
by cells that can be transplanted into patients as a form of therapy. Cellular 
uptake of Sleeping Beauty (SB), a genome editing system made of DNA, 
correlates with increased protein expression. Polymers with carbohydrates, 
called glycopolymers, have previously increased gene uptake in various human 
cancer cells, but success varied based on cell and polymer type. Rather than 
design and synthesize a new polymer to increase uptake into a specific cell line, 
a series of glycopolymers will be screened for protein production against five 
blood cell types. 
Gene therapy is the treatment of disease by altering gene expression in 
cells, which is a promising option for autosomal recessive diseases such as 
mucopolysaccharidosis type I (MPS I). Patients with MPS I lack a functioning α-
L-iduronidase (IDUA) enzyme to digest specific chains of sugars, which are 
generated by all cells as a normal part of the cell life cycle. Accumulation of those 
sugar chains in cells affects major organs during development and the most 
severe cases can lead to death. MPS I is currently treated by stem cell 
transplantation or by repeated enzyme injections. Neither option has fully treated 
the neurological or skeletal symptoms because both methods are dose-limited by 
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the amount of cells that can be grafted or the amount of IDUA enzyme that 
persists in circulation over time.260 
Gene therapy has the potential to improve treatment of MPS I compared 
to conventional treatment options by altering patients' cells to produce and 
secrete IDUA over time. To obtain long-term expression of a gene, it must be 
incorporated into the cell genome. Sleeping Beauty (SB) is a non-viral genome 
engineering system that makes an enzyme to "cut and paste” genes from 
plasmids (circular pieces of DNA unassociated with the genome) into the 
chromosomes of cells.102 These genes can be expressed for the lifetime of the 
cell, even after the cell replicates. Both the gene to be incorporated and the gene 
that codes for the enzyme are located on the same plasmid. Once the plasmid is 
inside the cell, the cell’s own machinery will read the SB gene, make the enzyme, 
then perform the gene transfer.  
A major limiting factor for gene integration is the amount of SB plasmid the 
cells take up. Cationic polymers are used to increase cellular uptake by shielding 
the negative charge on DNA, which would be repulsed by the negatively charged 
membrane of mammalian cells. Polymers with carbohydrates, called 
glycopolymers, have previously increased gene uptake in various human cancer 
cells, but success varied based on cell and polymer type.22, 155 Rather than 
design and synthesize a new polymer to increase uptake into a specific cell line, 
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a series of glycopolymers created in the Reineke Lab will be screened for protein 
production against primary human B cells. These polymers differ in the type of 
sugar used as well as the amount of charge in the structure, but all four 
glycopolymers demonstrated biocompatibility and increased gene expression in 
human cell lines compared to other commercially available cationic polymer 
controls.24, 83, 123, 261 
Two short-term specific aims outline how combining polymer chemistry 
and gene engineering will help achieve the long-term goal of improving MPS I 
treatment. 
Specific aim 1: Screen delivery efficiency of a suite of cationic 
glycopolymer gene delivery vehicles into an immortalized primary human 
cell line. 
An immortalized primary human B cell line was cultured and transfected in 
vitro. Three cationic glycopolymers were selected for the screen based on 
previous transfection efficiency in cell culture.58, 83, 262 P(MAG-b-MAEMt)-2, 
P(MAT-b-MAEMt)-2, and Tr477, with and without heparin. Commercial controls 
Glycofect, JetPEI, Fugene, and Lipofectamine were also screened. The Sleeping 
Beauty (SB) plasmid coded for green fluorescent protein (GFP), and gene 
expression was screened directly by measuring GFP production via flow 
cytometry. Many factors contribute to the production of protein, so polymer SB 
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complex uptake and cell viability will also be measured according to published 
methods.58, 83, 262 However, the most important factor for improving MPS I therapy 
is long-term production of protein, so polymer-cell combinations that give the 
highest amount of gene expression over time will be studied further in aim 2. 
Specific aim 2: Quantify the expression and chromosomal insertion of the 
iduronidase gene by delivery with the Sleeping Beauty transposon system into 
MPS I patient cells using glycopolymers as determined in aim 1. 
After initial screening of gene expression with the reporter protein, GFP, in 
normal human blood cells, the incubations will be repeated on cells from MPS I 
patients. The amount of patient samples is limited, so the experiment will be 
repeated using only the cells and polymer combinations that gave the highest 
gene expression in aim 1. The reporter gene will be replaced with the gene for 
IDUA, and expression will be determined by quantifying the amount of protein 
produced both short- and long-term via a fluorimetric assay.3 Once the long-term 
production of IDUA has been established by cellular uptake of SB guided by 
glycopolymers, future work may focus on transplanting those cell populations into 
MPS I model mice, and finally into human patients awaiting relief. 
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7.2.2 Experimental 
7.2.2.1 Materials 
All reagents were obtained at the highest available purity from Thermo 
Fisher Scientific, Inc. (Pittsburgh, PA) or Sigma-Aldrich Co. LLC. (St. Louis, MO) 
and used as received unless noted otherwise. A primary human B-Lymphocyte 
cell line (BLCL) immortalized using an Epstein-barr viral vector was ordered 
through the Coriell Institute (Camden, NJ). JetPEI was obtained from Polyplus-
transfection SA (Illkirch, France).  Glycofect was obtained from Techulon, Inc. via 
donation. Propidium iodide, UltraPureTM Agarose-1000, trypsin, (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), phosphate-buffered 
saline (PBS), Minimum Essential Medium with reduced serum (Opti-MEM) and 
Dulbecco’s Modified Eagle Medium (DMEM) were purchased from Life 
Technologies – Thermo Fisher Scientific (Carlsbad, CA). The pT2/CAL plasmid 
was prepared as described previously.35 The Luciferase Assay Kit and cell lysis 
buffer were obtained from Promega Corporation (Madison, WI). Bio-Rad DC 
Protein Assay Reagent A, Reagent B and Reagent S were obtained from Bio-
Rad Laboratories, Inc. (Hercules, CA). The cells were grown in complete DMEM 
[supplemented with 10% (v:v) fetal bovine serum and 1% antibiotic-antimycotic 
solution (containing penicillin, streptomycin, and amphotericin B)] at 37 ºC and 
5% CO2 in a humidified incubator. 
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All polymers were synthesized previously.58, 83, 262 
7.2.2.2 Instrumentation 
MTT, protein, and luciferase assay plates were analyzed using a Biotek 
Synergy H1 plate reader (BioTek Instruments, Inc., Winooski, VT). Cy5-uptake 
was measured on a FACSVerse (Becton Dickinson Biosciences, San Jose, CA) 
flow cytometer. Cell imaging was performed on an EVOS FL digital inverted 
microscope (Fisher Scientific, Pittsburg, PA). 
7.2.2.3 B Cell Culture and Seeding Methods 
B cells are non-adherent and had to be shaken gently during incubation 
periods. Additionally, this particular cell line preferred to grow at higher cell 
concentrations than the adherent cancer cell lines typically used in this lab (). 
Lastly, B cells need non-heat inactivated FBS protein supplementing their cell 
culture media. DMEM can be used, but it is recommended that RPMI media is 
used instead. Make a mixture of RPMI + 10%-by-volume FBS with 1%-by-volume 
penicillin-streptomycin antibiotic like you normally would for adherent cancer cell 
lines. 
To seed cells for an experiment, seed at an initial concentration of 250,000 
cells/mL, and leave 1-2 mL working volume in the well to allow the addition of 
polyplexes and more cell media. This avoids having to take the cells out of the 
wells, spin them down, and resuspend in fresh media just to feed them during 
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experiments. The cells will dilute over time, but will remain healthy if not overly 
diluted at any point. 
7.2.2.4 MTT and Luciferase Assay Methods 
MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) was 
used to estimate the cytotoxicity of the polyplexes. B cells were seeded at 
250,000 cells/well in 24-well plates 24 h prior to transfection. Polyplexes were 
formulated as described previously, then polyplex solution was diluted 2x with 
either OptiMEM or RPMI containing 10% FBS before dosing cells (overall 
volumes varied depending on pDNA dose, but pDNA concentration was kept the 
same). The transfection was ended 4 h later by diluting polyplexes with 1 mL of 
complete DMEM containing 10% FBS.  48 h after polyplexes were added to the 
cells, 0.5 mg/mL of MTT was added to each well and incubated for 1 h. Cells 
were lysed using DMSO and 200 µL aliquots were transferred to a 96-well plate 
for analysis using the plate reader (absorbance was measured at 570 nm). Non-
transfected cells were used for normalizing the data. 
For the luciferase assay, B cells were seeded at 250,000 cells/well in 24-
well plates 24 h prior to transfection. Polyplexes were prepared, diluted, and 
applied to the cells as described in the cytotoxicity section above. After 48 h, the 
cells were washed with PBS and treated with cell lysis buffer.  Aliquots (5 µL) of 
cell lysate combined with 100 µL luciferase substrate were examined in 96-well 
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plates using a luminometer to determine relative light units (RLUs). Data were 
measured in triplicate and normalized for the amount of protein in each sample. 
Sample averages were plotted with error bars representing standard deviations. 
7.2.2.5 Flow Cytometry for Uptake and Gene Expression Studies 
Flow cytometry experiments were performed to examine the cellular uptake 
of Cy5-labeled pDNA 1, 4, and 7 h post-transfection in both OptiMEM and RPMI 
+ 10% FBS B cell culture media. B cells were seeded at 250,000 cells/well in 24-
well plates 24 h prior to transfection. Polyplexes were prepared as described for 
the MTT and luciferase assays. After 1, 4, or 7 h, the polyplex media was 
removed and cells were detached from the plate and washed twice with PBS. 
Finally, 1 mL PBS was added and the cellular suspensions were kept on ice.  
The same flow cytometry procedure was used to measure GFP expression 
in cells except the post-transfection time was kept at 4 h, and the pDNA dose 
was varied from 1 to 2 ug pDNA/50,000 cells. The assay was performed in both 
RPMI + 10% FBS and OptiMEM. 
7.2.3 Results 
7.2.3.1 Experimental Variables 
B lymphocytes are non-adherent and much small than any cells previously 
studied in this group. Methodological and experimental variables were nailed 
down first, and are summarized in Table 7.1. 
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7.2.3.2 Cytotoxicity and Preliminary Gene Expression 
Initial MTT and luciferase expression screens were used to test not only 
cytotoxicity and gene expression, but also to screen experimental variables such 
as pDNA dose. Figure 7.1 shows the MTT and luciferase expression results 
while varying the pDNA dose per 50,000 cells. The pDNA concentration was kept 
at 0.01 ug/uL, so the overall polyplex volume had to increase with dose. No 
polyplex formation or pDNA dose significantly affected cell viability or luciferase 
expression. 
Table 7.1. Summary of experimental variables for B cell transfection. 
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Figure 7.1. Preliminary polymer and pDNA dosing screens. The pDNA was 
dosed at x µg per every 50,000 B cells, and polyplexes were formulated at the 
normal pDNA concentration (0.02 ug/mL). Transfections were performed in 
OptiMEM. (A) Cytotoxicity results from an MTT assay. (B) Luciferase 
expression normalized to mg protein per sample. No statistics were 
performed.  
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7.2.3.3 Cell uptake 
Further testing of cellular uptake in cell culture media with and without FBS 
showed almost no uptake when FBS was present. Uptake in OptiMEM showed a 
surprising amount of cellular uptake of P(MAG-b-MAEMt)-2 at N/P=20 (Figure 
7.2).  
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A)
B)
 
Figure 7.2. Cell uptake results in (A) RPMI + 10% FBS and (B) OptiMEM. The 
transfection time was varied from 1-7 h, and pDNA was dosed at 0.2 
µg/50,000 B cells. No statistics were performed. 
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7.2.3.4 Quantitative gene expression 
To explore whether this uptake would produce quantifiable gene 
expression, pDNA coding GFP was substituted for the luciferase plasmid and 
expression was measured by flow cytometry. Figure 7.3 shows expression 
results when transfected with RPMI + 10% FBS and with OptiMEM. The results 
surprising seem to contradict the uptake results in that higher levels of gene 
expression were seen after transfecting in the presence of serum than in 
OptiMEM. While the overall percentages are low (<5% cells expressing), the 
results are promising enough to continue screening if a satisfactory positive 
control can be obtained or created. A good positive control would be the same B 
cell line genome engineered to constitutively express GFP. Those cells would 
help flow cytometry gating and data compensation. 
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A)
B)
 
Figure 7.3. GFP expression results with a pDNA dose at x µg/50,000 cells 
and a 4 h transfection time. Transfection was conducted in (A) RPMI + 10% 
FBS and (B) OptiMEM. No statistics were performed. 
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7.2.4 Conclusion 
Overall, rather surprising gene expression results were obtained. 
Transfection in the presence of serum led to higher levels of GFP expression, but 
lower cell uptake. P(MAG-b-MAEMt)-2 was the most promising vehicle, although 
Tr477 with heparin was also mildly successful at transfecting immortalized primary 
B cells. 
7.2.5 Acknowledgements 
The author would like to thank Craig Van Bruggen for assisting with the flow 
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7.3 SUPPORTING FIGURES 
7.3.1 Chapter 2 Figures 
 
 
Figure 7.4. NMR spectrum of P(MAG51-b-PMAEMT30). 
 
Figure 7.5. NMR spectrum of P(MAG51-b-PMAEMT42). 
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Figure 7.6. NMR spectrum of P(MAG51-b-PMAEMT76). 
 
Figure 7.7. NMR spectrum of P(MAG56-b-PDMAEMT32). 
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Figure 7.8. NMR spectrum of P(MAG56-b-PDMAEMT53). 
 
Figure 7.9. NMR spectrum of P(MAG56-b-PDMAEMT71). 
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Figure 7.10. NMR spectrum of P(MAG57-b-PDMAEMT33). 
 
Figure 7.11. NMR spectrum of P(MAG57-b-PDMAEMT48). 
 220 
 
 
 
Figure 7.12. NMR spectrum of P(MAG57-b-PDMAEMT72). 
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A)
B)
C)
 
Figure 7.13. P(MAG-b-MAEMt)-1, -2, and -3. 
 222 
 
 
 
A)
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C)
 
Figure 7.14. P(MAG-b-DMAEMt)-1, -2, and -3. 
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A)
B)
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Figure 7.15. P(MAG-b-TMAEMt)-1, -2, and -3. 
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Figure 7.16. 1H NMR spectrum (500 MHz, D2O) of P(MAT)43. δ ppm: 5.26 – 
4.96 (bs, 86H), 4.00 – 3.04 (m, 516H), 2.35 – 2.21 (bs, 2H), 1.79 – 0.61 (m, 
217H). 
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P(MAT-b-AEMA)-1
P(MAT-b-AEMA)-2
P(MAT-b-AEMA)-3
Elution Time (min)
 
Figure 7.17. SEC traces of P(MAT-b-AEMA) series of polymer. Lower 
retention time indicates higher molecular weight. SEC conditions: eluent = 1.0 
wt% acetic acid/0.1 M Na2SO4; flow rate = 0.4 mL/min; light scattering 
detector λ = 662 nm; refractometer λ = 658 nm.  
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Figure 7.18. 1H NMR spectrum (500 MHz, D2O) of P(MAT-b-AEMA)-1. δ ppm: 
5.18 – 4.97 (bs, 86H), 3.94 – 2.94 (m, 600H), 2.03-1.49 (m, 64H), 1.16 – 0.66 
(m, 192H). 
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Figure 7.19. 1H NMR spectrum (500 MHz, D2O) of P(MAT-b-AEMA)-2. δ ppm: 
5.18 – 4.97 (bs, 86H), 3.94 – 2.94 (m, 689H), 2.03-1.49 (m, 87H), 1.16 – 0.66 
(m, 224H). 
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Figure 7.20. 1H NMR spectrum (500 MHz, D2O) of P(MAT-b-AEMA)-3. δ ppm: 
5.18 – 4.97 (bs, 86H), 3.94 – 2.94 (m, 744H), 2.03-1.49 (m, 100H), 1.16 – 0.66 
(m, 300H). 
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Figure 7.21. ImageJ TEM analysis 
 230 
 
 
 
 
Figure 7.22. DLS in DMEM after lyophilization 
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Figure 7.23. HepG2 cell viability in OptiMEM. 
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Figure 7.24. HepG2 gene expression in OptiMEM. A) Luciferase protein 
expression. B) GFP expression. 
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Figure 7.25. HepG2 cell uptake in OptiMEM. 
 
Figure 7.26. Cell survival MTT Assay following incubation of cells with pMAT-
co-AEMA (-1, -2, and -3) polyplexes for 48 h in DMEM containing 10% FBS 
with U87 cells. The numbers on the x-axis represent the N/P ratio of polyplex 
formulation for each respective polymer.  All results are normalized to a 
sample containing cells that underwent no treatment and were allowed to 
proliferate normally for 48 h in DMEM containing 10% FBS. All experiments 
were performed in triplicate with error bars marking the standard deviation. 
Samples that were found to be statistically different from cells only survival 
were marked with an * (according to Student’s t-test with p = 0.05). 
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Figure 7.27. Cellular internalization of pMAT-co-AEMA polyplexes formed with 
Cy5-labeled pDNA and incubated with cells for 4 h in DMEM containing 10% 
FBS in U87 cells. The numbers on the x-axis represent the N/P ratio of 
polyplex formulation for each respective polymer.  All experiments were 
performed in triplicate, where the error bars indicate standard deviation. All 
samples that were found to be statistically different from DNA only uptake 
were marked with an *. Samples that were found to be significantly higher than 
the positive control jetPEI are marked with a +, and samples found to be 
statistically equivalent to jetPEI are marked with a = (according to Student’s t-
test with p = 0.05). 
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Figure 7.28. Luminescence of cell lysate following addition of luciferin in U87 
cells. Cells were incubated with the polyplex formulations for 4 h in DMEM 
containing 10% FBS followed by an additional 48 h to allow for protein 
expression. The numbers on the x-axis represent the N/P ratio of polyplex 
formulation for each respective polymer. All experiments were performed in 
triplicate with error bars showing standard deviation. All samples that were 
found to be statistically different from cells only luciferase expression were 
marked with an *. Samples that were found to be significantly higher than the 
positive control pAEMA are marked with a +, and samples found to be 
statistically equivalent to pAEMA are marked with an = (according to Student’s 
t-test with p = 0.05). 
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7.3.2 Chapter 3 Figures 
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Figure 7.29. 1H NMR of MAEMt monomer. 
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Figure 7.30. 1H NMR of the PEG macroCTA. 
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Figure 7.31. (A) 1H NMR and (B) SEC traces (Red trace: light scattering; blue 
trace: refractive index) of P(EG-b-MAEMt). 
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Figure 7.32. (A) 1H NMR and (B) SEC traces (Red trace: light scattering; blue 
trace: refractive index) of P(MAEMt). 
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Figure 7.33. Cy7 fluorophore tagging results. (A) Cy7-tagged sample 
absorbance comparing free Cy7-polymer to complexed Cy7-polymer. (B) Cy7 
absorbance spectra for the two Cy7-labeled polymers in water. The degree of 
polymer tagging was determined using the peak absorbance at λ = 750 nm. 
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Figure 7.34. Gel electrophoresis of polyplex formulations with new polymers 
and with all polymers used in animal studies. All experimental polymers fully 
bound the plasmid DNA at N/P = 5. 
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Figure 7.35. EtBr intercalation polyplex stability study. All polyplex samples 
prevented EtBr intercalation into pDNA cargo as compared to a pDNA only 
positive control. Each fluorescent sample was measured in triplicate and 
samples that significantly differed from the D5W negative control were marked 
with an asterisk (Student’s t test p < 0.05). 
 
Figure 7.36. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity. 
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Figure 7.37. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.38. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.39. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (DH) in nm, and the y-axis is unitless intensity.  
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Figure 7.40. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.41. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.42. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.43. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.44. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.45. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.46. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.47. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.48. DLS correlation function of FBS only transformed by REPES 
analysis. Timepoints taken after addition of FBS solution. The x-axis is the 
hydrodynamic diameter (HD) in nm, and the y-axis is unitless intensity.  
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Figure 7.49. Representative DIC microscopy images at 20x magnification. 
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Figure 7.50. Coagulation times in seconds for human platelet poor plasma 
(PPP) only compared to PPP incubated with polyplexes at N/P=15 for 1 h. The 
green bars show results when testing with normal aPTT assay conditions. The 
purple bars are the results when 50% by volume PPP (150 additional µL) was 
added to the test tube during the assay, and the blue bars are the coagulation 
times when twice as much reagent was used. 
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Figure 7.51. Fluorescent organ images after D5W or polyplex injection. (A) 
D5W only. (B) PEG-b-MAEMT-Cy7 N/P=5. (C) P(MAG-b-MAEMT)-2-Cy7 
N/P=5. (D) P(MAG-b-MAEMT)-2-Cy7 N/P=15. 
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Figure 7.52. 1H NMR of TR4HP3SA. 
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Figure 7.53. 1H NMR of CD6HP8SA. 
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Figure 7.54. FT-IR spectra of TR4HP3SA, CD6HP8SA, ESO, 
TR4HP3SA/ESO (50/50), CD6HP8SA/ESO (50/50) before and after cure. 
A) B)
 
Figure 7.55. FT-IR spectra of cured A) TR4HP3SA/ESO and B) 
CD6HP8SA/ESO at different ratios. 
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Figure 7.56. The isothermal DSC curves for TR4HP3SA/ESO (50/50) at 165 
°C and CD6HP8SA/ESO (50/50) at 165 °C under nitrogen. 
A) B)
 
Figure 7.57. DSC curing thermograms of A) TR4HP3SA/ESO and B) 
CD6HP8SA/ESO at different ratios under nitrogen, 5 °C min-1. 
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Figure 7.58. TGA curves for hardeners TR4HP3SA, CD6HP8SA and ESO 
with heating rate of 10 °C min-1 under nitrogen. 
A) B)
 
Figure 7.59. Tan δ curve versus temperature for cured A) TR4HP3HA/ESO 
and B) CD6NP8SA at different ratios by DMA. 
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A)
B) C)
 
Figure 7.60. Hydrolytic degradation profile of cured CD6HP8SA/ESO at 
different ratios in A) water, B) 1 M HCl, and C) 1M NaOH. The error bars 
represent the standard deviation from the mean of 3 measurements. 
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Figure 7.61. (A) Average number of cells and (B) the percentage of those 
cells that are alive adhered to the TR4HP3SA/ESO 50/50 film by flow 
cytometry at day 1 and day 5 culturing. N=3 for each assay, and the error bars 
represent the standard deviation from the mean. No samples were statistically 
different (p<0.05) according to Student’s t-test. 
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Figure 7.62. (A) Average number of live cells and (B) percentage of live cells 
adhered to the TR4HP3SA/ESO 50/50 film and in the supernatant above the 
film by flow cytometry after 24 h culturing. N=3 for each assay, and the error 
bars represent the standard deviation from the mean. No samples were 
statistically different (p < 0.05) according to Student’s t-test on the polymer film 
and in the supernatant after 24 h. 
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Figure 7.63. Gating parameters applied to all flow cytometry samples, shown 
using representative sample CD6HP8/ESO 50/50 on day 3 of cell culture. A) 
All flow cytometry events gated to capture cell count data. B) Data from cell 
count gate replotted as histogram to define live cells as indicated by 
expression of calcein. 
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Figure 7.64. Representative raw flow cytometry data of cells grown on PLG 
from Day 1 - Day 5. A) Total number of cells counted. B) Percentage of those 
cells that are alive as determined by calcein staining. 
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Figure 7.65. Representative raw flow cytometry data of cells grown on 
CD6HP8SA/ESO 50/50 from Day 1 - Day 5. A) Total number of cells counted. 
B) Percentage of those cells that are alive as determined by calcein staining. 
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Figure 7.66. Representative raw flow cytometry data of cells from either the 
TR4HP3SA film or from the supernatant above the film collected after 24 
hours (or one day) of growth. A) Total number of cells counted. B) Percentage 
of those cells that are alive as determined by calcein staining. 
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Figure 7.67. Representative confocal micrographs of cells expressing calcein 
(λ= 515 nm) after 24 h growth on films. A) Cells on PLG. B) Cells on 
CD6HP8SA/ESO 50/50. Scale bar represents 100 µm.  
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Figure 7.68. Representative confocal micrographs of cells expressing calcein 
(λ= 515 nm) after 48 h growth on films. A) Cells on PLG. B) Cells on 
CD6HP8SA/ESO 50/50. Scale bar represents 100 µm.  
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Figure 7.69. Representative confocal micrographs of cells expressing calcein 
(λ= 515 nm) after 72 h growth on films. A) Cells on PLG. B) Cells on 
CD6HP8SA/ESO 50/50. Scale bar represents 100 µm.  
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Figure 7.70. Representative confocal micrographs of cells expressing calcein 
(λ= 515 nm) after 96 h growth on films. A) Cells on PLG. B) Cells on 
CD6HP8SA/ESO 50/50. Scale bar represents 100 µm.  
 274 
 
 
 
 
 
 
Figure 7.71. Representative confocal micrographs of cells expressing calcein 
(λ= 515 nm) after 120 h growth on films. A) Cells on PLG. B) Cells on 
CD6HP8SA/ESO 50/50. Scale bar represents 100 µm.  
